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Abstract 
 
The complement cascade is phylogenically ancient pathogen recognition and response system that 
forms the initial frontier of mammalian innate immunity. Complement forms the bridge between 
humoural and cellular immunity through the generation of the anaphylatoxins, C3a and C5a, to 
recruit leukocytes to a pathogenic insult. However, in recent years, novel roles for the complement 
system outside of innate immunity have been demonstrated, especially in the developing embryo. 
To add to these novel roles, this thesis explores the role of the complement anaphylatoxin receptors 
in neural development.  
 
Previous studies in our laboratory have indicated a novel role for C5aR1 in the prevention of neural 
tube defects in folate-deficient dams. In these studies, C5aR1 was localised to the neuroepithelium 
throughout the period of neural tube closure and the precursor to C5a, C5, was also shown to be 
present. It has previously been unclear, both in this study and others, what other components of the 
complement system are present in the developing embryo that may lead to the generation of 
anaphylatoxins. Here we demonstrate that the classical and alternative pathways, at the time of 
murine neural tube closure, lack expression of key propagators. Our data demonstrate the C2/4-
independent and extrinsic pathways remain patent as a plausible means of C5a generation. 
 
In order to trace C5aR1-expressing cells within the developing embryo, a transgenic mouse was 
created using a modified bacterial artificial chromosome approach. A CreErt2-IRES-EGFP transgene 
was inserted at the second exon of C5ar1 in order to induce expression from the C5aR1 promoter 
region. Resulting litters demonstrated transgene expression that was responsive to LPS stimulation 
and similar to previously reported C5aR1 expression within the CNS. However, crossing with a cre-
reporter line demonstrated that the protein produced from the transgene was non-functional. 
 
In separate studies, both C3aR and C5aR1 were shown to be expressed by neural progenitor cells 
from neural tube closure to birth, and both receptors localised to the apical attachment of progenitor 
cells. This thesis demonstrated C5a is a constituent of embryonic cerebrospinal fluid and that C5a-
C5aR1 interaction activates aPKC to promote neural progenitor proliferation. Blockade of C5aR1 
during development leads to behavioural abnormalities in the resulting litters and microstructural 
brain abnormalities on MRI. C3aR, conversely, promotes differentiation of neural progenitors. 
 
The functions of C5aR1 and C3aR seem to be somewhat redundant during development as 
anaphylatoxin knockout animals are not known to exhibit any gross neurological abnormalities. 
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However, here we demonstrate subtle deficits in memory and anxiety in these animals – perhaps 
resulting from impaired neuroplasticity or development.  
 
In summary, this thesis demonstrates the presence and function of the complement anaphylatoxin 
receptors in neural progenitor cells. As complement becomes a more viable target for the treatment 
of inflammatory disorders of pregnancy, this work provides a caution for clinicians by elucidating 
an important neurodevelopmental role for C3aR and C5aR1.  
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Chapter 1 
 
Introduction to the Complement Anaphylatoxin 
Receptors and Neural Progenitor Physiology
Chapter 1  Introduction 
 2	
1.1 Introduction 
This chapter presents an overview of the topics relevant to the thesis. This chapter is structured 
as a series of papers, as the relevant topics have either previously been published, or are being 
prepared for publication. In addition, specific notes on the key features of this thesis, C5aR1 
and embryonic neurogenesis, are covered in sections 1.2 and 1.3, respectively.  
Section 1.4 outlines the state of knowledge on the complement system in development. It has a 
wide scope, from fertilization to birth, in order to provide a context for the research chapters of 
this thesis. Sections 1.5 and 1.6 represent previously published reviews relevant to this thesis. 
Section 1.5 is a review published in FASEB Journal on the roles and signaling of the secondary 
C5a receptor (C5aR2, C5L2). Although C5aR2 is not a focus of this thesis, an understanding of 
its signaling and actions in disease models is essential as it shares the C5a binding capacity of 
C5aR1. Section 1.6 is a review of C3a published in The Journal of Immunology. This review 
highlights some of the emerging studies that are prompting a relook at the textbook definitions 
of the roles of complement proteins. The importance of this section lies in the story of the 
entrenchment of the canonical roles of complement, that of a potent pro-inflammatory 
mediator, despite evidence of complex, multifaceted actions in various situations. This is 
pertinent as this thesis presents a novel role for the complement system in the building of the 
embryonic brain, far from its accepted (and destructive) roles in the immune system. 
In addition, Appendix A contains literature review covering the roles of C3aR in health and 
disease, prepared for submission in the near future. This section provides background and 
further reading for the research chapters examining aspects of C3aR physiology. 
The introduction is structured in such a way to address the separate, but important, facets of 
developmental biology and immunology that contribute to the understanding of the proceeding 
chapters. The complement system has been well studied for its immunological roles over the 
past century, however the previous decade has demonstrated novel and unexpected roles in 
developmental biology. An understanding of both roles is essential to form a global 
appreciation of anaphylatoxin receptor impact on the fetomaternal environment.    
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1.2 A Note on C5aR1 
 
C5aR1 is an evolutionarily-ancient receptor that is highly conserved throughout multiple species1,2. 
It has a well-defined role in inflammatory disease as a mediator of leukocyte chemotaxis and 
degranulation3. In this section the genetics, structure and ligands of the receptor are discussed in 
order to provide context to the proceeding chapters of the thesis. 
 
Genetics 
The genetic locus for C5aR1 is located on chromosome 7 in the mouse (chromosome 19 in humans) 
and consists of two exons separated by a large 10kb intron. The first exon, the shorter of the two, 
contains the 131bp 5’ untranslated region (UTR) and the start codon (ATG) of the C5aR1 sequence. 
Exon 2 contains the remaining coding sequence and a large, 1.5kb 3’ UTR region. 
 
The important promotor regions of C5ar1 occur within 500bp of exon 1, and this region is notable 
for containing a CCAAT enhancer box sequence (C/EB), AP-4 and NFκB binding sites4. The C/EB 
region is the recognition site for transcriptional activity in cells of the myeloid lineage, such as 
macrophages and microglia. In the human genome these regions have been demonstrated to be 
conserved and important for expression of human C5aR15. However, the wider promotor region 
(~2kb 5’ to exon 1) of C5aR1 is not responsible for the upregulation of C5aR1 with differentiation 
of the U937 monocyte cell line, suggesting more complex regulation of the gene is still yet to be 
discovered5. Additionally, the expression of C5aR in non-myeloid lineages is dependent on other 
motifs within the C5aR1 promotor. Astrocytic c5ar1 expression has been shown to be independent 
of the C/EB motif used for myeloid expression, and instead employs regulatory elements either 
upstream of this site, or perhaps unknown elements within the large intronic sequence6. 
Highlighting this lineage-specific difference, the NFκB site within the C5aR1 promotor is a 
suppressor site in astroglia, but not microglia6. Whilst both cell types are located within the same 
tissue and perform a supportive role in brain function, microglia are of the myeloid lineage, whereas 
astroglia are of the neuroectodermal lineage.  
 
There is a paucity of reports within the available literature on the functions of the intron and 3’ UTR 
in C5aR1 expression and function. The length and phylogenic conservation of the intronic sequence 
has led to suggestions that it may be involved in the transcriptional regulation of the gene7. 
Interestingly, a recent knockin mouse generated to insert an IRES-EGFP sequence after the second 
exon of C5ar1 led to increased protein production and impaired trafficking8. In the homozygous 
knockin animal, C5aR1 protein was confined to the intracellular compartment, and was not 
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detectable within the cellular membrane. It was suggested that the disruption of the 3’ UTR caused 
the dysregulated production and impaired trafficking of the protein product, although this was not 
demonstrated within the study8.    
 
Expression 
Originally thought to be restricted to cells of the myeloid lineage, C5aR1 is expressed throughout a 
wide variety of tissues and cell types 9. However, notably, it is absent from cells of the lymphoid 
lineage. There has been recent debate as to the status of C5aR1 expression in this lineage, which 
appears to have been settled in the negative through the recent development of a C5aR1-EGFP 
reporter mouse8. Expression of C5aR1 also occurs within the CNS, which forms the heart of this 
thesis. Both cells of the neuroectodermal lineage (neurons, astrocytes, oligodendrocytes) and 
microglia express C5aR1 at detectable levels10,11. In the adult brain, neuronal expression of C5aR1 
is restricted to specific areas, namely the pyramidal neurons of the neocortex, neurons of the dentate 
gyrus and Purkinje cells of the cerebellum11. Additionally, neural progenitor cells of both the 
embryo and the adult mouse have also been demonstrated to express C5aR112,13. In particular, 
C5aR1 expression at the point of neural tube closure within the neuroepithelium has been 
demonstrated by our laboratory and, here, the receptor is localised to the apical surface of the cell12. 
Additionally, we have also demonstrated C5aR1 expression and function on embryonic stem cells, 
which is to our knowledge the earliest expression in development14. 
 
Structure and signalling 
C5aR1 is a 7-transmembrane G-protein coupled receptor and is grouped conceptually with the other 
anaphylatoxin receptors, C3aR1 and C5aR2 (C5L2, GPR77) (reviewed in 1.5/Appendix A and 1.6, 
respectively). The extracellular N-terminus of C5aR1 and the three extracellular loops participate in 
the binding of C5a3. C5aR1 demonstrates some promiscuity, both in its G-protein coupling, and 
recruitment of downstream effector pathways. Again, these interactions appear to be dependent on 
cell-line and state, for instance, in the human monocyte line U937 and macrophages, in vivo, C5aR1 
has previously been shown to couple to the pertussis toxin (PTX) sensitive G-protein Gαi2, however 
in the MONO-MAC-6 human monocyte line C5aR1 signaling is PTX-insensitive15-17. 
 
The picture become more complex as the focus moves toward second messenger signals, where 
contradictory results exist depending on the cell line of interest. In macrophages, C5aR1 signals via 
protein kinase C (PKC) δ to induce NFκB activation and translocation to the nucleus, whereas in 
neutrophils C5aR induces activation of IκB, the NFκB inhibitor18. In mesenchymal stem cells C5a 
induces chemotaxis that is pertussis toxin sensitive, indicating a Gi mediated response, and 
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signalling via MAPK and Akt pathways19. Additionally, other G-protein independent signaling 
processes have been shown for C5aR. Yeast-2-hybrid studies have revealed that C5aR1 has also 
been shown to associate with Wiskott-Aldrich Syndrome Protein (WASP), to directly participate in 
cell directional migration in neutrophils20 and C5aR1 has been implicated in angiogenesis as 
stimulation via C5a causes transactivation of the epidermal growth factor (EGF) receptor21.  
 
Agonists and Antagonists 
Studies into C5aR1 have utilised pharmacological tools to elucidate function from experiments. Our 
laboratory contributed to the development of the most widely used small molecule C5aR1 
antagonist, PMX5322. In characterising the antagonist activity of PMX53 it was found to have high 
affinity and activity at the human, rat and dog C5aR1, but low affinity and activity at the mouse 
C5aR1 in vitro23. This is supported by our experience with the antagonist on multiple mouse cell 
types in the in vitro environment. However, in vivo use of the antagonist appears to be without the 
limitations of the in vitro work, as often the use of PMX53 recapitulates the data generated in 
knockout studies12. This perhaps suggests that some biological modification of the molecule is 
required for adequate receptor binding. 
 
The structure of PMX53 has since been used to develop several other C5aR antagonists with 
favourable properties. For instance, PMX205 has greater lipophilicity and therefore is more suited 
for use in studies that require passage of the drug through the blood-brain barrier, whilst retaining 
similar efficacy (pIC50 3.1x10-8 M vs. 9.0x10-8 M for PMX53)24. A linearised version of PMX53, 
JPE1375, has also been developed and demonstrates potent in vitro activity on mouse C5aR25. 
Staphylococcus aureus express CHIPS (chemotaxis inhibitor protein of S. aureus), which is the only 
described biologically derived inhibitor of C5aR1. This protein likely plays a role in bacterial 
evasion of immune surveillance during pathogen colonisation26,27. PMX53 and JPE1375 are the 
frequently used antagonists in this thesis, however a comprehensive list of receptor antagonists can 
be found in table 1.2.1.  
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Name Type Action Affinity Reference 
CHIPS Bacterial-derived 
biologic 
C5aR1 antagonist, 
FPR antagonist 
Kd = 1.1nM (human) 27 
W54011 Synthetic organic C5aR1 antagonist Ki = 2.2nM (human) 
Reportedly similar activity for 
gerbil and monkey. 
28 
NDT9520492 Synthetic organic C5aR1 antagonist Ki = 4.4nM (human) 
Ki = 13.2nM (Gerbil) 
Ki = >10,000nM (mouse) 
 
29 
AcPhe-Orn-
Pro-D-Cha-
Try-Arg 
Synthetic organic C5aR1 antagonist IC50 = 12nM (human) 30 
PMX205 Synthetic organic 
Cyclic molecule 
modelled from tail 
of C5a 
C5aR1 antagonist IC50 = 31nM (human) 
Reported activity at mouse C5aR 
24 
PMX53 Synthetic organic 
Cyclic molecule 
modelled from tail 
of C5a 
C5aR1 antagonist IC50 = 21nM (human) 
Reported activity at mouse 
C5aR1 in vivo 
23, 24 
JPE1375 Synthetic organic 
Modelled from 
PMX53 structure 
C5aR1 antagonist IC50 = 111nM (human) 
Reported activity on mouse 
C5aR1 
25 
C089 Synthetic organic C5aR1 antagonist IC50 = 100nM (human) 31 
L-156,602 Streptomyces sp. 
isolate 
C5aR1 antagonist IC50 = 2000nM (human) 32 
A8Δ71-73 Synthetic organic  
Modelled from tail 
of C5a 
C5aR1 antagonist, 
C5aR2 antagonist 
IC50 = 27nM (human) 
Reported activity on mouse 
C5aR1/C5aR2 
33 
 
 
Table 1.2.1; Antagonists of C5aR1 
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There are fewer synthetic agonists of C5aR1 and, none that are highly selective for C5aR1 and 
which exhibit the potency of endogenous C5a. C5a is available commercially in a recombinant form 
produced in bacteria, or isolated from donor serum. The major difference between these two forms 
is the glycosylation of endogenous C5a that may contribute to increased affinity for C5aR1. 
Experiments in our laboratory have shown that isolated human C5a is ~3 fold more potent than the 
recombinant form for inducing calcium mobilisation in isolated peripheral polymorphonuclear 
leukocytes (Owen Hawksworth, personal communication). Serum carboxypeptidases metabolise 
C5a to the less potent C5adesArg, which retains some affinity for C5aR1, but has greater affinity for 
the second C5a receptor C5aR2. 
 
Other biological agonists of C5aR1 that have been identified include dimerised ribosomal protein 
S19, a cell death signal released during membrane breakdown, and the bacterial chaperone protein 
Skp34-36. Synthetic agonists are not widely used in the literature as they have been reported to have 
off-target effects on the other anaphylatoxin receptors. Perhaps the best studied is the synthetic 
peptide YSFKPMPLaR (EP54), which has EC50 values in the micromolar range for both C5aR1 and 
C3aR1 in multiple species23,37. The available agonists for studies into C5aR1 are detailed in table 
1.2.2. Due to the lack of selective and potent C5aR1 agonists, this thesis utilised bacterial 
recombinant mouse C5a for all in vivo and in vitro work. 
 
 
Name Type Action Affinity Reference 
C5a Endogenous 
ligand 
C5aR1 agonist, 
C5aR2 agonist 
EC50 = 8nM (human) 38 
C5adesArg Metabolite 
of C5a 
C5aR1 agonist, 
C5aR2 agonist 
EC50 = 21nM (human) 38 
YSFKPMPLaR Synthetic 
peptide 
C5aR1 agonist 
C3aR1 agonist 
EC50 = 3240nM (human) 
EC50 = 600nM (mouse) 
EC50 = 50nM (rat) 
Also active in dog, sheep, rabbit, guinea pig 
and pig 
23 
Skp Bacterial 
protein 
C5aR1 agonist Not calculated 36 
Table 1.2.2; Agonists of C5aR1 
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N-methyl-Phe-Lys-
Pro-D-Cha-Cha-D-
Arg-CO2H 
Synthetic 
peptide 
C5aR1 agonist IC50 = 25nM (human)  
Derived from competitive binding assay 
31 
 
Conclusion 
In summary, C5aR1 is a highly conserved and widely expressed G-protein coupled receptor that 
exhibits multiple signalling and expression patterns dependent on cell type and tissue location. This 
thesis utilises the well-characterised specific antagonists, PMX53 and JPE1375, to determine 
function in the context of development. 
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1.3 A Note on Neural Development 
 
Neural development requires the generation of neurons and astrocytes from a self-renewing 
population of progenitor cells. This population of cells borders the ventricular system in the 
developing mammalian embryo and is derived from induced ectodermal tissue overlying the 
notochord early in development. The structure and composition of the progenitor population 
changes as development proceeds. The present section presents a broad overview of this cell 
population to provide background for the role of the anaphylatoxin receptors on neural progenitors 
outlined later in this thesis. 
 
Anatomy of the developing brain 
The vertebral central nervous system has its embryological origins after gastrulation. Signals from 
the notochord induce the formation of a neural plate on the dorsal surface of the embryo. The neural 
plate then undergoes morphological changes to form the neural tube, through apical constriction the 
neural plate elevates laterally whilst invaginating centrally and allowing the lateral edges to meet1. 
At this stage there is also neural crest cell migration from the lateral edges, which contribute to the 
formation of craniofacial structures, cardiac, endocrine and peripheral nervous system tissues2.  
 
The neural tube is generally closed by 10dpc (Theiler stage 15) in the mouse embryo3. This event 
marks the beginning of neurogenesis and differentiation of the brain and spinal cord. The neural 
tube is subdivided into aneurysmal areas termed (rostral to caudal) the prosencephalon, 
mesencephalon and rhombencephalon (figure 1.3.1). The prosencephalon gives rise to the 
development of the telencephalon (forebrain) and diencephalon (thalamic tissues). The 
mesencephalon is the precursor to the midbrain, whist the rhombencephalon further divides into the 
metencephalon (pons and cerebellum) and the myelencephalon (medulla oblongata).  Each of these 
areas is evident by gross observation at 10.5dpc.  This thesis focuses on the progenitors of the 
dorsal telencephalon, which give rise to the cerebral cortex. 
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Figure 1.3.1: The anatomical regions of the developing brain. Stylised mouse embryo at 10.5dpc (Theiler stage 17), 
Colours represent the different regions of the developing brain. The procencephalon comprises the telencephalic vesicles 
(T, red) and the diencephalon (D, yellow). The mesencephalon (Mes) is outlined in green. The rhombencephlon 
comprises the metencephalon (Met, purple) and the myelencephalon (My, blue). Additional features are also labeled; 
OP, optic vesicles; OT, otic vesicles; LB, limb bud. 
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Structure of the cerebral neocortex 
The cerebral neocortex comprises six distinct neuronal layers that are numbered from the pial 
surface to the ventricular zone (VZ). The VZ of the dorsal telencephalon in rodents contributes to 
the pyramidal neuron populations of these layers, whereas interneurons are a product of neuroblast 
migration from the ventral telencephalon4. The histogenesis of the cerebral cortex begins post-
neural tube closure, with the earliest born neurons forming a preplate above the VZ during 11-
12dpc5. There follows the development of a subventricular zone (SVZ), comprised of basal 
progenitor cells, between the newly formed preplate and the progenitors of the VZ. From 14dpc to 
birth the VZ population reduces in number as neurogenic divisions exceed proliferative divisions, 
migrating neuroblasts split the preplate into a basal marginal zone and a apical subplate, located 
above the SVZ. This population of newly born neurons is termed the cortical plate and forms the 
majority of layers within the mature cerebral cortex. 
 
Timing of neuronal birth determines the position of a neuron in the mature cortex. The cells of layer 
VI are the first to migrate from the ventricular zone and later born neurons form layers V to I 
sequentially6. The specific location and projections of newly born neurons is thought to be guided 
by the differential expression of adhesion molecules by the neuroblast on leaving the VZ, rather 
than as a product of the layer environment7,8. Hence, the timing of neuronal birth determines both 
the position and fate of the neuron within the mature neocortex.   
 
Neural progenitor cells and neurogenesis 
Neural progenitors in the developing rodent brain comprise two major groups, those with an 
attachment at the ventricular surface, termed apical progenitors, and those appearing later, 
undergoing mitosis within the SVZ, termed basal progenitors.  
 
The apical progenitors are of two types. The neuroepithelial cells form the early neural structures of 
the embryo and give rise to later progenitors and neurons. These cells exhibit epithelial 
characteristics, such as the presence of apical tight junctions9. By 13.5dpc, the apical progenitors 
consist solely of radial glia, so named due to their astroglial structural and molecular properties; 
they can be easily labeled through their expression of GLAST and GFAP9. Both types of apical 
progenitors demonstrate nuclear interkinetic migration, whilst maintaining both an apical and basal 
attachment, the nucleus undergoes S-phase at the basal surface and M-phase apically10. Whereas 
neuroepithelial cells extend processes to the apical surface and the basal lamina of the ventricular 
zone, radial glia maintain their basal attachment at the pial surface. This extension towards the pial 
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surface acts as a scaffold for the migrating neuroblast to follow, and allows for the lamination of the 
neocortex10.  
 
 
 
Division within the apical progenitor population defines the fates of the daughter cells. Apical 
progenitors undergo three types of division; symmetric proliferative, asymmetric and symmetric 
neurogenic division. The two former types of division are well recognized and the inheritance of the 
apical membrane attachment by both (symmetric) or one (asymmetric) of the daughter cells 
specifies which remains as a progenitor cell9,11. In asymmetric division the loss of the apical 
attachment by one daughter cell leads to differentiation and migration of the cell into the SVZ or 
cortical plate. Recently, a novel type of symmetric division was identified whereby the apical 
attachment is expulsed into the embryonic ventricle and neither daughter cell remains as a 
progenitor, this has been termed symmetric neurogenic division12,13. It is suggested that these 
divisions account for ~20% of the symmetrically dividing cells, but this figure is dependent on 
embryonic age as division of this type are not observed in the early neuroepithelium13. 
 
 
The factors underlying the type of division an apical progenitor cell undergoes are varied and it has 
been difficult to experimentally differentiate cause and effect. It is suggested that signals from the 
cortical plate determine the ultimate productive capacity of the cells within the VZ, however how 
this occurs is still not entirely clear6. There is experimental and observational evidence that the 
Figure 1.3.2; Cell types of embryonic neurogenesis. Stylised 
diagram of the embryonic neocortex. The apical progenitors of 
the ventricular zone (neuroepithelial cells, radial glia) 
undergo interkinetic nuclear migration and divide at the 
apical surface. Neuroepithelial cells are the least lineage 
restricted cell type and can give rise to radial glia, basal 
progenitors or post-mitotic cell types. Radial glia are the most 
abundant progenitor in the mouse and extend their basal 
process to the pial surface. This process aids in neuroblast 
migration. The basal progenitors responsible for the majority 
of newly born neurons in the murine embryo and are located 
within the subventricular zone. Each of these progenitor types 
has the potential to generate the cells of the neuroectodermal 
lineage; neurons, oligodendrocytes and astroglia. 
Chapter 1  Introduction 
 15	
length of the cell cycle is the determining factor for whether a progenitor undergoes symmetric or 
asymmetric division. Specifically, the length of G1 phase has been shown to positively correlate 
with neurogenic division. Ectopic expression of the cylin dependent kinase 1/cyclin D1 complex in 
neural progenitor cells prevents results in a shortened G1 phase and a delay in neurogenesis, both in 
vitro and in vivo14. Additionally, the neurogenesis marker gene, Tis21, causes an increased G1 phase 
when transfected into progenitors and results in premature neurogenesis15-17.  
 
Interestingly, whist inheritance of the apical attachment itself appears to be a major contributor to 
the fate of the daughter cells, the proximity of the nucleus to signals arising from this attachment 
may also be a determinant of cell fate. The apical attachment contains a cluster of pro-proliferative, 
pro-polarising factors, such as the Par2/Par6/aPKC complex, that are clustered around the primary 
cilium18. It has previously been noted that the daughter cell nuclei fated to remain as a progenitor 
remains at the apical surface for a relatively longer period than its other-fated sister16,19. Hence, it 
has been suggested that this extended time allows for increased signaling to the nuclei from factors 
on the apical surface that promote maintenance of a progenitor state9. 
 
What remains an unknown however, are the factors that push an apical progenitor cells towards 
symmetric or asymmetric division. The mechanics of mitosis within progenitor cells suggest that 
the orientation of the mitotic spindle will dictate whether the apical attachment is transected during 
division. Interestingly, at the point of mitosis there is down-regulation of the polarity promoting 
moieties within the cell membrane, perhaps promoting a variability of orientation that results in 
both types of division20. Loss of mitotic spindle orientation in mice results in a microcephalic 
phenotype through a premature reduction in the progenitor pool21. Indeed, genes that control the 
orientation of the mitotic spindle at mitosis have been implicated, evolutionarily, in allowing for the 
cerebral expansion evident in mammalian, and particularly primate, brains21,22. 
 
At the point of differentiation, most apical progenitors give rise to basal progenitor cells. Basal 
progenitors lack a distinct polarity and remain within the subventricular zone throughout the cell 
cycle, in contrast to the animated migration of apical progenitors through the pseudostratified 
ventricular zone23. This cell population is the major contributor to the neurons of the mammalian 
cortex, as over 90% of neurons are derived from basal progenitors despite the ability of apical 
progenitor cells to contribute directly24. Basal progenitors are commonly demarked by their 
expression of the transcription factor, Tbr2, which gives way to expression of Tbr1 with the onset 
of differentiation25.  
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In the context of brain evolution, the basal progenitor cells of the subventricular zone appear to be 
the major embryonic contributors to cortical size. In the mouse, the basal progenitor cell population 
is relatively modest, accounting for 25-30% of mitotic cells in the developing brain. In humans and 
other primates, the basal progenitor population of the subventricular zone becomes the predominant 
progenitor region of the brain, with 80-90% of mitotic cells located in this area10. This observation 
has been suggested to account for the difference in brain size and complexity between rodents and 
primates, as an expansive basal progenitor population allows for greater neuron generation. 
Additionally, the basal progenitor population of mice is also a more homogenous cell population 
than that of the primate, which is composed of multiple subtypes of basal progenitor. For instance, 
the recognized outer subventricular zone progenitors (basal radial glia) of the primate brain have 
only recently been shown to occur in mouse development26. However, these account for only 3-5% 
of the basal mitoses in the mouse, whereas in the developing human cortex this region dwarfs both 
the VZ and SVZ and is the major contributor to neurogenesis27. 
 
Conclusion 
In conclusion, embryonic brain development relies upon the generation of the cortical layers from a 
distinct and self-renewing population of progenitor cells at the ventricular surface. The factors that 
govern the proliferation and differentiation of the progenitor population are not well defined in the 
literature, but observational and experimental studies demonstrate that the cell cycle, polarity and 
fate of the progenitor cell are intricately linked.  
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Introduction 
 
The complement system has long been associated with innate immunity, and the names and 
functions of its components have reflected this historical catagorisation1,2. However, despite 
entrenched historical bias towards complement’s role in innate immunity, in recent decades, new 
roles have emerged for this group of proteins in the scope of development. These roles extend from 
the gamete to post-natal stage and, in instances, are somewhat detached from the traditional role for 
complement as an innate sensor for pathogens. Given the emergence of these novel roles, and the 
focus of this thesis on the anaphylatoxin receptors in neural development, this section aims to 
provide context by describing the wider importance of the complement system in the process of 
reproduction.  
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From Gametes to Fertilisation 
 
Complement, both in its physiological roles, and in the pathogen response, is a delicate balance1,3,4. 
Fertilisation is no exception. Complement factors are present on both the sperm and oocyte, as well 
as secreted into the female reproductive tract by the epithelial lining. Within the female 
reproductive tract, complement acts as the first line of defence against ascending or introduced 
pathogens5. Both spermatozoa and oocytes express regulators of the complement system. Oocytes 
express CD59, CD46, CR1 and CR3 on the membrane, whilst CD55 is expressed on the zona 
pellucida6,7. However, expression of these regulators may be dependent on age and status of the 
oocyte7. 
 
C3 expression within the female reproductive tract and ovarian follicle is under hormonal control 
and can be modulated by exogenous administration of oestrogen or progesterone. C3 expression is 
stimulated by oestrogen and the effect of oestrogen is inhibited by the presence of progesterone8,9.  
Additionally, other important members of the complement system have been demonstrated to be 
present in the glandular epithelium, in a similar temporal expression pattern to C3, perhaps 
suggesting similar hormonal control. CD55 and factor B demonstrate a similar expression pattern to 
C3, whereas CR1 is under similar hormonal control, but localizes to the stroma10. 
 
The expression of complement factors in the female reproductive tract is not unexpected given the 
potential for exposure to pathogens. As previously mentioned, an active complement system in the 
reproductive tract may also aid in eliminating dysfunctional spermatozoa, as healthy spermatozoa 
express regulators to prevent MAC formation11. A third, and perhaps most interesting, role for 
complement in fertilization is to mediate the interaction between spermatozoa and the oocyte. The 
presence of iC3b in follicular fluid increases the rate of oocyte maturation12, whilst this discovery 
has origins in the investigation of IVF, it is interesting to note the increase in C3 expression at 
estrus. 
 
In the male reproductive tract, complement cascade proteins, such as C3 and C4, are present in the 
seminal plasma (SP) ejaculate that accompanies spermatozoa13. Overall, SP has been shown to have 
an inhibitory effect on complement activation14 and contains specific ‘prostasome’ complexes that 
concentrate complement regulators CD55, CD59, and CD46.  It is hypothesised that the role of 
prostasomes is to provide an immediate anti-complement defence for spermatozoa deposited into 
the female reproductive tract15. Upon migration through the female tract, the sperm will leave the 
SP along with the prostasomes, leaving a requirement for the sperm to possess their own 
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complement regulators. For this, a number of complement proteins have been identified on 
mammalian spermatozoa, including CD55, CD59, CD46, C1-INH, C1qR.  These proteins have 
been implicated in their canonical functions, protecting sperm from complement mediated attack; 
however, their expression is unique, with isoforms specific to the testes reported to be involved in 
facilitating fertilisation via effects on sperm motility, activation, and sperm interactions with the 
egg. 
 
After migration from the relative safety of the SP, spermatozoa have to run the gauntlet of the 
female reproductive tract for successful fertilization to occur and, accordingly, express complement 
regulatory proteins to prevent complement-mediated lysis. CD55 and CD59a are expressed on the 
plasma membranes of spermatozoa, whilst CD46 is strongly localized to the inner acrosomal 
membrane16. CD59a and CD55 expression provide a functional defense against MAC-mediated 
lysis11. Additionally, a complement 1 inhibitor-like protein (C1-INH) has been shown to protect 
spermatozoa from complement mediated lysis, and the dysfunction of this factor is linked to male 
infertility17. In addition, the presence of autoantibodies against C1-INH in human populations is 
also associated with male infertility18. Complement expression in spermatozoa may also be 
modulated through epigenetic mechanisms as, in folate deficient conditions, C3ar1 demonstrates 
altered methylation19. However, it is unclear whether other factors in the complement system are 
under similar epigenetic control. 
 
Components of the complement cascade are found in the follicular fluid of women undergoing 
ovarian stimulation for in vitro fertilization. There is evidence of independent regulation of 
complement in the follicular fluid when compared to serum, with tighter regulation of complement 
activation in follicular fluid20. Complement factors are expressed by the granulosa cells of the 
ovarian follicle for secretion into the follicular fluid. However, there is notable absence of the 
central complement factor, C5, perhaps indicating that MAC formation is not the central aim of 
expression in this environment21. 
 
Despite the role of complement as a spermicidal factor in the migration of sperm through the female 
reproductive tract, the interaction between spermatozoa and oocyte is enhanced by the presence of 
complement factors on the interacting gametes. Interestingly, whilst CD46 is abundant on the 
membranes of somatic cells, it is present only on the inner acrosomal membrane of spermatozoa, 
and hence, only available for interaction with the surrounding environment after the acrosomal 
reaction6,16. Additionally, oocytes express CR1/CR3 on the cellular membrane, and both AR-
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spermatozoa and zona-free oocytes bind iC3b strongly in vitro6. Hence, it has been suggested that 
iC3b may act as a linkage factor allowing membrane opposition during fertilization (figure 1.4.1).  
 
The importance of CD46-iC3b linkage in fertilization is highlighted by the observation of increased 
fertilization success in cultures supplemented with additional iC3b. Generation of iC3b at the local 
level may be achieved through the release of acrosin as a consequence of the acrosomal reaction, as 
acrosin has been demonstrated to have complement-lytic activity in vitro6. The C3 fragment, C3b, 
can then deposit on the inner acrosomal membrane leading to increased adherence of sperm and 
penetration of hamster oocytes22. Accordingly, abnormalities in CD46 have also been associated 
with human infertility23. Interestingly, however, the lack of C3 in C3 knockout mice has not 
resulted in sterile animals, suggesting that the CD46-iC3b-CR interaction has some redundancy in 
the fertilization process or a surrogate linking factor may also assume this role.  
 
Figure 1.4.1; Diagrammatic representation of complement involvement in the sperm-oocyte interaction. A) 
Factor B, factor D and C3 are all secreted by oviductal cells, which allows for alternative pathway activation and 
generation of C3b. B) Acrosin released by the spermatozoa during the acrosomal reaction can cleave C3 to C3b. C)  
Factor I is present in the oviductal fluid, but may require cofactors for generation of iC3b. The inner acrosomal 
membrane of the spermatozoa expresses CD46. The oocyte demonstrates expression of complement receptor 1 (CR1). 
D) Binding of iC3b to CD46 of the inner acrosomal membrane and CR1 of the oocyte allows for opposition of the 
gamete membranes, and successful fertilization.  
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It is unclear whether the literature describing a function for CD46 on the AR of mouse spermatozoa 
is translatable to humans, as several expression differences exist between the two species. Murine 
expression of CD46 is testis specific, with crry performing the systemic functions that CD46 
performs in humans24. However, the actions of CD46 in the inflammatory and reproductive 
scenarios may be mutually exclusive, and whereas the systemic actions of CD46 may have been 
redundant in the presence of murine crry, the reproductive actions are not. Support for an exclusive 
action of CD46 in reproduction has been demonstrated in a study utilising new world monkeys. 
Profiling of CD46 in these animals found a loss of expression of an extracellular domain, CCP1, in 
all tissue, except the testis, where CCP1 expression was preserved.  This site is a preferential 
binding site for a number of viruses, with evolutionary pressure for pathogen resistance likely the 
cause for the loss of CCP1 expression25. CCP1 does not interact with C3b, therefore loss of 
expression of this domain would not affect the canonical function of CD46. The preservation of the 
CCP1 domain in the testis of these animals suggests an importance for this region in reproduction, 
and an action of CD46 on sperm outside of C3b binding, explaining the continued fertility of C3 
knockout mice, but a reduced fertility when CD46 is targeted. In support of this, antibodies directed 
against CCP1 are able to reduce human spermatozoa-egg binding, whereas an antibody blocking the 
C3b binding site of CD46 had no effect26. Interestingly, CD46 knockout mice have been reported to 
have increased fertilisation rates due to increased spontaneous acrosome reaction27,  suggesting 
primate-rodent variations in CD46 function, or multiple functions of this protein. 
 
CD55 and CD59 also display expression patterns unique to the testis with evidence suggesting 
biological roles beyond protection from complement lysis. Expression of CD55 in the 
transmembrane form only occurs during a transient stage of spermatid development (stages 11-14), 
with a GPI-anchored form then expressed on the acrosomal membrane of mature spermatozoa28. 
Whilst it has been demonstrated that CD55 is involved in protection of spermatozoa from 
complement-mediated lysis in the female genital tract29, this stage-specific expression of CD55 
isoforms in sperm development is suggestive of functions separate to complement protection. This 
may include signalling roles of transmembrane-CD55 during spermatogenesis and a more fine-
tuned regulation of the acrosome reaction by a GPI-anchored CD55.  In mice, expression of a CD59 
isoform, CD59b, has been reported to be unique to the testis, with a strong localisation to the sperm 
head30. Whilst CD59b knockout mice being are initially fertile, they experiencing a sudden decline 
in sperm quality with an associated decrease in fertility, suggesting an intriguing role for CD59 in 
fertility31. 
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As with CD46, C1q receptors have also been implicated in sperm-oocyte interactions. Receptors for 
the collagen-like and globular head regions of C1q, cC1qR and gC1qR respectively, have been 
detected on human spermatozoa32, with C1q itself present in follicular fluid21. Following 
capacitation, membrane localisation of gC1qR increases with exogenous C1q increasing sperm 
agglutination and adhesion to C1q receptor expressing zona-free hamster eggs33 34.   
 
Blastocyst Stage 
 
At the blastocyst stage complement factors contribute to development of both the trophectoderm 
and inner cell mass. The complement regulators CD55, CD59a, Crry and CD46 are expressed on 
the trophectoderm of the blastocyst7. Whilst the apparent function of these regulators may be to 
protect the blastocyst from complement activation within the oviduct and uterus, they have also 
been shown to contribute to embryotrophic signaling. 
 
Oviductal cells express and secrete complement factors involved in the alternative pathway 
activation. Factor D and factor B form a C3 convertase and cleave C3 to C3b, leading to a 
concentration of C3b within the oviductal lumen35. Factor I, which participates in the C3b – iC3b 
conversion, is also secreted by oviductal cells, however, cofactors essential to this conversion are 
not expressed. The blastocyst itself provides the cofactors for generation of iC3b through Crry 
expression on the trophectoderm. The generated iC3b has been shown to bind to the trophoblast 
layer and exert embryotrophic effects, increasing blastocyst size and hatching rate35,36. 
 
To our knowledge, no in vivo studies of complement expression within the inner cell mass exist. 
However, in vitro maintained embryonic stem (ES) cells demonstrate increased susceptibility to 
complement mediated lysis when compared to terminally differentiated cell types37. This increased 
susceptibility may be a consequence of the sheltered nature of the inner cell mass in the pre-
implantation embryo, encased by the protective trophectoderm. Indeed, multiple studies have 
demonstrated trophectoderm-specific expression of complement regulators on the blastocyst7,35,36. 
The fragile nature of ES cells when exposed to activated complement may also represent a defence 
mechanism against the formation of teratomas within the mother and embryo, as fetal cells enter the 
maternal circulation and can survive within the maternal environment for extended time periods38,39. 
 
Despite the susceptibility of ES cells to complement mediated lysis, complement factors have also 
been shown to stimulate their proliferation and survival. Embryonic stem cells express the central 
complement factors C3 and C5 in addition to the two receptors for C5a, C5aR1 and C5aR240. 
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Interestingly, there is no demonstrated ES cell expression of the C3a receptor (C3aR). Akt and 
Erk1/2 signalling through the C5a-C5aR axis in ES cell culture contributes to proliferation and 
improves survival41.  
 
Organogenesis 
 
After implantation the embryo undergoes gastrulation and neurulation laying the foundations for the 
development of the major organ systems. This period, termed organogenesis, represents the critical 
peak for potential teratogenic effects42.  
 
Many components of the complement system are expressed during organogenesis and have been 
demonstrated across species, including the mouse, xenopus, cod and zebrafish43-45. The 
anaphylatoxins, in particular, exhibit unexpected roles in the normal development of the embryo. 
We recently identified a variety of complement factors expressed during the period of mouse neural 
tube closure (7.5-10.5dpc) (Chapter 2)44. Here, initiators, propagators and regulators of the classical, 
alternative and lectin pathways were assayed in order to determine which pathways of complement 
activation were active in the mouse undergoing neurulation. Interestingly, whilst components of all 
three pathways were present in the whole embryo, all three pathways lacked factors essential for 
their propagation (Chapter 2). In support of this, a significant portion of the complement system has 
been localized in the xenopus embryo and demonstrates unexpected expression patterns. In 
particular, C1qr, C3, C5a and C3ar1 localised to the neural structures during neurulation. Other 
complement factors were also expressed, including terminal components (C6, C8), regulators 
(CD46, CD55) and propagators (C1s, fH) of complement activation45. 
 
The neural localization of complement factors during organogenesis is of particular importance as 
this area has the strongest evidence of physiological function of these molecules outside of their 
traditional roles. We have previously demonstrated a novel role for C5aR signaling during neural 
tube closure under conditions of folate deficient stress. In both the human and mouse embryo, C5aR 
and C5 are expressed by cells of neuroepithelium, and C5aR, in particular, localizes to the apical 
membrane44. Deficiency or pharmacological blockade of C5aR combined with maternal folate 
deficiency produces a high (~50%) incidence of congenital malformations in the resultant litters46.  
Interestingly, the penetrance of malformations in these litters did not reach 100%, suggesting that 
C5aR signaling in neurulation is, to some extent, redundant. Additionally, the source of C5a for 
interaction with C5aR is as yet unknown, however given our previous results demonstrating 
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incomplete traditional complement pathways at this stage of development, the convertase in this 
situation is likely to be extrinsic or derived from the C4-independent lectin pathway (Chapter 2). 
 
In xenopus and zebrafish development, C3 and C3ar1 are localized to the neural crest and 
responsible for control of collective migration. Morpholino knockdown of C3aR during zebrafish 
development caused impaired dispersion of neural crest cells from their normal migratory stream. In 
vitro studies demonstrated a role for C3aR in co-attraction of neural crest during migration, and 
accordingly neural crest cells have been shown to secrete C347. In addition, both C9 and fH are 
actively-secreted by migrating neural crest cells, however the functions of these molecules in this 
environment is, as yet, unknown. Interestingly, the presence of initiating factors of the lectin 
pathway has also been shown on neural crest cells, and mutations in these factors cause craniofacial 
defects in human populations. Mutations in MASP1, MASP3 and Collectin kidney-1 have been 
identified in human populations with craniofacial defects48. Accordingly, MASP expression is 
localised to the brachial arches of zebrafish and mice and, in zebrafish models, morpholino 
knockdown of MASP1 impairs neural crest cell migration48. 
 
The apparent importance of the anaphylatoxin receptors in neurulation and neural migration is not 
translated to homozygous knockout animals, which are born without any gross morphological 
anomalies. Given that the studies involving acute pharmacological blockade or knockdown 
demonstrate severe derangement of the normal tissue development, it is pertinent to consider the 
value of these germline knockouts when investigating the role of complement in the developmental 
context.   
 
 
Post-neural tube closure to post-natal period 
 
During the fetal period in humans, the presence of complement factors in the fetal circulation rises 
in a linear fashion49,50. This translates to reduced complement-derived haemolytic activity that is 
proportional to the complement concentration50. It is unknown what percentage of complement 
activity is attributable to maternal production, however, even in term neonates, complement factor 
serum concentrations are still significantly below adult levels49. In addition, tracing maternal C3 
migration into the fetal circulation has previously indicated that there is no transplacental passage of 
these molecules51. Interestingly, there is correlation of fetal and maternal complement activation, as 
measured by C5a, suggesting that either C5a or the activation factors for complement do exhibit 
transplacental migration52. 
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In the developing organs of the fetus, complement factors demonstrate extra-immune functions. In 
the developing bones, complement factors of the alternative pathway show a complex and 
coordinated expression pattern within the growth plate and surrounding regions53. C1s, in particular 
has been highlighted as an initiating factor of cartilage degradation in bone growth, with induction 
activity of MMP-954. Whilst the presence of the complement anaphylatoxins and their receptors 
have not specifically been reported in the context of fetal development, they do show specific 
activity in initiating regeneration post fracture 55,56. It would be interesting to determine whether the 
adult model of bone regeneration bears similarities to the induction of fetal bone growth with 
regards to anaphylatoxin activity. 
 
Complement factors have been shown to play key roles in the developing nervous system (figure 
1.4.2). Although reports of complement factor expression in the developing neocortex have been 
within the literature for the past few decades, few functional characteristics have been ascribed to 
them57. Recently, we showed that C5aR is present on the apical membrane of neural progenitor 
cells, sharing its cellular location with key drivers of stemness and polarity such as the 
Par3/Par6/aPKC complex58. In this location C5aR signals via aPKC to maintain progenitor cells 
within the ventricular zone and increase proliferation. In embryonic mice, blockade of C5aR 
signaling results in behavioural abnormalities in adult life, and reduced neocortical size (Chapter 4). 
In support of this finding, previously Bénard and colleagues (2008) demonstrated a role for the 
anaphylatoxins in cerebellar histogenesis post-natally59. C5a promotes proliferation of the 
progenitor cells of the external granular layer, whereas C3a promotes migration to the post-mitotic 
internal granular layer. Whilst we could not demonstrate a cerebellar anatomical defect resulting 
from C5aR antagonism from 12.5-14.5dpc, this may be due to a time dependent effect of C5aR on 
neural progenitor cells. In the neocortex, the peak of murine neurogenesis is within the period we 
assayed, however formation of the cerebellar layers occurs later in development and extend to the 
post-natal period in rodents. Interestingly, again C5aR knockout animals demonstrate no gross 
neurological deficits in brain size nor have any behavioural deficits been reported as yet. However, 
chapter 6 of this thesis outlines subtle behavioural differences between C5aR-/- / C3aR-/- animals and 
their wild-type littermates. 
 
The classical pathway of complement activation has been implicated in a novel mechanism of 
synaptic pruning in the CNS. Complement-mediated synaptic pruning appears to be a phenomenon 
associated closely with circuits of the visual system postnatally, but not elsewhere in the CNS. Both 
C1qA and C3 deficient mice, in the post-natal developmental period, exhibit a higher number of 
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synaptic inputs in the lateral geniculate nucleus60. This is due to a failure of synaptic pruning, 
mediated by the classical pathway, and a subsequent lack of refinement of these afferent signals61. 
This model is an insight into the synapse loss associated with neurodegenerative disease, and 
outlines a mechanism through which aberrant complement activation may result in cognitive 
deficits. Additionally, several proteins with phylogenic links to members of the complement 
cascade have important roles in developmental processes. The C1q-like protein, C1ql1, is a secreted 
protein that binds to its receptor, Bai. It shares a close evolutionary link to the constituent proteins 
of C162. C1ql1 is expressed predominantly in brain areas involved in motor function and 
coordination63. Recently, it has been identified as a novel mediator of cerebellar development, 
specifically it aids in the maintenance of single climbing fiber connections in the cerebellum. It is 
interesting to note that both C1q and its closely related cousin, C1ql1, exhibit similar roles in 
managing the synaptic connections of neurons in different areas of the brain. The presence of both 
shared function and shared homology underlines the pleiotropic nature of complement proteins, 
especially in their evolutionary history. 
 
Whilst regulated and directed complement expression is an important component of normal brain 
development, dysregulation of the inflammatory aspects of complement has been shown to result in 
adverse developmental outcomes. Models of inflammation-induced preterm birth through the 
administration of intravaginal LPS demonstrate C5aR mediated fetal brain injury. The induction of 
inflammation in this model caused significant elevations in C5a concentration in both the amniotic 
fluid and fetal brain tissue. This elevation in C5a was linked to a reduction in cortical axons and 
soma as, in this model, C5aR knockout was shown to be protective against LPS-induced injury. 
Figure 1.4.2: Novel roles for complement in the developing central nervous system. Left; C5a and C5aR have 
been demonstrated to promote the proliferation of neural progenitor cells post-infarct and developmentally, which is 
explored in this thesis. Centre; C1q has been shown to tag redundant synapses for elimination during brain 
development. Right; C3aR mediates coattraction of neural crest cells during collective migration.  
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Interestingly, administration of statins in vivo and in vitro also demonstrated a protective effect 
against LPS/C5a-induced brain injury, suggesting a statin-mediated interruption of C5aR 
signaling64. The susceptibility of the brain to complement-induced brain injury may also be, in part, 
explained by the lack of specific complement regulators in the membrane of these cells. Human 
fetal neurons demonstrate expression of CD59 and CD46, but lack expression of CD55, which 
regulates complement amplification at the cell surface65. 
 
Complement and the placenta 
 
Normal pregnancy is associated with systemic maternal complement activation and concentration of 
complement activation products in the maternal serum positively correlate with gestational age66. 
The presence of the foreign and highly vascular placental tissues in close association with the 
maternal circulation may go some way to explain this phenomenon. Placental tissue also actively 
secretes components of the complement cascade and up-regulates the secretions in the presence of 
pro-inflammatory cytokines, perhaps as a defensive mechanism against potential pathogens67,68. 
Additionally, other novel roles for complement factors are apparent in placental development, such 
as the secretion of ASP (C3adesArg) by placental macrophages correlated to maternal BMI69. This has 
been suggested to alter the fetal insulin homeostasis and result in poor outcomes for births from 
mothers with high BMI. As such, there has been focus in the available literature on describing the 
methods of complement regulation by cells of the placenta. However, the complement system, as 
with the embryo, is not confined solely to mediating inflammation in the context of placental 
development. 
 
Interestingly, IVF culture causes an decrease in murine placental expression of C3 and C5 at E10.5, 
in the mouse, and an increase in the terminal factor C970. Complement factors are also increased 
during the preimplantation period, in the follicular fluid of human IVF cycles71. It is interesting to 
note, in light of this association, that IVF currently is associated with a significantly greater risk of 
adverse outcomes than spontaneous conception72. Additionally, adverse outcomes extend 
throughout childhood for IVF-conceived infants, with increases in atopic conditions, hospital 
admissions and systemic disease73. However, these outcomes are multifactorial and the sample 
population is skewed due to the difficulties of conception already present in those self-selecting for 
IVF treatment. Additionally, there appears to be no gross morphological differences in placentas 
from IVF-assisted pregnancies and spontaneous conceptions, at least in the first trimester74. 
Regardless, the correlation of increased complement expression in IVF pregnancies raises questions 
over the level of involvement of dysregulated inflammation in contributing to adverse IVF 
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pregnancy outcomes, as it does in other placental pathologies explored in this section. It would be 
interesting to ascertain whether the elevated placental expression of complement factors in IVF 
pregnancies is a causal or promoting factor in these poor outcomes. 
 
Complement regulators are expressed in the placenta throughout gestation. The expression of 
CD55, CD59 and CD46 has been found to increase in syncytiotrophoblasts with gestational age75. 
Additionally, there is preferential expression at the fetomaternal interface, as has been shown for 
CD46, where expression is localised to the embryo-derived trophoblast epithelium on chorionic villi 
surrounded by the maternal blood spaces75. This pattern of expression suggests regulation of the 
maternal complement system by placental regulators, and indeed in mouse models this hypothesis 
holds true. Loss of placental Crry expression, the analogue of human CD46, causes dysregulated 
complement activation and C3b deposition on the trophectoderm, leading to embryonic lethality by 
E16.576.  
 
In early placental development, C1q is expressed by extravillous trophoblasts. Action of C1q, 
through C1qR, in cultured trophoblasts induces Erk1/2 phosphorylation and promotes migration. 
C1q-/- mice exhibit reduced trophoblast invasion into the decidua, suggesting that the in vitro results 
have biological relevance77. It has been suggested that C1q acts to form a molecular bridge between 
the decidual endothelial cells and migrating trophoblasts in the development of the placental 
vascular architecture78. Absence of C1q results in defective placentation and a predisposition to the 
development of preeclampsia in mice79. Additionally, C1q-/- animals demonstrate reduced fetal 
weight and increase resorptions, as might be expected given the histological picture of placental 
dysfunction77. Matings between wild type and C1q-/- animal demonstrate that the effect is due to 
fetal, rather than maternal, loss of C1q79. 
 
Preeclampsia is characterised histologically by increased deposition of C4b when compared to 
healthy human controls. Additionally, placental expression of some complement regulators also 
increase in placentas from preeclamptic pregnancies, notably CD55 and CD59 expression increases, 
but there is no change in CD46 expression80. It is unclear whether the unchanged CD46 in 
preeclaptic pregnancies contributes to the pathogenesis of preeclampsia by not inhibiting the 
complement activation. However, this is unlikely given that a recent report demonstrated no 
increased prevalence of preeclampsia in women with known, function-impairing CD46 mutations81. 
This is interesting given that mice lacking the functional analogue, Crry, exhibit fetal loss by 
E16.576, perhaps suggesting some functional redundancy of complement regulators in human 
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pregnancy. Mutations in other regulators have been reported in the literature in case-studies and 
may warrant further investigation as genetic risk factors for development of the disease82. 
 
At the protein level, complement factors are responsive biomarkers of the inflammation associated 
with preeclampsia. Early elevation in factor Bb levels in the first trimester is a positive predictor of 
preeclampsia development83. Additionally, active preeclampsia is associated with elevations in C5a, 
but not C3a, both in the maternal and fetal circulation52. Histologically, preeclampsia is associated 
with MAC deposition on the cytotrophoblasts of the intravillous space. This MAC deposition may 
be a downstream effect of the disease as, in vitro, oxygen deprivation stimulates MAC deposition 
and the low O2 environment of preeclamptic placentas could mediate this effect84. However, the 
presence of MAC deposition in vivo may further exacerbate the disease process as, in culture, MAC 
deposition causes an increase trophoblast differentiation84. 
 
This elevation and activation in complement proteins during preeclampsia may be a cause, rather 
than result, of the spectrum of symptoms and placental dysfunction. In the DBA/2 x CBA/J model 
of intrauterine growth restriction (IUGR) and fetal loss, a spectrum of placental dysfunction is 
apparent that mimics preeclampsia clinically85. In this model blocking complement action at several 
levels, including use of anti-fB, anti-C5, C5aR antagonism and supplemental Crry, results in 
increased fetal weights and reduced resoptions86. It is suggested that the inhibition of the 
complement system restores the balance of pro- and anti-angiogenic factors in the placenta as 
complement inhibition was noted to increase free VEGF and decrease the anti-angiogenic factor, 
sVEGFR-186. 
 
This impaired regulation of complement activation also contributes to adverse pregnancy outcomes 
in other placental inflammatory diseases, and it is not unreasonable to think that the mechanisms 
remain similar to those outlined in the preeclampsia studies. Antiphospholipid syndrome (APS) is 
an autoimmune disease that is clinically characterised by the presence of a complement-mediated 
thrombophilia87,88. The syndrome has also been linked to increased risk of developing preeclampsia 
and other pregnancy complications such as IUGR and fetal loss89,90. In mouse models, complement 
has been shown to be pivotal to the pregnancy complications associated with APS, as inhibition of 
C3 cleavage, through the use of C3-deficient animals of C3 convertase inhibitors, can prevent the 
growth restriction and fetal loss87,91,92. 
 
Active systemic infection, or ascending infection of the female reproductive tract, is also a risk 
factor for preterm birth and fetal loss during pregnancy. The role of the complement system in 
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responding to pathogenic insult is well understood, but the complement activation during active 
infections negatively affects placental health and development. Systemic infection during early 
placental development in the mouse results in histologically abnormal placentae, with reduced 
spongiotrophoblast density93. Absence of C5aR during this period prevents the loss of 
spongiotrophoblasts and, in turn, increases fetal survival93. In the later stages of pregnancy, 
systemic inflammation can precipitate pre-term birth, but interestingly, this effect is separate from 
the mechanisms that precipitate miscarriage, as C5aR knockout animals are not protected93. 
However, the inhibition of C5aR during the inflammation leading to preterm birth can be beneficial 
in reducing the associated brain injury experienced by the fetus64. Systemic inflammation in mouse 
models of sepsis result in highly elevated C5a concentrations in the amniotic fluid and fetal brain; 
this aberrant C5a expression results in microstructural cortical abnormalities, and may explain the 
poor developmental outcomes of children born pre-term64,94.  
 
As opposed to systemic inflammation, the presence of local vaginal inflammation shows the action 
of C5aR are directly involved in the cervical ripening leading to preterm birth. Here, C5aR 
increases the expression of matrix metalloproteinases within the cervical stroma, and leads to the 
cervical remodeling necessary for delivery95. Interestingly, C5aR-/- mice are also resistant to 
progesterone-inhibitor (RU486)-induced delivery95, which may be suggestive of some physiological 
balance between C5aR activation and progesterone in the timing of normal birth.  
 
Conclusion 
 
In conclusion, this section has outlined the evidence for involvement of complement proteins in 
reproduction, from presence of complement factors on gametes, to the promotion of post-natal brain 
development. Here complement factors have been described as present in both the embryo and the 
placenta and, in addition, maternal complement activation can also affect fetal development. The 
complement system in development functions, in its traditional role, as a barrier to pathogen 
colonisation, but also has novel and unexpected roles in the histogenesis of the developing embryo. 
This forms the context of this thesis, which examines specifically the roles of the anaphylatoxin 
receptors, C5aR and C3aR, on neural progenitor cell populations. 
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Abstract 
 
C5a is the paramount pro-inflammatory mediator of the complement cascade, and has been 
previously thought to act only through a single, G protein-coupled, C5a receptor (C5aR, also termed 
CD88). In 2000, a second C5a receptor, C5L2 (previously known as GPR77), was discovered; yet, 
despite 12 years of intensive research, its biological, or pathophysiological, function is both 
enigmatic and controversial. Unlike C5aR, this receptor does not couple to G-proteins, and early 
studies promoted the hypothesis that C5L2 functions as a decoy receptor. However, recent data 
have provided other evidence for more complicated and conflicting interactions between C5L2 and 
other inflammatory mediators. C5L2 has been recently demonstrated to physically interact with 
both C5aR and β-arrestin to negatively regulate C5aR signalling towards an anti-inflammatory 
manner, and to reduce pathology, in several disease models in vivo. In direct contrast, other groups 
have demonstrated that C5L2 stimulation caused release of HMGB1 both in vivo and in vitro, and 
enhanced pathology in sepsis models, suggesting a clear pro-inflammatory signalling role. These 
astoundingly contradictory data challenge our precepts and complicate the foundational bases for 
the possible targeting of C5L2 as a therapeutic option in inflammatory disease: C5L2 may be the 
great masquerader in complement biology; its function dependent on the cell type, species and 
disease context. Because of these unusual and unforeseen complexities, we present the current state 
of knowledge on C5L2 structure, expression and, most controversially, its putative function(s).  
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Background 
 
The complement system plays a pivotal role in immunity, and is often described as the first line of 
defence against pathogens. At the apex of the complement zymogen cascade lies C5, a 190kDa 
precursor to the effector molecules, C5a and C5b. C5b has a well-defined function in initiating the 
formation of the membrane attack complex, and C5a historically been described as a trigger for the 
cellular immune response, signalling through its receptor C5aR1. Through C5aR, C5a is a potent 
leukocyte chemoattractant and mediates inflammatory responses, and as such, is involved in many 
diseases including sepsis, rheumatoid arthritis, asthma, ischemia-reperfusion injuries and 
inflammatory bowel disease2. However, recently a second receptor for C5a has been discovered that 
does not fit neatly with the perceived functions of C5a, generating controversy in the literature. This 
second receptor, C5L2, remains a source of intrigue for the complement research community. We 
now attempt to sift through the reports, mine the frustrations of the frustrated, cut through the mists 
of ambiguities, and peer into the enlightened darkness of the past, to provide a small beacon of light 
and hope for the next wave of research into the most recent of many enigmas of complement.  
Succinctly; what is C5L2, why is it there, what does it do, and why do we care?        
 
Structure 
C5L2 was first cloned in 2000 and it has closest homology with C5aR (CD88)3. The following year, 
it was identified that C5L2 is encoded by GPR77 in humans on chromosome 19, q13.33-13.34, 
located downstream of the gene encoding C5aR, and in 2002, was confirmed that C5L2 binds C5a 
with high affinity4. C5L2 binds to C5a with the same high affinity as C5aR (Kd ~2.5nm), but to its 
degradation fragment, C5a-desArg, with a much higher affinity (Kd ~12nm) than C5aR (Kd 
~660nm). C3a-desArg, also referred to as acylation-stimulating protein (ASP) has been identified to 
have a direct interaction with C5L2 on adipocytes and macrophages, which may contribute to the 
inflammatory-adipose phenotype5. However, these results are controversial since it has been shown 
that C5L2 does not bind C3a or ASP/C3adesArg and it is unlikely to be directly related to lipid and 
carbohydrate metabolism6. This viewpoint is currently unresolved, and there are no corroborating 
studies outside the research group making these claims.  How this plays out remains to be seen. 
 
C5L2 is a 337 amino acid, seven transmembrane protein that is grouped in the G-protein family of 
receptors, together with C5aR. C5L2 shares 38% sequence homology with C5aR, is conserved 
across mammalian species (figure 1.5.1), however C5L2 exhibits sequence differences in the highly 
conserved DRY motif located at amino-acid residues 137-139. The DRY motif is an important 
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region of the third intracellular loop of G-protein coupled receptors (GPCRs), and enables coupling 
of G-proteins7. In C5L2, the DLC sequence of the third intracellular loop appears to be 
evolutionarily linked to the conserved DRY sequence of other GPCRs. In support of this 
conclusion, mutating the leucine residue of the DLC sequence to an arginine has been shown to 
promote intracellular calcium release in C5L2-transfected RBL cells8. There is also an apparent lack 
of an NPXXY motif, which has previously been demonstrated to be essential for phospholipase C 
and mitogen activated protein kinase activation in formyl peptide receptor signalling, a group of 
phylogenetically related proteins9. In addition C5L2 has a shortened third, typically G-protein 
binding, intracellular loop (figure 1.5.1). These differences have all contributed to the original 
prevailing hypothesis that C5L2 is a non-signalling, decoy receptor2. 
 
On the extracellular domains, C5L2 has a similar pattern of tyrosine and acidic N-terminal residues 
to C5aR, which have been shown to be a major feature of extracellular binding of C5a10. C5L2 also 
shares similarities with C5aR in the number of charged and hydrophobic residues in the loops and 
transmembrane regions, which are involved in interaction with the C-terminus of C5a11. 
Specifically, there is conservation of tyrosine residues 10 and 13 at the N-terminus, which have 
been shown to be critical for C5a binding by C5aR2. However, mutation of these residues in C5L2 
diminishes the affinity for C5adesArg, but not C5a10. Affinity for C5a is reduced in the presence of 
Figure 1.5.1: Amino acid sequence alignment C5L2. Human (top), 
mouse (middle) and rat (bottom) were aligned using ClustalW2 (European 
Bioinformatics Institute). Transmembrane regions (TM), intracellular (IC) 
and extracellular (EC) loops are annotated. * indicates conserved residues. 
Regions identified as important for G- protein coupling in other GPCRs, 
but mutated in C5L2, are annotated as # (DRY region) and ## (NPXXY 
region). Numbers on the left indicate the residue number. 
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mutations to aspartic acid residues 22, 18 and 25, of which D18 was demonstrated to also be of 
importance in C5a-C5aR coupling10. 
  
Expression 
C5L2 is generally seen to be expressed in similar tissue and cellular locations to C5aR, in 
agreement with their adjacent location on the genome. Currently, there are no known natural cells 
expressing just one of the two receptors - for whatever reason(s), they are natively expressed in 
tandem.  The expression of C5L2 has been widely demonstrated on inflammatory cells, including 
neutrophils, immature dendritic cells, macrophages, lymphocytes and monocytes3,12. However, 
similar to C5aR, it is also expressed on some non-immune cell types such as adipocytes, skin 
fibroblasts, vascular smooth muscle cells, astrocytes, neurons and cells from tissues such as liver, 
heart, lung and spleen3,12-16. This co-expression of C5L2 and C5aR suggested an functional link 
between the receptors and seemed to give weight to the ‘decoy receptor’ hypothesis of C5L2 
function – where C5L2 functionality depends on the presence of C5aR. However, recent non-
overlapping expression of these receptors has been demonstrated in the diseased nephron17, 
indicating differences in the key promotors of expression for C5aR and C5L2.  
 
In relation to the localization of C5L2 within a cell, although C5aR is predominantly expressed on 
the cell surface expression, in line with the majority of GPCRs; C5L2 appears to be expressed 
predominantly intracellularly. Using ligand-binding and flow-cytometric analyses, transfected RBL 
cells have been demonstrated to have lower C5L2 cell surface expression when compared to C5aR2. 
In this model, used extensively for the investigation of C5aR/C5L2 function, C5L2 is abundantly 
expressed on intracellular vesicles2. In relation to primary cells, human neutrophils also display a 
predominant intracellular localisation under both normal conditions and stimulation with C5a18. 
Indeed, C5L2 was demonstrated, presumably due to its intracellular location, not to take part in the 
binding of C5a by human neutrophils18. Our laboratory has also demonstrated isolated mouse 
peritoneal macrophages, human THP1 monocytic cells, and isolated human peripheral blood 
monocytes all show major intracellular expression of C5L2 (figure 1.5.2). This is in direct contrast 
to the prevailing, and now well-accepted view, for cell-surface expression of C5aR in these same 
cells (figure 1.5.2). The intracellular localisation of C5L2 is now well established, and could have 
ramifications for the perceived function of the receptor. However, whether C5L2 remains 
intracellular between all cell-types and disease states is unknown and could potentially explain 
some of the disputed functional charecteristics. Indeed, in rat C5L2-transfected HeLa cells, the 
expression appears to be predominantly cell-surface by confocal microscopy13, lending weight to 
this hypothesis. 
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The regulation of C5L2 protein expression has been demonstrated to be related to C5a stimulation. 
It has been shown that C5a decreases C5L2 protein in rat polymorphonuclear cell lysates during 
sepsis19. This control of expression is likely a direct product of the C5a-C5L2 axis, as the presence 
or absence, of C5aR appears to have little influence on expression of C5L219. In support of this, no 
significant changes in C5L2 expression have been found between wild type and C5aR-/- mouse 
neutrophils20. Another important regulator of C5L2 expression is the gram-negative bacterial cell 
coat component, lipopolysaccaride (LPS). LPS is a potent ligand for Toll-like receptor 4 (TLR4). 
that is of considerable interest to complementologists for its potential signalling interactions with 
C5aR21. In PBMCs, LPS has been demonstrated to increase C5aR-mediated responsiveness to C5a 
via the downregulation of C5L2 expression22.  
Figure 1.5.2: C5L2 is expressed intracellularly in human and mouse mononuclear cells. Intracellular and surface expression 
of C5aR and C5L2 were visualised using standard immunofluorescent methods in (A) isolated mouse peritoneal macrophages, (B) 
human monocytes, and (C) human acute monocytic leukaemia cells (THP-1 cells), adhered to coverslips. Cells in panel A were 
incubated overnight (4°C) with rabbit anti-mouse C5L2 (1:500 dilution, gifted from P. Monk) and rat anti-mouse C5aR (Clone 
10/92, 1:100 dilution, Serotech), with a permeabilisation step (0.25% Triton X-100) prior to primary antibody addition. Cells in 
panels B and C were incubated with mouse anti-human C5L2 (clone 4C8, 1:500 dilution, gifted by C. Mackay) and mouse anti 
human C5aR (clone S5/1, 1:500 dilution, Hycult) either with, or without, a permeabilisation step. Cells were then incubated with 
appropiate fluorescent secondary antibodies (Alexafluor, Invitrogen), and nuclear stained with DAPI (panel A and C), and 
Alexafluor 688-conjugated phalloidin (F-actin, Invitrogen; panel A). These images demonstrate that whilst C5aR is localised 
predominantly on the cell surface, C5L2 is predominantly localised intracellularly in all cell types. Panels A and C were imaged at 
100x magnification using confocal microscopy. Panel B was imaged at 40x magnification using standard epifluoresence. 
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The upregulation of C5L2 expression is regulated by factors such as IFN-γ, noradrenaline, 
dibutyryl-cAMP insulin, and thiazolidinedione in various cell types6,15,23,24. In addition, C5L2 
expression also appears to be dependent on the activity of sphingosine kinase 1(Sphk1), an enzyme 
responsible for generating the signalling lipid, sphingosine-1-phosphate (S1P), which is a key 
mediator in phagocyte function25-27. Mice deficient in Sphk1 have reduced C5L2 expression when 
compared to wild type mice on the same background, and have no macrophage Erk1/2 
phosphorylation in response to C5a. The authors postulated that inflammatory cytokines and C5a 
activate Sphk1, which can generate S1P during inflammation. S1P then increases expression of 
C5L2 to negatively regulate inflammation28. Oestrogen receptor agonists also increase C5aR 
mRNA expression, whereas the regulation of C5L2 is dependent on the type of agonist. Oestrodiol 
increased C5L2 expression, whereas a selective pharmacological agonist of the oestrogen receptor 
alpha agonist resulted in the downregulation of C5L2 mRNA29.  
 
Molecular function 
 
The physiological role of C5L2 is still both enigmatic and controversial; three conflicting 
observations about the function of C5L2 have been presented since its discovery in 2000. Two 
hypotheses describe an anti-inflammatory role for C5L2 in the immune system18,30, whereas a third 
provides evidence for C5L2 acting as a pro-inflammatory entity, triggering release of cytokines 
such as the damage-associated protein HMGB120. These activities seem mutually exclusive, 
however, we believe that not only is this not necessarily so, but quite apposite. The evidence for 
each of the postulated functions is described below and summarized in figure 1.5.3. 
 
 
Anti-inflammatory role as a recycling decoy receptor 
The decoy receptor model for C5L2 was initially described, based on the lack of structural motifs 
known to participate in G-protein coupling4,8. However, Scola and colleagues in 2009 provided the 
first physical evidence for this model in transfected CHO, HL-60, Hela and RBL cells30. The 
authors noted, C5L2-mediated, clathrin-dependent internalization of C5a and C5a des Arg in 
differentiated HL-60 and HeLa cells. This effect was not inhibited by a C5aR antagonist, strongly 
suggesting that ligand degradation occurs after uptake by C5L2. Using human PMNs, C5L2 was 
confirmed to be the main receptor of C5a-desArg. Their experiments suggested C5L2 functioned by 
removing active complement fragments from the extracellular environment, preventing C5aR 
activation30. In this model, the binding of C5a to C5L2 induces internalisation of the complex and 
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endosomal degradation of C5a; C5L2 is then returned to the cell surface. The anti-inflammatory 
actions of this model depend upon C5L2 sequestering the available C5a (and C5adesArg) to prevent 
the pro-inflammatory interaction between C5a and C5aR. 
     
 
Anti-inflammatory role via beta-arrestin pathway 
Bamberg and colleagues developed another anti-inflammatory model of C5L2 function, whereby 
C5L2 complexes with beta arrestin to negatively regulate inflammation. Whilst, antibody blockade 
of C5L2 induced an increased level of C5a-mediated chemotaxis and ERK1/2 phosphorylation, 
there was no influence on ligand uptake or C5aR endocytosis in human PMNs. This result contrasts 
with the previous hypothesis that C5L2 acts as a decoy receptor. Bamberg and colleagues (2010) 
demonstrated that C5L2 functions independently of calcium mobilisation, and inhibits the C5aR-
mediated response to C5a through interactions with β-arrestin18. It was proposed that binding of 
C5a to C5aR activates intracellular C5L2 and triggers phosphorylation of both receptors by G-
protein receptor kinases (GRK), facilitating their association with β-arrestin. The C5aR-β-arrestin 
complex activates ERK1/2, but the C5L2-β-arrestin complex results in ERK1/2 inhibition. The net 
signal is determined by the summation of the two competing pathways18.  
 
The evidence for this hypothesis is supported by the intracellular localisation of C5L2. Bamberg 
and colleagues used human PMNs to demonstrate a contrasting expression pattern for C5aR and 
C5L2; C5aR is localised to the cell membrane, whereas C5L2 is expressed predominently 
intracellularly. Indeed, in the transfected RBL and CHO cells used to support the decoy receptor 
hypothesis, the majority of C5L2 appears peri-nuclear, which remains unexplained in the ‘decoy 
receptor’ model30. C5aR and C5L2 were also demonstrated to colocalise after administration of 
C5a. However the investigators used a high dose of C5a (100nM) to induce co-localisation, despite 
demonstrating that C5L2 negatively regulates C5a induced ERK1/2 phosphorylation at 1nM. This is 
an important discrepancy to highlight as the investigators rely heavily on co-localisation of 
C5aR/C5L2/β-arrestin to support their hypothesis. Other studies have also investigated C5L2/β-
arrestin co-localisation in different cell types with contrasting results, suggesting that this 
hypothesis may not be globally applicable30-32. However, a recent study has supported this 
hypothesis through demonstrating green fluorescent protein-labeled beta-arrestin-2 localisation to 
cytoplasmic vesicles upon stimulation with C5a, demonstrating an EC50 for this effect of 2nM. 
Additionally, these authors demonstrated that the beta-arrestin coupling was independent of any G-
protein coupling33. Although there have been previous non-supportive studies for this hypothesis, 
these studies focussed their attention on beta-arrestin-1, rather than beta-arrestin-230.  
Figure 3: Three conflicting mechanisms for C5L2 function. Each row represents a separate mechanism of 
C5L2 function. Decoy receptor model (Top row); 1. C5L2 binds C5a, preventing C5a-C5aR interaction. 2. 
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Pro-inflammatory role through intracellular signalling, and release of cytokines (IL-6, TNF- and 
HMGB1).  
In direct contrast to both the ‘decoy receptor’ and ‘beta-arrestin’ models of C5L2 function, a pro-
inflammatory function for C5L2 has been postulated. It has been noted by several groups that the 
cytokine expression profile of wild type and C5l2-/- neutrophils differs when exposed to C5a. C5L2 
appears to be the trigger in the C5a induced upregulation of IL-6, TNF-α and complement receptor-
3 in neutrophils13. C5l2-/- neutrophils also demonstrate impaired C3aR/C5aR-induced ERK1/2 and 
Figure 1.5.3: Three conflicting mechanisms for C5L2 function. Each row represents a separate mechanism 
of C5L2 function. Decoy receptor model (Top row); 1. C5L2 binds C5a, preventing C5a-C5aR interaction. 2. 
C5L2 cannot couple G-proteins, no second messenger signalling occurs 3. C5L2 internalises upon binding C5a. 
4. C5 is degrade in intracellular vesicles. 5. C5L2 returns to the cell surface. Beta-arrestin complex (Middle 
row); 1. C5L2 is located intracellularly, C5a binds C5aR at the cell surface. 2. Upon C5a binding a C5aR/G-
protein/C5L2 complex is formed causing phosphorylation of the C-terminus of both receptors. 3. 
Phosphorylation allows beta- arrestin binding. 4. Complex of receptors and beta-arrestin is internalised in early 
recycling endosome. 5. Presence of beta-arrestin prevents MAPK pathway signalling through C5aR. Signalling 
(Bottom row); 1. & 2. C5L2 competes with C5aR for C5a binding. 3. Binding of C5a to C5L2 results in MAPK 
phosphorylation independent of C5aR action. 4. MAPK pathway signals through unknown mechanism to the 
nucleus. 5. Signalling results in HMGB1 release from nucleus. The top two rows, Decoy receptor and Beta-
arrestin, are hypothesised to be anti-inflammatory in action. Whereas, the bottom row, Signalling, is 
hypothesised to be proinflammatory in action. 
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AKT activation, suggesting that C5L2 is a positive modulator for both C5a- and C3a-induced 
responses12.Perhaps the most compelling evidence of a pro-inflammatory function for C5L2 comes 
from the caecal-ligation and puncture model of sepsis. C5l2-/- mice had reduced mortality when 
compared to wild-type littermates, and significantly reduced plasma inflammatory cytokine 
concentrations20. The function of C5L2 in this system was postulated to be as a trigger for the 
release of cytokines, including transcription factor and pro-inflammatory mediator HMGB1, from 
circulating leukocytes. Rittirsch and colleagues used inhibitors of MEK1/2, JNK1/2 and p38 to 
attenuate the release of HMGB1 in peritoneal macrophages20. In contrast to the ‘beta-arrestin’ 
model of C5L2 activity, these data suggest that the release of HMGB1 via C5L2 signalling is 
dependent on MAPK activity, an intriguing finding given that C5L2 lacks the traditional 
intracellular moieties that permit G-protein coupling. In addition, the HMGB1 release in C5L2-/- 
macrophages was also attenuated when stimulated with LPS, indicating LPS signaling via Toll-like 
receptor 4 (Trl4) depends on the integrity of C5L2. In addition, deficiency of C5l2 leads to a 
reduced inflammatory cell infiltration in vivo and C5a-induced downstream signalling in cells. C3a-
induced signalling and F-actin formation were reduced in C5l2-/- cells. Also, defective in vivo 
inflammatory responses and haematopoietic cell regeneration in c5l2-/- mice were reported12. Other 
observations also support a proinflammatory function for C5L2, for instance, C5L2-deficient mice 
are protected from the development of airway hyperresponsiveness mucus production in two 
models of experimental allergic asthma34.  
 
This seemingly proinflammatory role for C5L2 is contradictory to the observations in C5L2 
knockout mice, where the biological activity of the C5a/C5aR axis is enhanced both in vivo and in 
vitro. In studies in non-disease models, the biological role of C5L2 thus appears to be limiting to the 
pro-inflammatory response to the anaphylatoxin. Other studies demonstrate that up-regulation of 
C5L2 may be of benefit in inflammatory states driven by C5a, including sepsis, asthma, cystic 
fibrosis, and chronic obstructive lung disease35. Deficiency of C5L2 results in reduced 
inflammatory cell infiltration, suggesting that C5L2 is critical for optimal C5a-mediated cell 
infiltration in certain in vivo settings. Furthermore, like mice incapable of C3a/complement 3a 
receptor (C3aR) signalling, C5L2-deficient mice are hypersensitive to LPS-induced septic shock, 
show reduced ovalbumin (OVA)-induced airway hyper-responsiveness and inflammation, and are 
mildly delayed in haematopoietic cell regeneration after gamma-irradiation12. 
 
Therefore, the question remains, how to integrate these seemingly conflicting observations to 
develop a complete understanding of C5L2. At least in part, some answers may lay in the various 
models used to investigate the function of this protein (which may indeed be central to the lack of 
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consensus surrounding the function(s) of C5L2). The models using transfected CHO and RBL cell 
lines to investigate C5L2 function, although useful for investigating ligand-receptor interactions, 
come with major caveats with regard to function.  For instance, the expression of the putative 
second messenger for C5L2, beta-arrestin2, may be lower or absent from these cell lines.  
 
 
C5L2 physiology and pathophysiology 
 
C5a has been implicated in many diseases such as sepsis36, rheumatoid arthritis37, asthma and 
allergy35,38-40, ischemia-reperfusion injuries41-43, inflammatory bowel disease44-46, atherosclerosis47, 
and neurodegeneration16,48-50. However, many of these studies have focussed on C5aR without 
specifically investigating the role of C5L2. Modulating the actions of C5L2 may yet prove to be a 
useful therapeutic tool. However, the function of C5L2 in disease is still a highly debated topic. The 
function of this receptor, as to whether it attenuates or propagates inflammation, varies between 
disease state and even between cell types in the same disease. 
 
Sepsis 
In mouse models of sepsis blocking C5L2 produced increased levels of pro-inflammatory 
mediators, IL-6 and TNF-a13. Moreover, rat C5L2 was shown to have anti-inflammatory properties 
as its reduction resulted increased NOS2 and kB gene expression15.  In addition, a higher level of 
C5L2 in PMNs from sepsis patients who survived was found in comparison to non-survivors, a 
finding which appears to cement an anti-inflammatory role for C5L2 in sepsis19. However, there is 
evidence that the organ dysfunction associated with sepsis may be mediated, in part, through C5L2. 
In rats 24 hrs after CLP there is significant apoptosis of adrenomedullary cells, as assessed by the 
TUNEL technique. These effects were reversed by dual-blockade of the C5a receptors, C5aR and 
C5L2, however the authors did not attempt blockade of each receptor independantly51. Since 
blockade of both C5a receptors abolished adrenomedullary apoptosis in vivo, it was suggested that 
C5aR and C5L2 may be promising pharmacological targets in the clinical setting of sepsis. 
Although, such targetting of C5L2 may exacerbate the other sequalae of sepsis that C5L2 has been 
demonstrated to mitigate. 
 
To add to the confusion of the specific role for C5L2 in sepsis, there is the observation that C5L2 
knockout mice have increased survival in mid-grade sepsis20. This series of experiments 
demonstrated that C5L2 was required for release of the pro-inflammatory mediator, HMGB1, in the 
presence of both C5a and LPS. In addition, HMGB1 release from C5aR-/- macrophages was 
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diminished in the presence of inhibitors to MEK1/2, JNK1/2 and Akt, indicating that C5L2 is 
involved in intracellular signal transduction in this model. However, in high-grade sepsis only the 
blockade of signalling from both C5aR and C5L2 improved survival, perhaps suggesting that the 
severity of the disease affects the functions of C5L2. 
 
Metabolism 
C5L2 knockout mice demonstrate insulin resistance and high pro-inflammatory serum cytokines 
when placed on a high fat/high sucrose diet52. There is some evidence that this diabetogenic 
phenotype is the result of a disrupted interaction between C5L2 and acetylation-stimulating protein 
(ASP), which is also known as C3a-desArg, the breakdown product of C3a. The ASP/C5L2 
interaction may induce adipocyte differentiation and it is suggested that the downregulation of 
C5L2 in adipocytes contributes to insulin resistance. Interestingly, progesterone has been 
demonstrated to downregulate C5L2 in both mature adipocytes and preadipocytes, providing and 
interesting angle for research into gestational diabetes53. In these studies C5L2 has been reported to 
have a high binding affinity for both human and mouse C5L2 (kd 118 and 31nM, respectively), 
however this direct interaction has been disputed by other groups that have been unable to 
demonstrate any interaction between C5L2 and ASP5,6.  
 
Despite the controversy over the putative interaction between C5L2 and ASP, both proteins have 
been demonstrated to effect metabolism at the level of the central nervous system. Both C5L2 and 
C5aR are present in the anterior pituitary gland and C5a was demonstrated to stimulate 
adrenocorticotropic hormone release, however whether this effect is through C5aR or C5L2 is 
unclear54. In addition, administration of ASP into the third ventricle promotes an anorexogenic state 
through modulation of neuropeptide Y and pro-opiomelanocortin expression55. 
 
Asthma 
Although C5aR has previously been demonstrated to promote the development of asthma39, little 
attention has been given to C5L2. However, Zhang and colleagues (2010) show that C5L2 knockout 
mice are protected from the development of allergic asthma34. This protection was determined to be 
due to C5L2 expression on dendritic cells promoting the inflammatory T-cell phenotype of asthma. 
Interestingly, the altered cytokine production of C5L2 dendritic cells was also present in vitro when 
cells were stimulated with house dust mite allergen, suggesting that the role of C5L2 in this model 
may not be through the direct binding of C5a. Rather, C5L2 may act as a modulator of other pattern 
recognition receptors to promote the asthma phenotype. 
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Conclusion and future therapeutic perspectives 
 
The actions of C5L2 in health and disease is not only far from conclusive, the field is in 
considerable and seemingly paralysed disarray. In contrast to the well-documented, global pro-
inflammatory role for C5aR, relentlessly emerging evidence strongly indicates that the situation for 
C5L2 is much more complex, or at the very least, bewildering. There may be no such thing as a 
unifying theory for C5L2 function, and its role in various contrived experimental, and clinical 
situations; indeed, there is no reason, a priori, to so suppose.  Three separate models of C5L2 
receptor function in complement biology currently exist; two anti-inflammatory models and one 
proinflammatory model. Indeed, the three models of C5L2 function need not be mutually exclusive; 
all three rely upon evidence gathered from separate species, cell types, and experimental models. 
The anti-inflammatory models of C5L2 function have been originally based on observations made 
without immune challenge, whereas the proinflammatory hypothesis has its major genesis in 
observations of C5L2 function in septic animals. In addition, the original observation regarding the 
lack of G-protein coupling motifs is not unprecedented, for in recent years other GPCR-classed 
receptors have been found to signal via pathways other than coupling G-proteins such as β2-
adrenergic and AT1a receptors56. C5L2 may turn out to be the great masquerader of complement-
mediated inflammology, its function dependent on the cell type or disease present. 
 
Based on the multifarious described roles for C5L2, the therapeutic targeting of C5L2 (be it for 
activation or inhibition), becomes a more difficult endeavour. We have to realise the proper 
functional role of C5L2 in host immunity and disease pathology before rationally targeting it for 
future clinical treatment. If C5L2 has an anti-inflammatory role, increasing its expression or activity 
may be beneficial. However, if it plays a pro-inflammatory role, such as suggested in sepsis, then 
specific C5L2 inhibitors or antibodies may bring benefits. Perhaps it has all these roles in some 
situations: perhaps it has some of these roles in all situations.   
 
To date, there is no selective activator of C5L2 available, although recent preliminary findings with 
our collaborating researchers have identified potential selective C5L2 activating peptides57, which 
are currently under further investigation in our laboratories. Polyclonal20 and monoclonal18 
antibodies have been developed to target mouse and human C5L2 respectively. In addition, the C5a 
mutant A8Delta71-73, originally reported as an inhibitor of C5aR, is also known to inhibit C5L258. 
At the pharmacological level, C5L2 is also a difficult receptor to target using classical methods, the 
intracellular location of C5L2 means that ligand access is diminished. The lack of G-protein 
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coupling, clearly defined signalling and consequences of activation also make C5L2 therapeutic 
screening a challenge. In addition, C5L2 may also be functionally dependent on other receptors, 
meaning that therapeutics developed from transfected cell lines may not translate well into the 
clinical scenario. 
 
Quo vadis. The puzzle with C5L2 is not that it cannot be effectively studied, but rather that it can 
be, and has been, for more than a decade, with the full armamentarium of the tools of modern 
biology, at every level of investigation- molecular, cellular, tissue and whole animal.  The puzzle is, 
that it is still such a puzzle. Unlike the classical receptor for C5a, C5aR, which is both historically 
and universally acknowledged to be of a proinflammatory bent, the specious nature of C5L2 has 
engendered confusion within the community of adepts.  This quagmire leads us to propose the 
following scenario:  it will remain the proverbial riddle for the proverbial near future, but the 
reasons for this are neither complex, nor controversial.  There have been many reports now, from 
many reputable complement laboratories, on C5L2:  it can be reasonably said that there are diverse 
views and that these are sometimes seemingly contradictory, but this is not so unusual, nor so 
unexpected. But, is this normally the case for a single discrete receptor, especially in light of its 
hugely-studied cognate primary receptor, the latter for which there is little disagreement as to its 
fundamental raison d'être?  No, it is not; C5L2 seems different in this way. Pharmacologically, 
single receptors have clearly restricted, and somewhat ideologically comforting functions, albeit 
with varying degrees of cellular expressions or locales:  C5L2 is apparently breaking free from this 
ideology. How can one receptor do obverse things in diverse cells or diverse systems?  Because it 
can- or, because it must?    
 
Perhaps we can offer a conciliatory viewpoint for C5L2.  It is a strange receptor, in that its 
behaviour seems so different when studied by different groups in different systems at different 
times.  But, perhaps, this is indeed the reality, and our simple minds seek a simple explanation, 
which is simply not yet available. Or, perhaps it is the Janus receptor, the ultimate masquerader at 
the complement ball, there to confuse and taunt us to a new level of understanding.  Certainly, it is 
quite unlikely to have evolved for this reason, so the challenge for us is now clear.  We need to 
clean up this mess-possibly of our own making, and resulting from our limitations- and resolve 
whether the situation is more complex than we allow, or whether we are merely asking the wrong 
questions.  Neither situation carries with it a mutual exclusivity, but nor does it offer a clear set of 
experiments to solve our dilemma. Rarely has the function of a receptor been so troublesome, and it 
is especially galling is that it is happening now, when we have so many technically sophisticated 
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investigative tools to employ in our quest to comprehend.  This is the both our conundrum and our 
dilemma.  Complement is never easy, and C5L2 has made it less easy.        
 
The situation is truly more complicated than we are used to, for we have been led astray by the boss 
receptor for C5a, with its relatively simplistic and easily comprehensible functions, so that we feel 
dismayed and confused that there is no similarly easy nor shining path for clarifying the proper 
place of this infuriating mole receptor. We are used to receptors (like C5aR) having stupefyingly 
clear roles in multiple systems, and we are disappointed if new receptors like C5L2 do not fall into 
our little boxes, because it is all so new and we are not mentally prepared for the new. Is this 
because it is a rogue mutated GPCR that is no longer coupled to G proteins for signal transduction? 
Has this then skewed its function over evolutionary time in all the various cells and species so that 
we now are all at sea in our primitive attempts to unravel its place in complement biology? Perhaps 
so, or even, probably, more so. Uncomfortably, we do not know, for we have been caught 
unawares, and we have now not the mentation, or perhaps force-of-will, to proceed clearly apace in 
any given direction. We need a new and fresh perspective; one that does not easily gather at cosy 
international meetings. 
 
The case now seems to us to be this. C5L2 may indeed have many different roles and functions in 
many different systems, cells, tissues, organs and/or species. This is an uncomfortable place to 
inhabit, for this will make it difficult to do both predictable or predictive research, and to reach an 
enabling consensus about C5L2 in the foreseeable future.  So rarely is the challenge so clear, or so 
great, by a new ligand-binding site for C5a (dare we yet call it a receptor without clear agreement as 
to its signalling properties?). However, we seem to agree that all the signs are that C5L2 is an 
important player in C5a biology, and the portents are that agents modulating C5L2 receptors may 
well have therapeutic carry: we just can’t say what right now these agents are-or may be, nor what 
utility they may have.  Agonists, maybe; antagonists, perhaps- these are the challenges, both 
proximal and distal:  they are multifarious and guidance will neither come soon, nor easily, but we 
believe the area to be both intrinsically interesting and worthy of pursuit, and it could well reap 
clinical dividends in the not-so-soon future. The place of C5L2 in complement pathophysiology is 
yet to be unravelled from its tangled skein, but it certainly seems a worthy and challenging target at 
which to aim, if we have a renewed force of clear and determined intent, to not be defeated by this 
arriviste.              
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Abstract 
 
The complement activation product, C3a, is often described as a pro-inflammatory mediator, 
alongside its downstream cousin, C5a. However, this description may be misleading and too 
simplistic to encapsulate the true functions of this so-called anaphylatoxin, in health and disease. 
Recent, and emerging studies have shown that C3a has several anti-inflammatory facets in vivo. For 
example, in the acute inflammatory response, C3a appears to act in direct opposition to C5a, though 
via different receptors. C3a is a functional or physiological antagonist of C5a, in these 
circumstances, where C3a prevents the accumulation of neutrophils in inflamed tissues by 
independently regulating bone-marrow mobilization of inflammatory cells. This acute, protective, 
and opposing activity of C3a to C5a is also illustrated in models of endotoxic shock and bacteremia. 
These studies at the whole animal level have demonstrated a more complicated and multifaceted 
picture of C3a biology than has previously been seen in vitro. Here, we briefly reinvestigate the 
discovery and original classification of C3a as a pro-inflammatory mediator; this has inadvertently 
entrenched a simplistic view, and in our opinion, wrongly so, of the roles of this molecule. We then 
highlight the emerging studies demonstrating anti-inflammatory effects for C3a in the immune 
response, with a particular focus on the in vivo environment in acute disease models. It is our hope 
this review will illuminate these apparently contradictory roles for C3a in responding to immune 
insult, and challenge the general dogma surrounding C3a, which, historically, is ubiquitously 
described as a pro-inflammatory mediator. 
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Introduction 
The complement cascade is a key component of the immune system, and is essential in providing a 
balanced response to injury and infection. Complement can be activated through multiple initiating 
pathways, but all routes will lead to the cleavage of the central complement components C3 and C5 
to generate the small bioactive fragments C3a and C5a1. Both C3a and C5a are frequently and 
consistently described in the literature as ‘pro-inflammatory mediators’, despite a limited number of 
reports of true pro-inflammatory activity for C3a in vivo. Furthermore, many reports in fact 
demonstrate an anti-inflammatory role for this major complement cleavage product in infection and 
disease. To add to the confusion, the only in vivo C3a receptor (C3aR) ‘antagonist’ (SB290157), 
which is frequently used in research reports, has been demonstrated to act as a partial agonist2, thus 
clouding interpretations of results in disease models where the agent has been used 3. We wish to 
use this review to draw much-needed attention to the potential anti-inflammatory roles of C3a, so as 
to refocus the discussion on its revised position in the immune response, allowing new strategies for 
therapeutic targeting of C3a.  
 
Whilst the modern literature surrounding C3a and C5a frequently describe divergent functions for 
these peptides, their discovery and characterisation may explain why they are so often portrayed 
together as pro-inflammatory mediators. Through the work of Hans Buchner, Jules Bordet and Paul 
Ehrlich in the late 19th century it was shown that serum contained both a heat-labile and a heat-
stable bacteriocidal element. The heat stable element, in immunised animals, was later 
demonstrated to be antibody, whereas the heat labile element was termed complement by Ehrlich, 
as it ‘complemented’ the antibody response. The anaphylatoxins were discovered through 
incubation of serum with antigen-antibody complexes, thus activating the classical pathway, and 
named for their histamine-releasing ability4. Although unconfirmed at the time, the origin of the 
anaphylatoxin activity was suspected to be complement due to its heat-labile nature5. This 
anaphylatoxin activity was finally ascribed to complement split products with the identification of 
multiple serum components of complement and the purification of C3a and C5a in the late 1960’s. 
Initial experiments demonstrated that the release of the elusive anaphylatoxin was dependent on the 
presence of the initiating factors of the complement cascade and that the anaphylatoxin was released 
at, or shortly after, the involvement of C36. With purification, both C3a and C5a were shown to 
induce smooth muscle contraction through release of histamine in a mutually redundant manner, 
both having similar ‘activity’ at the guinea pig ileum7,8. This led to the adoption of the term 
‘complement anaphylatoxin’ for these peptides, although this label has been challenged recently9 as 
it does not encompass their widespread functions. 
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C3a Generation, Structure and Signalling 
Cleavage of C3 results in the formation of two split products, C3a and C3b. C3a is generated at the 
convergence of all known complement activation pathways and its sibling at the point of cleavage, 
C3b, continues the propagation of the complement cascade10. Classically, cleavage of C3 results 
from the action of one of the C3 convertases, which are multi-protein complexes formed from the 
upstream cleavage events of complement activation. Additionally, C3 can be cleaved by multiple 
serine proteases present at sites of inflammation, most notably blood proteases such as thrombin, 
and immune cell-derived proteases such as cathepsin 11-13.  
 
Structurally, C3a is a 77-amino acid peptide consisting of three helical regions and a series of non-
regular residues at the C-terminal responsible for binding at C3aR14,15. Short portions of the C-
terminus have been demonstrated to be necessary both for agonist activity at C3aR, and intrinsic 
antimicrobial activity 15-19. The activity at C3aR of the terminal residues in isolation is far lower 
than that of the native molecule and there is evidence that these flexible C-terminal residues are 
stabilized in the conformation necessary to bind C3aR by the upstream alpha helix 20. This C-
terminal region of C3a has hence been a nidus for drug design research, both in terms of therapies 
capable of modulating C3aR activity and those that take advantage of the intrinsic antimicrobial 
abilities of the molecule 16,21-23.   
 
After its generation, C3a is cleaved quickly at the C-terminal arginine to form C3a-desArg. This 
molecule has no detectable activity at C3aR 24, but has been shown by some groups to bind the 
second receptor for C5a, C5aR2 (C5L2) 25,26. The interactions with C5aR2 been shown to have 
effects on metabolism and in this sphere C3adesArg is also homologous to acetylation-stimulating 
protein (ASP). There is now much interest in the ASP-C5aR2 interaction, which appears to regulate 
metabolism at both the central nervous system (CNS) and adipose tissue levels27,28.  
 
This review focuses on the interaction of C3a with its canonical receptor C3aR. However it should 
be noted that there are additional factors emerging in the literature that also intersect with the C3a-
axis (detailed below and summarized in Figure 1.6.1). C3aR is a classical 7-transmembrane, G-
protein coupled receptor, which shares close homology to the receptors for C5a, C5aR1 and 
C5aR229. C3aR binds C3a through a proposed ‘two-site’ binding model, consisting of functionally 
different recognition and activation sites30. This is, in essence, very similar to the general model 
reported for C5a acting at C5aR1, which may be expected, owing to the shared evolutionary origins 
of both proteins31. However, unlike C5aR1, the N-terminus of C3aR is not charged and is 
functionally insignificant with regards to C3a binding32. At the C-terminus, C3aR couples to 
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heterotrimeric G-proteins and has demonstrated a promiscuity of G-protein interaction dependent 
on cell type33-36. Intriguingly, the internalization and recycling of C3aR, which is dependent on 
GRK mediated receptor phosphorylation, is inhibited by the presence of C5a in human 
granulocytes37,38. Studies in this area were perhaps the first reports of functional antagonism 
between C3a and C5a at the molecular level. Until recently, C3a was thought to be the only ligand 
for C3aR, however the neuropeptide TLQP-21, a cleavage fragment of the VGL pro-peptide, has 
been shown to bind and activate murine C3aR through conformational change of the ligand upon 
receptor binding39,40. 
 
Of further note, the actions of C3a need not be mediated solely through its canonical receptor, 
C3aR. For example, there is some evidence of a second, unidentified, receptor, at least in the CNS. 
Using a transgenic mouse expressing a recombinant C3a peptide under the control of the GFAP 
promoter, Boos and colleagues demonstrated that elevated CNS C3a worsened outcomes in 
experimental autoimmune encephalitis (EAE)41. Accordingly, in animals that lacked C3aR the 
disease outcomes were improved. However, C3ar1-/- animals with ectopic C3a expression 
Figure 1.6.1: Diagrammatic representation of receptor-ligand interactions surrounding C3a. C3a, generated 
from complement pathway activation interacts with its canonical receptor, C3aR, and the receptor for advanced 
glycosylation end-products (RAGE). Functional interaction with RAGE is dependent on formation of a C3a-CpG 
oligonucleotide (oligo) complex. The VGF cleavage product, TLQP-21, is also a ligand of C3aR. The terminal 
arginine of C3a is cleaved by serum carboxypeptidases (CPase) to form C3adesArg, which is homologous to acetylation-
stimulating protein (ASP). C3adesArg may bind and signal through one of the receptors for C5a, C5aR2. 
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demonstrated significantly better clinical outcomes than C3ar1-/- animals alone, suggesting that the 
actions of C3a in CNS disease may not be confined solely to its interaction with C3aR. This finding 
was corroborated in a second paper demonstrating a protective effect for CNS C3a expression in 
LPS-induced endotoxic shock, that was not diminished in the absence of C3aR42. 
 
Similarly, C3a has also been shown to bind to the receptor for advanced glycosylation end-products 
(RAGE) with a high affinity, but this interaction is more complex than a simple ligand-receptor 
interaction43,44. RAGE is a promiscuous receptor that primarily recognizes a plethora of molecules 
associated with cellular damage45. Ruan and colleagues (2010) demonstrated that C3a is able to 
form a complex with CpG oligonucleotides to enhance IFN-α release from mononuclear leukocytes. 
Intriguingly, there is as yet no demonstrable effect of a C3a-RAGE interaction alone, despite strong 
and specific binding between the two43. 
 
C3a Activity on Immune Cells 
C3aR is expressed by all leukocytes of myeloid (and several non-myeloid) lineages, however the 
functional characteristics of the receptor, and the response to C3a, are dependent on cell type. In the 
past few decades the literature concerning C3a and its actions at the cellular level has demonstrated 
a ‘bipolar’ role for this molecule in different immune cell types. For example, despite a canonical 
pro-inflammatory histamine degranulation response for C3a on mast cells46, our laboratory has 
recently shown a potent anti-inflammatory response for C3a on neutrophils, by attenuating their 
mobilization into the circulation following injury47,48. Uninhibited mobilization can lead to an 
increase in neutrophil numbers at the site of injury, which can significantly worsen disease 
progression. Figure 2 summarizes the opposing actions of C3a on different immune cell 
populations, which are detailed further below. 
 
The reports on the function of C3a on neutrophils are complicated in the literature, owing to the 
difficulty in the past of obtaining pure neutrophil cell isolates. Indeed, many of the earliest reports 
indicating that C3a induced neutrophil activation, were later refuted due to contamination with non-
neutrophil granulocytes49. What is now clear, is that despite high expression of functional cell-
surface C3aR on neutrophils, C3a does not chemo-attract, or stimulate degranulation of neutrophils, 
despite inducing downstream signalling through Erk1/2 and Akt 49,50. Interestingly, the signaling 
produced by C3a stimulation of neutrophils was shown to be dependent on the presence of C5aR2, 
suggesting that C5aR2 may contribute to C3a signaling through interactions with C3aR50. Any 
chemotactic or degranulating activity previously ascribed to C3a action on neutrophils was 
suggested to be a byproduct of eosinophil or basophil contamination of the cultures, leading to the 
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release of secondary factors causing the observed effect49. However, our recent studies indicate that 
at the level of the bone marrow, C3a prevents migration of neutrophils into the circulation by acting 
in direct opposition to neutrophil mobilizing factors such as granulocyte colony stimulating factor 
(G-CSF), in a manner reminiscent of stromal derived factor-1 (SDF-1)47.  
 
C3a and C3adesArg can also induce signalling in human monocytes and monocyte-derived 
macrophages, however, this interaction, with TLR-4 co-stimulation, induces the production of pro-
inflammatory mediators such as IL-1β, TNF-α, IL-6 and PGE2 34, 51-56. This suggests that in the 
chronic phase of inflammation where monocyte/macrophage responses become more predominant 
over neutrophils, C3a may indeed act as a classical pro-inflammatory mediator; this view is 
supported by evidence that C3ar1-/- animals have modest pathology reductions in chronic disease 
models such as rheumatoid arthritis57. Interestingly, by contrast to the effects of C3a on purified 
monocytes56, in vitro investigations into the effects of C3a on LPS-induced cytokine release by 
peripheral blood mononuclear cells (PBMCs; a pooled mixture of monocytes and lymphocytes) 
demonstrate differences in action depending on the type of the cell. C3a augmented the 
proinflammatory cytokine production of adherent cells, but suppressed that of non-adherent cells52. 
Depending on the adhesive state of cells, C3a and C3adesArg suppressed TNF-α, IL-1β and IL-6 
synthesis in lipopolysaccharide (LPS)-primed non-adherent peripheral blood mononuclear cells 
(PBMCs) and B lymphocytes, and enhanced their synthesis in adherent cell systems52,53,58.  
 
Interestingly, despite a marked lack of degranulation effect of C3a on neutrophilic granulocytes, in 
other granulocytes, C3a induced a degranulation response. For example, in human eosinophils, C3a 
induces calcium mobilisation, oxidative burst and degranulation59,60, and in mast cells, C3a and 
C3adesArg can induce histamine secretion in a dose-related fashion61,62 63. This eosinophil and mast 
cell-specificity has highlighted C3aR as a drug-target candidate for allergic conditions. Such 
inferences have been strengthened through observations that C3ar1-/- animals exhibit reduced 
responses in atopic diseases such as allergic asthma and allergic dermatitis64, again suggesting a 
pro-inflammatory role for C3a in these situations.  
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Administration of C3a has also been demonstrated to augment the T-cell response, promote T-cell 
proliferation and prolong the inflammatory response through suppressing regulatory T-cells (Treg) 
production65-67. Additionally, it has recently been discovered that T-cells generate intracellular C3a 
that contributes to survival68. In support of this, T-cell populations are reduced in C3ar1-/- mice in 
several models of disease65,67,69. Whilst broad T-cell expression of C3aR remains controversial70, T-
cell receptor stimulation upregulates C3aR mRNA expression in isolated T-cell populations and the 
presence of C3aR appears to promote a Th1 response, as measured by the defining cytokine, IFNγ66. 
Figure 1.6.2: Functions of C3a on the cell types of the immune system. Right panel - C3a acts in a pro-
inflammatory manner to: increase cytokine release from lipopolysaccharide(LPS)-primed, adherent peripheral blood 
mononuclear cells (PBMCs); induce degranulation in eosinophils and mast cells; increase inflammatory mediator 
production in macrophages/monocytes; modulate the T-cell response through the suppression of regulatory T cells 
(Treg) and induction of a TH1 polarised reponse. Left panel – C3a acts in an anti-inflammatory manner to: decrease 
cytokine release from LPS-primed, non-adherent PBMCs; Induce direct antimicrobial actions on pathogens; inhibit 
the mobilization of neutrophils from the bone marrow reservoir. 
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This is supported by observations, in vivo, of increased IFNγ production in mice lacking the 
complement-suppressive factor, Daf71. C3aR-signalling also acts in concert with C5aR1-signalling 
to suppress the production of TGF-β1 from dendritic cells, reducing the stimulus for differentiation 
to Treg cells67.  The induced Treg cells heavily suppress the proinflammatory CD4+ T-cell function, 
leading to abrogation of the inflammatory process. In addition, C3aR signaling in the tissue antigen-
presenting cells suppresses IL-4 production, inhibiting a TH2 polarised response72. However this 
effect on T-cell biology is not entirely APC-mediated, as altered Treg responses also occur with 
adoptive transfer of C5ar1-/-/C3ar1-/- T cells into a wild type animal67. C5ar1-/-/C3ar1-/- Treg cells 
also demonstrate prolonged survival and enhanced function, suggesting that C3aR/C5aR1 stimulus 
of T cells is also important in regulating inflammatory responses69. 
 
C3a in Disease 
 
(i) Ischemia-reperfusion injury 
Gut ischemia-reperfusion (IR) injury, through transient occlusion of the mesenteric arterial tree, 
causes an increase in circulating neutrophils upon reperfusion that are critical to the generation and 
promulgation of tissue injury73. Tissue injury also directly activates the complement system leading 
to the generation of the anaphylatoxins, C5a and C3a46. The role for C5a in the progression of this 
pathology is both very well understood and unambiguous; C5a functions at the level of injury to 
cause extravasation and degranulation of the circulating neutrophils74-76. By direct contrast, in a 
model of gut IR we have demonstrated that the role for C3a in this acute pathology is 
overwhelmingly anti-inflammatory47.  Thus, the historical model for C3a as being a “weaker” form 
of C5a as a pro-inflammatory mediator is no longer uncomplicated.    
 
C3a levels in both blood and intestinal tissues increase after a period of ischemia, likely from 
activation of the complement system in response to damage-associated molecular patterns47,77. One 
function of this C3a release, through its interactions with C3aR, is to attenuate the neutrophilia 
associated with injury by confining unmobilized neutrophils to the bone marrow reservoir. Mice 
lacking C3aR have a significantly greater increase in circulating neutrophils post-IR than their wild 
type counterparts47. This correlated with increased neutrophil migration into ischemic tissue and 
worsened histopathological outcomes. The effect of the C3a-C3aR axis in this acute injury also 
appears to be restricted solely to an effect on neutrophils, as circulating levels of other leukocytes 
remained similar to wild type animals. Additionally, the wild-type phenotypic response to IR could 
be fully restored through wild-type bone marrow transfer to C3ar1-/- animals, indicating that the 
anti-inflammatory actions of C3a take place at the level of the bone marrow rather than the site of 
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injury47. Finally, we showed a direct requirement for C3aR to restrict G-CSF mediated neutrophil 
mobilisation from the bone-marrow, in the absence of tissue injury47. 
 
As neutrophils are the major contributing cell type responsible for propagation of the acute 
inflammatory response, this emerging evidence of anti-inflammatory activity for C3a through the 
retention of neutrophils in the bone marrow forms the crux of the thesis for this review: that C3a 
should not be grouped with C5a as a purely pro-inflammatory anaphylatoxin. Indeed, several other 
in vivo studies in the literature demonstrate a more complex role for C3a in disease models, 
particularly in the acute setting.  
 
(ii) Sepsis 
In sepsis, it has previously been noted that elevated C3a and C5a correlated with fatal outcomes in 
hospital patients, but determining cause and effect in these studies is not possible78,79. The 
significant difficulty with research into the effects of the complement anaphylatoxins is that their 
genesis also amplifies the terminal elements of the complement cascade. In the past, without the use 
of knockout mice or specific antagonists, it has been difficult to tease these aspects apart. 
C3 deficient animals have been utilised for investigation of complement-mediated pathogen 
clearance during sepsis, and it has been demonstrated, perhaps unsurprisingly, that the lack of C3 
reduces survival rates and increases pathogen load in experimental models80. It might be expected 
that the increased pathogen load due to the loss of the terminal elements of the complement system, 
(namely C3b opsonisation, C5a-induced activation of leukocytes and membrane attack complex 
lysis of pathogens) explains the premature death of C3 deficient animals. It remains to be seen 
whether the scale of the direct antimicrobial actions of C3a are of sufficient magnitude to contribute 
towards this effect17. However, this concept seems to be supported by demonstration of a protective 
effect for administration of exogenous C3 in septic animals81.  
Attributing the effects of C3 deficiency to an attenuation of complement action is complicated by 
the fact that the presence of C3 is not required for the formation of the terminal elements of the 
complement cascade, as C5 can be cleaved by serum proteases13,82. These proteases are upregulated 
in C3-/- animals, leading to pathophysiologically significant generation of C5a and MAC83. In 
keeping with this, the differences demonstrated in bacterial load between C3-deficient and C3-
supplemented animals do not appear as dramatic as the survival curves suggest 81. It is difficult to 
appreciate in this study whether the bacteriocidal or the C3a-mediated actions of C3 
supplementation contributed to improved sepsis survival, but the initial report using a C3ar1 
knockout mouse included an investigation into sepsis survival, following lipopolysaccharide (LPS) 
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challenge, concluded that C3aR signaling contributed to improved survival84. Additionally, this 
study also demonstrated elevated circulating levels of the pro-inflammatory cytokine IL-1β in the 
C3ar1-/- animals. Further studies by the same group used heat-inactivated Escherichia coli 
administration as a model of gram-negative bacteremic sepsis. This also demonstrated a protective 
effect for C3aR, as C3ar1-/- animals had significantly elevated mortality rates when compared to 
their wild-type counterparts85. C5aR1-/- animals, conversely, were protected from the bacteraemia, 
again demonstrating the divergent roles of the two anaphylatoxins85. 
Although these authors did not include measurements of circulating neutrophils in the LPS- or E. 
coli-challenged animals, the recent studies surrounding the actions of C3a in inflammatory disease 
suggest that a reactive neutrophilia may have been the cause of the reduced survival in the C3ar1-/- 
animals. In support of this, the authors note that the elevated IL-1β previously attributed to high 
C3ar1-/- mortality in the LPS model was unlikely to be the cause of death in bacteremia and instead 
suggested that the role of C3a is to regulate the inflammatory response generated through C5a 
signaling85,86. 
 
(iii) Renal disease 
Several studies have outlined the pathogenic role complement plays in the development of 
autoimmune lupus nephritis; indeed, blockade of C5a signaling can attenuate disease progression in 
mouse models 87. High concentrations of C3aR and C3 are present in the glomeruli, correlating with 
disease severity88, seemingly suggesting a pathophysiological role for the C3a-C3aR axis in this 
disease, and, perhaps, a therapeutic target for treatment of lupus nephritis. It has previously been 
demonstrated that infusion of the C3aR antagonist, SB290157, in the MRL/lpr mouse model of 
lupus nephritis resulted in increased survival and reduced renal inflammation89. However, the same 
mouse model backcrossed with C3aR knockout mice indicates that the loss of C3aR accelerates 
renal injury and increases mortality90. This contradictory result was attributed to the ill-defined 
pharmacological activity of the widely used C3aR antagonist, SB290157, which has been reported 
to have agonist activity upon binding C3aR2. However, although the pharmacology of SB290157 
may be controversial, the conclusion drawn by the authors may now be reinterpreted to take into 
account the acute ‘anti-neutrophil’ effects of C3aR discovered recently47. It is uncontroversial that, 
at least at the level of the nephron, C3aR is involved in the pathogenesis of renal disease, including 
the induction of metaplasia in nephron epithelial cells central to the disease91,92. These actions 
appear synergistic to the role of C5aR1 at the tissue level, but may be redundant in the presence of 
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elevated C5a concentrations, which is much more potent than C3a as a pro-inflammatory mediator 
at the receptor level.  
Contrary to reports of gut IR, there is a slight improvement in disease outcomes for C3ar1-/- animals 
subjected to renal IR injury91.  In this study the authors demonstrated that C3a administered directly 
to renal tubule epithelial cells increased the production of chemotactic factors directing leukocytes 
to the site of injury. Interestingly, a decrease in global leukocytes was demonstrated in the diseased 
C3ar1-/- kidney isolates, as indicated by CD45+ flow cytometry. However, there was no difference 
from wild type mice with regards to granulocyte infiltration, suggesting the dynamics of this model 
may be more complex than presented. Quantification of circulating granulocytes was not recorded 
in this model, but it is tempting to hypothesise that the C3ar1-/- animals exhibited an injury-induced 
neutrophilia, as has previously been reported47, which is tempered by the decreased cytokine 
production at the tissue level, as noted by these authors. This hypothesis could also explain the lack 
of a difference in granulocyte tissue infiltration observed. 
Finally, preliminary work on pyelonephritis also suggests that C3a reduces neutrophil infiltration 
and tissue damage. Intriguingly, C3ar1-/- animals demonstrated a higher bacterial load within the 
infected kidney, despite a greater neutrophil response93. This highlights the intricate and subtle 
balancing act performed by the complement system in the acute response to injury. 
	
Conclusion	
The terminology surrounding the effects of C3a in the literature warrants revisitation. C3a is 
frequently and consistently described as pro-inflammatory in nature in the literature, and grouped 
conceptually with its cousin, C5a, as a like-minded anaphylatoxin. The reality is rather more subtle 
and nuanced. It is true that C3a does indeed have several pro-inflammatory facets, but here we have 
highlighted numerous studies from a wide variety of independent laboratories that consistently 
point to significant anti-inflammatory functions for C3a, in direct functional opposition to C5a. It 
should also be noted here that different mediators that arise from the same metabolic pathway, as do 
C3a and C5a, are often physiological antagonists in vivo. A good example are the prostanoids, 
where individual mediators (eg PGE2 versus PGF2α, or Thromboxane A2 versus PGI2), are well 
recognized to act on their cognate receptor, and, with opposing effects, are therefore physiological 
antagonists of each other. We should therefore not be surprised by the concept that C3a and C5a 
may also function as physiological antagonists of each other. In fact, C3a and C5a have directly 
opposing effects of blood pressure mediated entirely through prostanoid activity94,95. Collectively, 
the studies presented in this review contravene the current general dogma, and suggest a change to 
Chapter 1  Introduction 
 70	
the nomenclature, or at least a wide-ranging recognition of the unforeseen complexity of the 
pathophysiological roles of C3a. At the very least, there should be earnest attention and debate, to 
leaven our understanding of what is clearly a complex and multifaceted issue. 
 
The response of C3a to injury is a dichotomy.  In the acute setting, C3a prevents mobilization of 
neutrophils, limits their accumulation into tissues, and therefore reduces the inflammatory response 
at the tissue level. In certain chronic disease models however, such as asthma and rheumatoid 
arthritis, C3a clearly demonstrates certain pro-inflammatory actions and contributes to disease 
progression57,64,96. The difference in response of inflamed tissues to C3a, between the acute and 
chronic phases of inflammation, may well be due to the differing cell types involved (eg. 
neutrophils vs monocyte/macrophages; see Figure 1.6.2). However, the different facets of C3a in 
disease are not mutually exclusive, but instead depend upon the balance between the pro- and anti-
inflammatory effects of the molecule (Figure 1.6.3). Even in models of disease that demonstrate a 
Figure 1.6.3: The balance of C3a actions determines the disease phenotype. C3a induces both pro- and anti-
inflammatory effects that contribute to the disease phenotype. Anti-inflammatory effects of C3a dominate the acute 
phase of inflammation and targeting of C3aR with an agonist at this stage may result in beneficial effects on 
pathological outcomes. In contrast, the pro-inflammatory aspects of the molecule dominate the chronic phase of 
inflammation and diseases characterized by their chronicity, such as rheumatoid arthritis and asthma, may benefit from 
treatment with a C3aR antagonist. 
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worse outcome with disruption of the C3a-C3aR axis there are also measurable benefits, such as 
reduced tissue pro-inflammatory cytokines in the gut IR model47. It is the balance of these actions in 
disease that determines the ultimate outcome (Figure 1.6.3). 
 
This dual role of C3a in inflammation also poses significant opportunities for the development of 
therapeutics. It may be possible to harness the anti-inflammatory activity of C3a in the acute 
inflammatory phase through the use of C3aR agonists, of which there are emerging several 
promising candidates97,98. We recently demonstrated the validity of this approach in the intestinal 
I/R model47. Equally, the pro-inflammatory aspects of C3a in chronic disease may warrant the 
targeting of C3aR using a “clean” and selective antagonist to reduce, for example, the cytokine-
mediated pro-inflammatory response. Future rational design of therapeutics targeting the C3aR 
should take these dual roles of this receptor in the inflammatory response into account. 
 
In this review we aimed to revisit the historical and recent literature on the pathophysiological role 
of C3a in complement-mediated inflammation.  In our view, several major conceptual errors have 
been casually promulgated in the last 30 years over C3a.  These first appeared with the earliest 
experiments comparing C5a- and C3a-induced degranulation of mast cells in vitro. Pharmacological 
activity should not be confused with potency or efficacy. That C3a and C5a both cause efficacious 
mast cell degranulation in vitro, but at widely differing potencies (varying by at least an order of 
magnitude)99, does not make them both potent pro-inflammatory mediators. This is where the myth 
began, aided by the imprecision of terminology carried forth by succeeding researchers. It is time 
for a rethink, and a careful, and more nuanced consideration, of the roles of C3a in inflammation, 
which seem far more catholic than its more famous and celebrated cousin, C5a. We suggest that 
future authors recognize this detail through the description of C3a as an inflammatory modulator, 
rather than a purely pro-inflammatory peptide. 
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1.7 This Thesis 
Thesis Statement 
This PhD project focuses on the physiological role played by the anaphylatoxin receptors in the 
development of the brain. This research expands the understanding of neural progenitor physiology 
in the hope that a greater understanding of the physiological processes underlying development may 
be applied to the discovery and prescription of novel therapeutics to treat developmental and 
degenerative diseases of the CNS. 
 
Hypothesis 
It is hypothesised that the role of the anaphylatoxin receptors on the neural progenitors of the 
embryonic brain is likely to be that of a modulator of progenitor function. 
 
Aims 
The present thesis aimed to demonstrate the role of the anaphylatoxin receptors on neural progenitor 
biology through the following aims: 
1. To investigate the localisation and expression of C5aR and C3aR during brain 
development. 
2. To determine the functional role of C5aR and C3aR on neural progenitors during 
brain development. 
3. To elucidate the second messenger signalling involved after C5aR activation on 
neural progenitor cells. 
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Structure of this Thesis 
This thesis projected comprises five experimental chapters linked by the theme of the complement 
system in neural development.  In chapter 2 the presence and location of complement factors is 
demonstrated within the neurulating embryo. In chapter 3, an attempt at creating a transgenic mouse 
capable of lineage tracing C5ar1-expressing cells is described, with the aim that the mouse be used 
for developmental studies. Chapter 4 comprises the majority of the work associated with this thesis 
and represents an investigation into the role of C5aR on neural progenitor cells of the embryonic 
telencephalon. Chapter 5 describes similar work with a shifted focus to C3aR1. Chapter 6 explores 
adult behavioural abnormalities attributable to genetic absence of the complement anaphylatoxin 
receptors. Finally, Chapter 7 is a summary of the experimental chapters and provides insights on the 
future directions of the field. 
  80	
 
Chapter 2 
 
Expression of Innate Immune Molecules During 
Embryonic Development
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2.1 Background 
 
The following chapter is comprised of a manuscript submitted to Developmental and Comparative 
Immunology describing the presence of numerous innate immune molecules throughout the period 
of neurulation in the mouse embryo. The significance of this manuscript lies in the fact that we were 
unable to demonstrate the existence of all components of the three canonical pathways at this period 
of embryogenesis. This observation then begs the question of individual function for each of these 
moieties, independent of their place within the complement cascade.  
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2.2 Abstract 
 
The innate immune system is the first line of defence against pathogens and infection. Recently, it 
has become apparent that many innate immune factors have roles outside of immunity and there is 
growing evidence that these factors play important functional roles during the development of a 
range of model organisms. Several studies have documented developmental expression of 
individual factors of the toll-like receptor and complement systems, and we recently demonstrated a 
key role for complement C5a receptor (C5aR1) signalling in neural tube closure in mice. Despite 
these emerging studies, a comprehensive expression analysis of these molecules in embryonic 
development is lacking. In the current study, we therefore examined the expression of key innate 
immune factors in the early development period of neurulation (7.5-10.5dpc) in mice. We found 
that complement factor genes were differentially expressed during this period of murine 
development. Interestingly, the expression patterns we identified preclude activation of the classical 
and alternative pathways and formation of the membrane attack complex. Additionally, several 
other classes of innate immune molecules were expressed during the period of neurulation, 
including toll-like receptors (TLR-2, -3, -4 and -9), receptor for advanced glycation end-products 
(RAGE), and their signalling adapters (TRAF-4, TRAF-6, TAK-1 and MyD88). Taken together, 
this study highlights a number of innate immune factors as potential novel players in early 
embryonic development. 
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2.3 Introduction 
 
The first discovery of function of a protein often has the consequence of branding that factor with a 
label that is difficult to remove. This consequently may impart subtle and unintended bias on 
subsequent experimental endeavours. This is true for many innate immune factors; for example, the 
misguided labelling of complement factor C3a as a pro-inflammatory mediator (Coulthard and 
Woodruff, 2015). However, there are many examples of individual proteins possessing multiple, 
mutually-exclusive and context-dependent functions. Such bifurcation of function is particularly 
evident in the developmental context. 
 
There are multiple recent reports of early developmental expression of innate immune factors 
(Carmona-Fontaine et al., 2011; Denny et al., 2013a; Hawksworth et al., 2014). In the adult, the 
hepatocytes of the liver are responsible for the production of many of the circulating factors of the 
innate immune system. In the developing mouse embryo, the liver bud forms around 9.5dpc (Bort et 
al., 2006) and contains hepatoblasts, capable of differentiating to cholangiocytes and hepatocytes 
from 13.5 dpc onwards (Kung et al., 2010). The early hepatoblasts of the liver bud have been 
demonstrated to produce several circulating serum proteins, such as albumin and alpha-fetoprotein 
(Germain et al., 1988), however their ability to form the complement factors produced by the adult 
liver has not, to our knowledge, been assayed. Cells of the myeloid lineage likely to express the 
receptors of the innate immune system first appear in the yolk sac of the developing embryo, before 
migration into the aortic region and liver bud (Palis et al., 1999). These progenitor cells reach the 
primitive circulatory system around 8.5dpc and the liver around 9.5dpc (Palis et al., 1999). 
 
Recently, our group demonstrated that the complement C5a receptor (C5aR1) is expressed by 
neuroepithelial cells during human and mouse neurulation, and is critical for proper mammalian 
embryonic development under conditions of folate-deficiency (Denny et al., 2013a). C5a is the 
ligand for C5aR1, and is produced as a cleavage product of complement factor C5 (Klos et al., 
2013). In the immune system, C5a can be generated through four separate initiation pathways: 
classical, alternative, lectin and extrinsic protease, each with its own unique propagating zymogens 
(Manthey et al., 2009; Woodruff et al., 2014). Additionally, numerous regulators modulate the 
generation of C5a and the action of other cleavage by-products such as C5b, which goes on to form 
the terminal membrane attack complex (MAC) (Woodruff et al., 2011). Given that C5a may be 
generated through multiple pathways, and that complement generation and deposition is highly 
regulated in an immune context, there remains an unanswered question: how C5a may be generated 
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and modulated in the context of mammalian embryonic development, given the importance of its 
canonical receptor in neurulation (Denny et al., 2013b).  
 
Aside from the complement system, the innate immune system also comprises factors such as toll-
like receptors (TLR), formyl peptide receptors (FPR), chemokines, and cytokines. This diverse 
collection of molecules acts to immediately recognise, opsonise and neutralise pathogens and 
damaged cells either directly or through the recruitment of leukocytes. In addition, these factors 
stimulate the activity of the adaptive immune system to respond to the pathogenic insult. 
Interestingly, whilst many of these factors have well-established roles in innate immunity, many of 
them were either first discovered, or have recently been discovered, to have non-immune functions 
(Hashimoto et al., 1988; Hori et al., 1995; Lathia et al., 2008; Okun et al., 2010).  
 
Toll-like receptors were initially discovered for roles in dorso-ventral patterning of developing 
drosophila larva (Hashimoto et al., 1988) and were only later demonstrated to be part of a larger 
family with roles in pathogen recognition. In mice, this family extends to 13 members, each 
recognising molecular patterns associated with tissue damage or pathogen invasion (Arumugam et 
al., 2009). Conversely, the complement system has long been investigated as an important player in 
innate immunity, and only recently ascribed non-immune roles (Carmona-Fontaine et al., 2011; 
Denny et al., 2013a; Haynes et al., 2013; Kimura et al., 2003; McLin et al., 2008; Rahpeymai et al., 
2006; Rooryck et al., 2011). 
 
McLin and colleagues demonstrated that a number of complement factors are expressed during the 
early development of xenopus (McLin et al., 2008). This has piqued interest in what early 
developmental processes complement may be facilitating. Subsequently, complement C3a and its 
cognate receptor C3aR have been demonstrated to direct cranial neural crest cell chemotaxis 
(Carmona-Fontaine et al., 2011), and the complement lectin pathway components, collectin 11 
(collec11) and MASP1, have also emerged as important participants in craniofacial development 
(Rooryck et al., 2011).  
 
Given the pleiotropic nature of many innate immune molecules, it is not clear if an early, non-
immune developmental role is unique to complement or whether expression of innate immune 
factors during development is a broader phenomenon. This study, therefore, sought to investigate 
which innate immune factors were expressed in early stages of embryonic development, specifically 
during the period of neural tube formation and closure (7.5 – 10.5dpc).  
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2.4 Methods 
 
Tissue Collection 
Animal breeding and tissue collection were performed in accordance with guidelines from the 
National Health and Medical Research Council of Australia and was approved by the University of 
Queensland Animal Ethics Committee. Pregnant C57BL/6J dams at 7.5 to 10.5 days post 
conception (dpc) were obtained from University of Queensland Biological Resources for use in this 
study. The day of vaginal plug discovery was designated 0.5 dpc. Mice were sacrificed by cervical 
dislocation and embryos were removed from the uterus and extra-embryonic membranes and 
transferred into a 4% formaldehyde/PBS solution freshly prepared from paraformaldehyde, or snap-
frozen in liquid nitrogen.  
 
RT-PCR 
Total RNA was obtained from aggregated litters at 7.5, 8.5, 9.5 and 10.5dpc using RNeasy kit 
(Qiagen, The Netherlands) according to the manufacturer’s instructions. RNA was DNase-treated 
(Turbo-DNase, Life Technologies, USA) and 1 µg of total RNA was reverse transcribed (Tetro RT, 
Bioline, UK). Specific primers for each gene were designed using the NHMC primer design tool. 
The primers and corresponding annealing temperatures used are detailed in table 2.4.1. 
 
Name Forward Reverse Product Temp 
C1qb 5’-CAGAACACCAGGATTCCATACA-3’ 5’-AAACCTAGAAGCAGCAGTAACA-3’ 102bp 60° 
C2 5’-CTCATCCGCGTTTACTCCAT-3’ 5’-TGTTCTGTTCGATGCTCAGG-3’ 872bp 58° 
C4 5’-ACCCCCTAAATAACCTGG-3’ 5’-CCTCATGTATCCTTTTTGGA-3’ 320bp 58° 
Cfb 5’-ACAGAGACCATCGAAGGAGC-3’ 5’-GGTTCTATTCCAGCCTTCAGG-3’ 426bp 59° 
Cfd 5’-ACTGCATGGATGGAGTGACG-3’ 5’-TTCGATCCACATCCGGTAGG-3’ 554bp 58° 
Mbl-2 5’-CCCTGCCTGCAGTGACACCA-3’ 5’-AGCACCCAGTTTCTCAGGGCT-3’ 443bp 58° 
Masp1 5’-ACTTTCCGGTCAGATTTCTCCA-3’ 5’-TAGCCACCGATGTAGTTGTGA-3’ 143bp 60° 
C3 5’-CCAGCTCCCCATTAGCTCTG-3’ 5’-GCACTTGCCTCTTTAGGAAGTC-3’ 159bp 58° 
C5 5’-GCTGCTAAGTACAAACATAGTGTGCC-3’ 5’-GGACAGGTTTATGGGGGCTTTCT-3’ 184bp 58° 
C9 5’-TCTCCCCAGCAGAACACTCT-3’ 5’-TGCTTTGTTTCCTGAAGGCT-3’ 911bp 58° 
AI182371 5’-CCGGGATTGCCTCTTTTCCT-3’ 5’-TCTGGGCGTTACAAGTCGTC-3’ 79bp 58° 
C3ar1 5’-CCCCCAGCCTCTTCTTTATC-3’ 5’-AGCCTAAGGCCCTTCTCTTG-3’ 732bp 56° 
C5ar2 5’-AACCACACCACCAGCGAGTATTATG-3’ 5’-AGCCCTCTTGCCTACACCGGC-3’ 1040bp 56° 
C1qr 5’-ATCGCTTGATGCTGATGCGATGC-3’ 5’-ATGCTGAGTCGATGCTGGATGCT-3’ 869bp 58° 
Cd11b 5’-CCATGACCTTCCAAGAGAATGC-3’ 5’-ACCGGCTTGTGCTGTAGTC-3’ 147bp 58° 
Crry 5’-TCCTTGTGAGATACCCCCAG-3’ 5’-TTCTCATTTCACGTTGCTGC-3’ 858bp 58° 
Cd55 5’-CAAGTACAGGAACCCCCTCA-3’ 5’-CTGTGGCGATTCTGCTTACA-3’ 729bp 58° 
Cd59a 5’-TGTGAAGCCTGTGGAAACTG-3’ 5’-TTTTGAGCGTGTCAGAGTGG-3’ 895bp 58° 
Cfh 5’-CATGGGTCAGTTTCTTGCATTAG-3’ 5’-CTTCAGCACTCTACACTTCTCC-3’ 90bp 58° 
Properdin 5’-TTCACCCAGTATGAGGAGTCC-3’ 5’-GCTGACCATTGTGGAGACCT-3’ 149bp 58° 
Tnfα 5’-TGTCCCTTTCACTCACTGGC-3’ 5’-CATCTTTTGGGGGAGTGCCT-3’ 117bp 60° 
Mcp-1 5’-AGCACCAGCCAATCTCACT-3’ 5’-TCTGGACCCATTCCTTCTTG-3’ 301bp 60° 
Tlr2 5’-GGGTGTGTGATGGCCGCTCC-3’ 5’-TCGCCGAGCCCATTGAGGGT-3’ 781bp 58° 
Table 2.4.1; Primer sequence, amplicon length and PCR conditions used in this study. 
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Name Forward Reverse Product Temp 
C1qb 5’-CAGAACACCAGGATTCCATACA-3’ 5’-AAACCTAGAAGCAGCAGTAACA-3’ 102bp 60° 
C2 5’-CTCATCCGCGTTTACTCCAT-3’ 5’-TGTTCTGTTCGATGCTCAGG-3’ 872bp 58° 
C4 5’-ACCCCCTAAATAACCTGG-3’ 5’-CCTCATGTATCCTTTTTGGA-3’ 320bp 58° 
Cfb 5’-ACAGAGACCATCGAAGGAGC-3’ 5’-GGTTCTATTCCAGCCTTCAGG-3’ 426bp 59° 
Cfd 5’-ACTGCATGGATGGAGTGACG-3’ 5’-TTCGATCCACATCCGGTAGG-3’ 554bp 58° 
Mbl-2 5’-CCCTGCCTGCAGTGACACCA-3’ 5’-AGCACCCAGTTTCTCAGGGCT-3’ 443bp 58° 
Masp1 5’-ACTTTCCGGTCAGATTTCTCCA-3’ 5’-TAGCCACCGATGTAGTTGTGA-3’ 143bp 60° 
C3 5’-CCAGCTCCCCATTAGCTCTG-3’ 5’-GCACTTGCCTCTTTAGGAAGTC-3’ 159bp 58° 
C5 5’-GCTGCTAAGTACAAACATAGTGTGCC-3’ 5’-GGACAGGTTTATGGGGGCTTTCT-3’ 184bp 58° 
C9 5’-TCTCCCCAGCAGAACACTCT-3’ 5’-TGCTTTGTTTCCTGAAGGCT-3’ 911bp 58° 
AI182371 5’-CCGGGATTGCCTCTTTTCCT-3’ 5’-TCTGGGCGTTACAAGTCGTC-3’ 79bp 58° 
C3ar1 5’-CCCCCAGCCTCTTCTTTATC-3’ 5’-AGCCTAAGGCCCTTCTCTTG-3’ 732bp 56° 
C5ar2 5’-AACCACACCACCAGCGAGTATTATG-3’ 5’-AGCCCTCTTGCCTACACCGGC-3’ 1040bp 56° 
Tlr3 5’-GAAACGCGCAAACCCCGGTG-3’ 5’-AGGACGCCTGCTTCAAAGTCCC-3’ 756bp 58° 
Tlr4 5’-CTGAGCAGCCGCTCTGGCATC-3’ 5’-GCCAGGCTATCTGTGAGCGTGT-3’ 763bp 58° 
Tlr9 5’-CCGCAAGACTCTATTTGTGCTGG-3’ 5’-TGTCCCTAGTCAGGGCTGTACTCAG-
3’ 
260bp 58° 
Fpr1 5’-CATTTGGTTGGTTCATGTGCAA-3’ 5’-AATACAGCGGTCCAGTGCAAT-3’ 101bp 60° 
Fpr2 5’-TGGGCTCAGAACCACCGCAC-3’ 5’-GTGCCCAAAAGGGCCACAAGC-3’ 401bp 60° 
Fpr3 5’-TGGGCTCAGAACCACCGCAC-3’ 5’-CACATCCCACAGCCCCCTCCT-3’ 724bp 60° 
Rage 5’-CAGCGTGGCTCGAATCCTCCC-3’ 5’-GCCACAGGATAGCCCCGACG-3’ 869bp 58° 
Traf4 5’-CAAGTGTGGGGCCCGCATGA-3’ 5’-GAGGTCCGGCCCCCAATCCA-3’ 978bp 60° 
Traf6  5’-ACGTGGGCGAGCTCAAACGG-3’ 5’-CATGGACGCTACACCCCCGC-3’ 601bp 60° 
MyD88 5’-CAGGCGAGCGTACTGGACGG-3’ 5’-GCAAGGCGGGTCCAGAACCA-3’ 914bp 60° 
Tak1 5’-GGAGCTCCGGCAGTTGTCACG-3’ 5’-GCCCGTTACCTGCAGTCGCC-3’ 992bp 60° 
Actb 5’-GTGGGCCGCCCTAGGCACCAG-3’ 5’-CTCTTTGATGTCACGCACGATTTC-3’ 540bp 60° 
	
Section In situ hybridisation 
Section in situ hybridisation was performed as per Simmons et al. (Simmons et al., 2007). Briefly, 
cRNA digoxigenin-labelled probes were generated through ligation of PCR products into a pGEM-
Teasy vector (Promega, USA) and transcription with SP6 and T7 RNA polymerase (Promega). 
Resulting probes were diluted 1:2000 in hybridisation buffer and hybridised overnight on 16 µm 
9.5dpc embryo sections at 65°C. Following washes with 50% formamide and RNase treatment to 
remove excess probe, sections were blocked and exposed to anti-digoxigenin-AP antibody (Roche, 
Switzerland) at 1:2500 dilution overnight at 4°C. For color development, embryos were incubated 
in 40 mg/ml NBT and 20 mg/ml 5-bromo-4-chloro-3-indolylphosphate (Roche, Switzerland). Slides 
were re-fixed in 4% paraformaldehyde, mounted with DEPEX (Sigma-Aldrich, Missouri) and 
imaged using a digital slide scanner (Aperio, AT2). 
 
Whole mount in situ Hybridisation 
In situ hybridization was performed as per Christiansen et al. (Christiansen et al., 1995). Briefly, 
embryos at 9.5 dpc were fixed overnight at 4 ̊C in 4% paraformaldehyde/0.01M PBS, and taken 
through a dehydration and rehydration series with methanol. Embryos were permeabilized using 10 
mg/ml proteinase K and incubated at 65 ̊C overnight with 0.5 mg cRNA probe. After removing 
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excess probe, embryos were blocked with 10% goat serum/2% BSA in TBS. Alkaline phosphatase–
conjugated anti-digoxigenin IgG (Roche), preadsorbed against embryo antigens, was added in the 
pre-blocking solution and incubated overnight at 4 ̊C. For color development, embryos were 
incubated in 40 mg/ml NBT and 20 mg/ml 5-bromo-4-chloro-3-indolylphosphate (Roche). Embryos 
were taken through an ethanol dehydration series to remove excess color, re-fixed in 4% 
paraformaldehyde overnight, and imaged using a stereomicroscope (Leica, M205 FA 
stereomicroscope). 
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2.5 Results and Discussion 
 
In the present study, we demonstrate that complement factors normally produced for circulation by 
adult hepatocytes were also expressed in the murine embryo during the period of neurulation. This 
period coincides with the early stages of liver development and the movement of myeloid 
progenitors into the embryo proper. Indeed, in this study, we demonstrate the clear presence of the 
myeloid cell marker CD11b at 9.5 and 10.5dpc, whereas it was beyond detection at 7.5dpc. This 
coincides with the migration of myeloid progenitors into the embryo.  We have also demonstrated 
the production of a number of circulating complement factors preceding mature hepatocyte 
development, suggesting that alternative cell types are responsible for complement factor 
production in the early embryonic period.  
 
3.1 Expression of factors essential for complement activation  
To determine whether the canonical complement pathways are active during the period of 
neurulation in the mouse embryo, we assayed key factors essential for their propagation. The 
classical pathway was investigated with the expression of C1qB, complement C2 (C2) and 
complement C4 (C4). Complement C2 was not detectable by RT-PCR throughout the period of 
neurulation in mouse embryos 7.5-10.5dpc. Very little complement C4 was detectable at 7.5 and 
8.5dpc, and was beyond detection at 9.5 and 10.5dpc. In contrast, C1qB, part of the initiating factor 
of the classical pathway (but also a factor with complement-independent roles), was only expressed 
at E9.5 and E10.5 (figure 2.5.1). This suggests that the combination of factors usually required to 
initiate the classical pathway, are either not expressed at all (C2), or are not expressed co-ordinately 
(C4 and C1qB), during the same period. Thus, it is unlikely the classical pathway is used for 
complement activation during the period of neurulation.  
 
Activation of the alternative pathway is characterised by cleavage of complement factor B (CfB) 
into the fragments Ba and Bb, which leads to the formation of a C3 convertase. This cleavage of 
CfB occurs through factor D (CfD), an obligatory and rate-limiting serine protease that catalyses the 
formation of the alternative pathway C3 convertase (Klos et al., 2009). While CfB could be detected 
during the period of neurulation, CfD could not (figure 2.5.1), suggesting that the C3 convertase 
cannot be assembled via the alternative pathway at this stage in embryonic development. 
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Finally, we assessed expression of lectin pathway components mannose-binding lectin-2 (MBL-2) 
and mannose-associated serine protease 1 (MASP1). While MBL-2 was most apparent at 7.5 and 
8.5dpc, MASP1 was clearly expressed at all stages (7.5-10.5dpc; figure 2.5.1), unlike any of the 
other pathway components assayed. Importantly, the lectin pathway has been shown to be able to 
act independently of C4/C2 (a C4/C2-bypass pathway) (Selander et al., 2006), and so despite the 
limited and absent expression of C4 and C2 in the embryo, this complement activation pathway 
could still be functional. Expression of MASP was also demonstrated by in situ hybridisation at  
  
Figure 2.5.1. Complement activation pathway gene expression is restricted during the period of neurulation. 
RT-PCR analysis was conducted on embryos ranging from E7.5 to E10.5. ‘-‘ represents a negative reverse 
transcriptase control. ‘Con’ represents a positive control tissue relevant for the gene of interest. Arrows indicate 
expected band and size. C1qB, complement factor 1q, subunit B; C2, complement factor 2; C4, complement factor 4; 
CfB, complement factor B; CfD, complement factor D; MBL-2, mannose-binding lectin 2; MASP1, mannose-binding 
lectin serine protease 1; ActB, beta actin. 
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Figure 2.5.2. In situ hybridisation reveals restricted expression patterns of innate immune factors in the 
developing mouse embryo. Wholemount and section in situ hybridisation was performed on E9.5 embryos for the 
complement regulators CD55 (A-D) and CD59a (E-H), the lectin pathway component MASP1 (I-L), and innate 
immune receptors RAGE (M-P) and TLR4 (Q-T). All five genes were expressed in the neuroepithelium with CD59a 
expression enriched in the dorsal part of the neural tube, whereas MASP1 and RAGE appeared more prominent in 
ventral portions of the neural tube. The sense (negative control) probe is shown in D, H, L, P, T. Section in situs 
were counterstained with nuclear fast red. Scale bar = 100 um. 
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9.5dpc, and was prominent in the mesoderm and ventral neural tube. The dorsal neuroectoderm and 
ectodermal tissues demonstrated no expression (figure 2.5.2). 
 
3.2 Expression of central complement factors and regulators 
To investigate the expression of the broader complement system, a number of factors, receptors and 
regulators were screened for expression during mouse neurulation. The central anaphylatoxin 
precursors, C3 and C5, were both expressed throughout the period of 7.5-10.5dpc (figure 2.5.3). 
Additionally, we evaluated the expression of the gene with designation AI182371, which is located 
upstream of murine C5 on chromosome 2, and annotated as haemolytic complement-like. AI182371 
was also expressed throughout the period of neurulation (figure 2.5.3). By contrast to the central 
complement factors C3 and C5, the terminal complement component C9 was absent (figure 2.5.3), 
suggesting that formation of the MAC is not possible in the early embryo, and not the central aim of 
complement activation at this stage of embryogenesis. Both C3 and C5 cleavage fragments, C3a 
and C5a, have already been demonstrated to have extra-immune functions in developmental 
processes such as neural crest cell migration (Carmona-Fontaine et al., 2011) and proliferation of 
neural progenitors in rat cerebellum (Bénard et al., 2004).  
 
Other receptors that mediate the effects of complement factors were evaluated for expression in 
mouse embryos. C1qR expression was detectable throughout the period of 7.5-10.5dpc, whereas the 
expression of CD11b, a component of complement receptor 3 (CR3), was only evident towards the 
end of neurulation (9.5-10.5dpc) (figure 2.5.3). We have previously demonstrated the presence and 
a function for C5aR1 during this period of development (Denny et al., 2013a), however here we 
now show that the related complement peptide receptors C3aR and C5aR2 (C5L2) are also 
expressed throughout neurulation (figure 2.5.3). The expression of these receptors, in coordination 
with their respective ligands (C1q, C3, C5), suggests they may transduce signals from generated 
complement components during this period of embryogenesis. 
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Finally, the complement system is under tight regulation by a range of factors that either enhance or 
dampen convertase formation or activity. CD55, CD59a, complement factor H (CfH) and properdin 
were all expressed throughout the period of neurulation (figure 2.5.3). Complement receptor-1 
related gene/protein Y (Crry), which functions to inhibit the formation of the C3 convertase, was 
only detectable at 7.5 and 8.5dpc. Furthermore, both CD55 (a C3/C5 convertase inhibitor) and 
CD59a (a terminal MAC inhibitor) had a broad expression pattern in embryos at 9.5dpc, as shown 
by in situ hybridisation (figure 2.5.2). Interestingly, in the neural tube, while CD55 appeared to be 
Figure 2.5.3. Complement factors and regulators are expressed during the period of neurulation. RT-PCR analysis 
was conducted on embryos ranging from E7.5 to E10.5. ‘-‘ represents a negative reverse transcriptase control. ‘Con’ 
represents a positive control tissue relevant for the gene of interest. Arrows indicate expected band and size. C3, 
complement factor 3; C5, complement factor 5; C9, complement factor 9; AI182371, haemolytic complement-like factor; 
C1qR, complement factor C1q receptor; C3aR, complement factor 3a receptor; C5aR2, complement factor 5a receptor 2; 
CD11b, cluster of differentiation molecule 11B (integrin alpha M); Crry, complement receptor 1-related gene/protein y; 
CD55, cluster of differentiation molecule 55 (decay-accelerating factor, DAF); CD59a, cluster of differentiation 
molecule 59a (membrane attack complex inhibition factor); CfH, complement factor H; Properdin (factor P). 
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evenly expressed throughout, CD59a appeared to be enriched in the dorsal half of the neural tube 
(figure 2.5.2). Given the absence of C9 at these stages of embryogenesis, this suggests CD59a may 
play a role in development that is unrelated to its role in regulation of the complement terminal 
complex.  
 
Collectively, these data suggest that many of the components of the complement system, including 
activators, factors, receptors and regulators, are expressed throughout the period of neurulation in 
the developing mouse. However, not all factors necessary for the propagation of the complement 
pathways of innate immunity (classical, lectin, alternative) are present at this period of development 
(figure 2.5.5). We therefore postulate that a MASP-1-mediated pathway, or activation by extrinsic 
proteases, may mediate the formation of C3a and C5a, in these early stages of development. 
 
3.3 Expression of other innate immune system factors 
Our studies also highlight the presence of other innate immune factors during the period of 
neurulation in the mouse. TLR-2, -3, -4 and -9 were all found to be present throughout this period 
(figure 2.5.4). Expression of TLR4 was demonstrated by in situ hybridisation at 9.5dpc and showed 
a broad expression pattern, particularly concentrated in the cephalic regions (figure 2.5.2). These 
results are consistent with previously demonstrated roles in development for these receptors, 
however, to our knowledge this is the earliest demonstrated mammalian expression within the 
available literature. Expression of TLR-2, -3, -4 and -9 has previously been established in the 
embryonic brain for 13.5dpc onwards (Kaul et al., 2012). Functionally, TLR-2 and TLR-3 
signalling has been shown to inhibit neurogenesis at later stages of embryonic development (Lathia 
et al., 2008; Okun et al., 2010). A functional role for TLR-4 and -9 in mouse embryogenesis has yet 
to be elucidated. TNFα was detected by RT-PCR from 7.5-10.5dpc (figure 2.5.4). Expression of 
TNFα has previously been demonstrated in 10dpc embryos (Chie et al., 1994). However, little is 
known of the function of this molecule during embryogenesis. TNFα knockout mice have no 
reported developmental abnormalities and do not differ in embryonic weight or litter size when 
compared with their wild-type cousins (Pasparakis et al., 1996). Whilst TNFα has a demonstrated 
role in miscarriage, its presence during normal development in embryonic tissues suggests an as yet 
unknown role for this factor (figure 2.5.4).  
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To our knowledge, this is the earliest demonstrated expression of MCP-1/CCL-2 during 
embryogenesis, detectable at 7.5-10.5dpc (figure 2.5.4). MCP-1 has previously been assayed at the 
blastocyst stage of development, and was found to be undetectable, however the blastocyst was 
found to exhibit control over MCP-1 production in endometrial cultures (Caballero-Campo et al., 
2002). Interestingly, polymorphisms of the CCL-2 gene resulting in lower MCP-1 serum 
Figure 2.5.4. Expression of innate immune factors and signalling adaptors during the period of neurulation. RT-
PCR analysis was conducted on embryos ranging from E7.5 to E10.5. ‘-‘ represents a negative reverse transcriptase 
control. ‘Con’ represents a positive control tissue relevant for the gene of interest. Arrows indicate expected band and 
size. TNFa, tumour necrosis factor alpha; MCP-1, monocyte chemoattractant protein-1; TLR, toll-like receptor; FPR, 
N-formyl peptide receptor; RAGE, receptor for advanced glycation endproducts; TRAF, TNF receptor associated 
factor; MyD88, myeloid differentiation primary response gene 88; TAK1, transforming growth factor-beta-activated 
kinase 1. 
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concentrations have been linked to increased risk of neural tube defects in human populations (Lu et 
al., 2008). However, previous experiments in our laboratory have been unable to demonstrate an 
increased risk of neural tube defects in MCP-1 deficient mice even in the presence of maternal 
folate-deficiency as an environmental stressor (unpublished data). Interestingly, multiple bands 
were detectable with these primers at all ages except 10.5dpc. As these extra bands were not present 
in the liver or 10.5dpc cDNA, they may represent other isoforms of MCP-1 that are restricted in 
terms of their temporal expression during embryonic development. 
 
The formyl-peptide receptor family, like TLRs, responds to endogenous damage associated 
molecular patterns, and functions in the immune response to bacterial infection (Le et al., 2002). 
Although FPR expression has been demonstrated in human umbilical vein endothelial cells, no 
reports of FPR expression in development exist (Lee et al., 2008). In the present study, we assayed 
the three known members of the formyl peptide receptor family for expression during the period of 
mouse neurulation by RT-PCR. Interestingly, despite abundant expression of complement factors 
and toll-like receptors, we found no evidence of expression for FPR-1, -2 or -3 from 7.5-10.5dpc in 
the mouse. The absence of these receptors, and the presence of other immune factors, suggests an 
orchestrated pattern of immune molecule expression, as opposed to embryonic expression of the 
adult immune system. Interestingly, the FPR genes and complement receptor C5aR1 are grouped 
into the same sub-family of G-protein-coupled receptors, based on sequence homology. That C5aR1 
is expressed during neurulation and the FPRs are not, demonstrates specificity in embryonic 
expression of C5aR1 rather than widespread expression of innate immune factors in general. 
  
RAGE has previously been noted to be expressed in the later stages of rodent development, and has 
a functional role in neurogenesis in this period (Fang et al., 2012; Hori et al., 1995). Additionally, 
RAGE is also present in the early placenta and blastocyst stages of development (Haucke et al., 
2014; Konishi et al., 2004). The present study has demonstrated through RT-PCR that RAGE is 
also expressed throughout the period of neurulation in mouse development (figure 2.5.4). 
Additionally, in situ hybridisation analysis revealed expression in a range of tissues at 9.5dpc, 
particularly in the mesoderm and ventral neural tube. No expression was evident in the dorsal neural 
tube (figure 2.5.2). 
 
In the immune context, many of the innate immune receptors we have shown to be expressed in the 
early embryo, require a number of intracellular second messenger signalling molecules. Thus, we 
finally investigated the transcripts of four common adaptor proteins during neurulation (TRAF-4, 
TRAF-6, TAK-1, MyD88) and found all to be expressed throughout this developmental period 
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(figure 2.5.3). This suggests that many of these innate immune receptors may in fact utilise these 
same second messengers for signalling during embryonic development, as they do in their immune 
context. 
 
This study raises the major outstanding question of function for these molecules at this point in 
development; what does expression of these factors mean in a biological context? In terms of the 
complement components, we have provided evidence that the generation of the anaphylatoxins C3a 
and C5a may be via restricted pathways, lectin and extrinsic protease, during neurulation, as there 
are significant factors required for canonical pathway propagation that are lacking (figure 2.5.5). 
This may be due to the anaphylatoxins merely acting as signalling cues in development, rather than 
having to respond to a wide variety of stimuli and insults, as in the context of mounting an immune 
response. However, this study does not preclude the transfer of maternal circulating complement 
components into the embryonic tissue, which may rescue potential deficiencies in canonical 
complement activation. However, this scenario raises the further question of why some, but not all, 
complement pathway components are produced by the embryo, and specifically why there is an 
absence of factors central to canonical complement activation and propagation. Importantly, 
complement expression is evident in tissues other than the liver, which supplies much of the 
circulating complement factors in the adult. These data, coupled with emerging reports 
demonstrating novel roles for a diaspora of innate immune factors in development (Carmona-
Fontaine et al., 2011; Denny et al., 2013a; Hawksworth et al., 2014), suggest that we look again at 
the function of innate immune factors during neurulation. 
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Figure 2.5.5. Diagrammatic representation of active complement pathways during mouse neurulation. The three 
canonical complement activation pathways (classical, alternative, lectin) are depicted. Green boxes indicate factors 
that are expressed throughout the period of neurulation, orange boxes indicate variable expression and red boxes 
indicate factors that were not detected during this period. Black arrows demonstrate theoretically intact complement 
pathways, whereas grey arrows demonstrate pathways that are limited by the non-expression of complement factors. 
Importantly, only the C2/4-independent lectin pathway and C3/5 cleavage by intrinsic proteases are theoretically 
functional at this stage of development. Formation of the membrane attack complex is limited by a lack of detectable 
C9 expression.  
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2.6 Conclusions 
 
This study highlights the expression of innate immune molecules throughout the period of mouse 
neural tube closure. The expression of these factors appears before the development of the murine 
immune system and suggests alternative functions within this period of development, although 
maternal supplementation of the absent factors cannot be excluded. Whilst the functions of these 
molecules at this juncture remains to be determined, and the corollary of human expression 
confirmed, their presence could potentially inform the use of anti-inflammatory therapeutics 
targeted towards these factors in pregnancy. We have previously shown that inhibition of 
complement C5a activity throughout this embryonic period induced severe neurulation-related 
defects when combined with a folate-deficient diet (Denny et al., 2013a), and it is not inconceivable 
that the milieu of innate immune molecules identified within this study could have roles of similar 
importance. Given that the developmental role of C5aR1 was only uncovered under conditions of 
folate deficiency, it would be of interest in future studies to re-examine the knockout or 
pharmacological inhibition of other immune factors under similar types of stressors in order to 
evaluate whether novel gene-environment interactions additionally exist for these factors. 
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3.1 Introduction 
A desirable tool in developmental biology is one that allows for the marking of specific cells and 
their progeny in order to discern the effects of stimuli on the fate of cells. To this end, this PhD 
project aimed to develop a transgenic mouse model that allowed for lineage tracing of C5aR 
positive cells, specifically for demonstrating the effect of C5aR modulation during neurogenesis.  
 
The Structure of murine C5ar1 
The genetic structure of C5ar1 has been reviewed in chapter 1.1, however a brief summary is 
contained here. C5ar1 is comprised of two exons and a 10kb intron. The initial exon contains a 
131bp 5’ UTR and the first codon of the coding sequence (ATG). Exon 2 contains the remainder of 
the C5aR sequence and a relatively large (~1.5kb) 3’UTR. The promotor region of C5ar1 is ill-
defined, but significant regulatory sequences are present within the 500bp prior to the 
transcriptional start point; these include C/EB, AP-4 and NFκB-binding site sequences1. 
Importantly, the importance of each regulatory motif differs between cell type, and suggests a 
complex, multifaceted expression pattern1. 
 
Methods of creating a transgenic mouse 
Two broad methods exist for inserting a transgene into an the genome of an organism. The first 
involves random recombination (RR) of the transgene into the genome and the second uses targeted 
homologous recombination (HR) to modify existing genes. There are both advantages and 
drawbacks to each method.  
 
The initial attraction to the HR method is due to the targeted approach, the ability to predict and test 
where the transgene will insert into the genome has the advantage of reducing the risk of adverse 
outcomes for the mouse line. The RR method however, runs the risk of inserting within essential 
portions of the genome that may be involved in any aspect of the resulting organisms physiology.  
This has the potential to distort future experimental results that subsequently become attributed to 
the expression of the transgene rather than its unfortunate insertion in the genome. Consequently, 
the researcher must be aware of this limitation when designing experiments with this type of 
transgenic animal. 
 
The advantage of the HR method in terms of targeted insertion also comes with the caveat that there 
will invariably be loss or alteration of endogenous gene expression. A previous attempt at creating a 
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C5ar1-IRES-GFP transgenic mouse by utilising the HR method was frustrated by the aberrant 
expression of C5aR in the transgenic lines. In this mouse the researchers had attempted to control 
GFP expression from the C5aR promoter without compromising endogenous C5aR expression, 
however they discovered that the alteration of 3’ genomic sequences resulted in an intracellular 
expression of C5aR protein, rather than the natural cell surface expression2. The alteration of 
endogenous gene expression is not a desirable characteristic of a mouse designed to study the 
physiological or pathophysiological role of the gene product and, in this instance, the RR method 
has the advantage. 
 
Additionally, the HR method, by virtue of its targeted nature, is limited to two copies of the 
transgene existing in the genome of the transgenic animal. The RR method, by contrast, has the 
potential for the insertion of hundreds of transgene copies into the genome, this may provide for 
greater sensitivity in the case of low-expression genes.  
 
Initial attempts at achieving a lineage tracing mouse 
In order to achieve this aim this project employed the modified BAC method of inserting the 
desired transgene. This method is useful as it allows for expression of the transgene from the C5ar1 
promoter without compromising expression of endogenous C5aR. The transgene comprised an 
oestrogen-inducible cre recombinase and enhanced green fluorescent protein separated by an 
internal ribosome entry site (CreErt2-IRES-EGFP). In addition, a floxed kanamycin/neomycin 
resistance cassette was included to allow for in vitro selection of successful recombination. The 
insertion site for the transgene was the beginning of the second exon of C5aR immediately after the 
termination of the single 10kb intron. This site was chosen as earlier experiments using 15kb of the 
5’ sequence immediately before the first exon inserted into the linear pJazz vector failed to yield 
any demonstrable expression when transfected into known C5aR-expressing cell lines (data not 
shown). From this initial attempt, we hypothesised that the 10kb intron in the C5ar1 sequence may 
contain elements essential for the efficient transcription of C5aR and therefore decided upon the 
BAC method to retain more of the peripheral motifs surrounding the C5ar1 gene. 
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3.2 Methods 
 
Plasmids 
The plasmids used in this chapter are presented in table 3.2.1.  BAC clone RP24-556B7 was 
obtained from the Children’s Hospital of Oakland Research Institute (CHORI), containing the 
genomic sequence for C5ar1 and surrounding regions of chromosome 7. pSC101-BAD-gam-tet 
was a kind gift from Dr David Simmons, and is commercially available as part of the Red/ET 
recombination system (GeneBridges). The transgene was generated through standard cloning 
techniques to incorporate elements of pIRES-EGFP, pErt2CreErt2 and pML3 in order to generate a 
sequence of an oestrogen-inducible cre recombinase (Ert2CreErt2), internal ribosome entry site 
(IRES) and enhanced green fluorescent protein (EGFP) under the control of a CMV promotor, with 
a distal floxed kanamycin/neomycin resistance cassette (FLP-kan/neo-FLP) (plasmid 7, table 3.2.1).  
# Plasmid 
Name 
Source Description Antibiotic 
Resistance 
1 BAC – clone 
RP24-556B7 
BACPAC 
(CHORI, 
California, 
USA) 
Bacterial artificial chromosome of the region of 
mouse chromosome 7 containing C5ar1 
Chloramphenicol 
2 pSC101-BAD-
gam-tet 
Dr David 
Simmons 
Commercially available plasmid expressing 
proteins that mediate recombination. 
Temperature sensitive ori allows for propagation 
at 30°C 
Tetracycline 
3 pIRES-EGFP Dr David 
Simmons 
Expression of EGFP under control of CMV 
promotor. EGFP is proceeded by an multiple 
coloning site/internal ribosome entry sequence 
allowing for addition of a coexpressed protein  
Ampicillin 
4 pErt2CreErt2 Dr David 
Simmons 
Expression of tamoxifen-inducible cre 
recombinase under the control of CMV promotor 
Ampicillin 
5 pML3 Dr David 
Simmons 
Contains FLP-kan/neo-FLP to aid in transgene 
selection through antibiotic resistance 
Ampicillin/Kanamycin 
6 pErt2CreErt2-
IRES-EGFP 
Generated from 
plasmids 3 & 4 
Ert2CreErt2 sequence inserted within the MCS 
of pIRES-EGFP 
Ampicillin 
7 pML3-
Ert2CreErt2-
IRES-EGFP 
Generated from 
plasmids 5 & 6 
Ert2CreErt2-IRES-EGFP sequence inserted 
proximal to FLP-kan/neo-FLP sequence to 
provide template for transgene amplification 
Ampicillin/Kanamycin 
 
Table 3.2.1: Description of plasmids utilised in generation of the transgene 
Chapter 3 Creating a transgenic mouse 
 107	
 
HeLa cell culture and transfections 
HeLa cells expressing a cre-responsive DsRed-nuc reporter gene were cultured at 37°C/5% CO2 in 
Dulbecco’s modified eagle medium (DMEM, Sigma) supplemented with 10% fetal calf serum and 
100U/mL penicillin / 100µg/mL streptomycin.  For transfection, cells were grown to 70% 
confluency in 24 well plates and transfected using the Lipofectamine 3000 lipid-mediated 
transfection system (Life Technologies) according to manufacturer’s instructions. Cells were 
examined for the presence of fluorescence 24-48 hours post-transfection under fluorescent 
microscopy. To determine the functionality of plasmids containing an oestrogen-inducible cre 
recombinase, cultures were supplemented with 1µM 4-OH-tamoxifen and observed for the 
development of nucleus-localised red fluorescence.  
 
Generation of transgene through PCR 
The transgene was amplified from pML3-Ert2CreErt2-IRES-EGFP using primers directed to the 
start sequence of the Cre recombinase and just distal to the second FLP of the kan/neo resistance 
cassette. The forward primer was supplemented at the 5’ end with a 50bp homology sequence 
corresponding to the intronic sequence just proximal to the beginning of the second exon of C5ar1. 
The reverse primer was similarly supplemented at the 5’ end with a 50bp homology sequence 
complementary to the initial 50bp of exon 2. Primer sequences are listed as primer set 1 in table 
3.2.2. Amplification was achieved over 35 cycles with Phusion high-fidelity taq using an annealing 
temperature of 63°C and an extended extension time of 5 minutes to account for the amplicon 
length of 5kb. The resulting product was isolated using 1% agarose gel electrophoresis and a 
Zymoclean gel extraction kit (Zymo research). Concentration was assessed using a nanodrop 
spectrophotometer (Thermo Scientific). 
 
Recombination 
BAC-containing E. coli were grown inoculated into LB media containing 25µg/mL 
chloramphericol (Sigma) and grown to logarithmic growth phase (2.5hrs, 37°C, 225rpm). Cells 
were centrifuged and washed twice before resuspension in 50µL ice-cold dH2O. The resuspension 
was then complemented with 50ng pSC101-BAD-gam-tet plasmid and incubated on ice for 5 
minutes before transfer to 1mm electroporation cuvettes. The cell-plasmid suspension was 
electroporated using the GenePulser system (Biorad) with settings as follows; 1800V, 25µF, 200Ω. 
This method and settings was also used for all subsequent bacterial electroporations. Post-
electroporation, 950µL SOC media (NEB) was added and the cell suspension incubated at 30°C, 
225rpm for 70 minutes. The culture was then plated onto pre-warmed LB plates containing 
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25µg/mL chloramphenicol/15µg/mL tetracycline for growth overnight at 30°C. Lower growth 
temperatures after transformation with pSC101-BAD-gam-tet allows for plasmid replication 
through the temperature sensitive ori site. Viable colonies were expanded in 3mL cultures overnight 
at 30°C and used to inoculate 1.4mL LB broth cultures for growth at 30°C. After two hours cultures 
were supplemented with 10% arabinose solution and incubated for a further hour at 37°C to induce 
expression of the mediator proteins required for recombination from the pSC101-BAD-gam-tet 
plasmid. Cultures were then collected and  
electroporated with 50ng of the transgene product, as previously described, before plating for 
overnight growth on LB agar containing 25µg/mL chloramphenicol/50µg/mL kanamycin to select 
for bacterial cells that had successfully recombined the transgene into the BAC (figure 3.2.1). 
Resulting colonies were screened for correct recombination by PCR using primers directed against 
Figure 3.2.1: Diagram demonstrating the recombination method used in creating the transgene. (A) Template 
plasmid indicating sites used for primer amplification of transgene, primers contained 5’ 50bp homology regions to 
the insertion site in the BAC. (B) C5ar1 genomic sequence (below) and transgene (above) indicating the site of 
insertion at the start point of exon 2. (C) Final sequence of recombineered BAC at the C5ar1 locus. 
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the transgene and known surrounding C5ar1 sequence (table 3.2.2; primer set 3). Correct 
recombination was confirmed through sequencing of the PCR products (table 3.2.2; primer 4) at the 
Australian Genome Research Facility (AGRF). 
 
Pronuclear injection 
The recombineered BAC was prepared for pronuclear injection by linearisation and dialysis with 
microinjection solution (10mM Tris HCl, 0.1mM EDTA, 100mM NaCl, 30µM spermine, 70µM 
spermidine, pH 7.5) across a 0.05µm membrane (Millipore). The resulting solution was diluted in 
microinjection solution to a concentration of 1ng/µL and delivered to the Transgenic Animal 
Service of Queensland (TASQ) to perform the pronuclear injections. Four viable mouse lines 
resulted from pronuclear injection of the recombineered BAC and were screened for presence and 
function of the transgene. 
 
Tissue collection and tamoxifen treatment 
To assess for the genomic presence of the transgene within the mouse lines, tail-tips were digested 
in DNA digestion buffer (50mM Tris-HCl, 100mM EDTA, 100mM NaCl, 1% SDS, pH 8.0) 
supplemented with 0.5mg/mL proteinase K (Sigma) overnight at 55°C. PCR utilising transgene 
specific primers, aligned with the cre-recombinase sequence (table 3.2.2; primer set 2), was used to 
assess for the presence or absence of the transgene within the crude lysates. Mice in all colonies 
were bred to produce heterozygous or wild-type progeny through the mating of a wild-type 
C57BL6 male to heterozygous females. 
 
For in situ hybridisation, tissues were fixed via intracardiac perfusion of DEPC treated 4% 
paraformaldehyde (PFA), collected and sectioned at 16µm using a cryostat. For RNA or protein 
isolation, mice were sacrificed via cervical dislocation and tissue samples snap-frozen in liquid 
nitrogen. 
 
For tamoxifen treatment to induce cre-mediated recombination, heterozygous female mice were 
bred to males of the cre-reporter line, B6;129S6-Gt(ROSA)26Sortm(CAG-tdTomato)Hze/J, a kind gift from 
the A/Prof Linda Richards (Queensland Brain Institute). Offsping were genotyped for the presence 
of both the cre transgene and the tdTomato-cre responsive allele. Eight week-old mice positive for 
Cre/tdTomato or tdTomato alone were administered 75mg/kg tamoxifen (Sigma Aldrich, USA) 
dissolved in corn oil, or corn oil alone as a vehicle control, by intraperitoneal injection over a five 
day period. Mice were perfused by intracardiac injection of 4% PFA seven days after the last 
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tamoxifen administration. Brain, kidney, liver and spleen tissue samples were isolated into 4% PFA 
for histological analysis. 
 
RT-PCR 
RNA was isolated from snap-frozen tissues using an RNeasy column purification kit (QIAGEN) 
and DNase treated with TurboDNase (Ambion) to remove contaminating genomic DNA. RNA was 
reverse transcribed to cDNA with tetro reverse transcriptase (Bioline) for use in RT-PCR analysis. 
Presence of transgene transcript was assessed in mice determined heterozygous for the transgene  
through genotyping and wild-type littermates were utilised as a negative control. PCR for cre 
recombinase was performed as outlined in table 3.2.2 (primer set 2) and PCR products were 
analysed using 1% agarose gel electrophoresis.  
 
 
 
LPS injections and qPCR analysis 
Heterozygous males from the transgenic colony were subjected to intraperitoneal injection of 
1mg/kg lipopolysaccharide in 100µL dH2O, in order to promote a systemic inflammatory response 
or 100µL dH2O as a sham control. Mice were sacrificed after 24 hours by cervical dislocation and 
tissues snap-frozen for RNA analysis. RNA was isolated as previously described and resulting 
cDNA used to determine relatively transcript levels of C5ar1 (table 3.2.2; primer set 6) and cre 
recombinase (table 3.2.2; primer set 7). Transcript levels were determined by qPCR with SYBR 
# Name Forward Sequence Reverse Sequence Amp. 
length 
Anneal. 
temp. 
1 Transgene CTGGGAATGTGTCTACCAACTCACA
CAATCTACCTGTTTGATTTGCTTAGG
CT GGA GAC ATG AGA GCT GCC 
GTTCCATAGTGATCATAGTTGATTTC
AAAGCTGCTGTTATCTATGGGGTCCT
TTCGATTGACGGTCGAGGAAGTT 
5kb 62°C 
2 Cre CGTACTGACGGTGGGAGAAT TGCATGATCTCCGGTATTGA 500bp 60°C 
3 BAC screen AGAGGAGGTCGGCCACCG CGGGATGGGCGGAGTTAG 624bp 60°C 
4 BAC Seq. AGTAGATGGACCACCATGAT  N/A 60°C 
5 C5ar1 RT-
PCR 
GCTGGTTACCACAGAACCCAGG CGGTACACGAAGGATGGAATGG 559bp 63°C 
6 C5ar1 
qPCR 
GGGATGTTGCAGCCCTTATCA CGCCAGATTCAGAAACCAGATG 131bp 60°C 
7 Cre qPCR CGTACTGACGGTGGGAGAAT CCCGGCAAAACAGGTAGTTA 166bp 60°C 
8 r18s qPCR GATCCATTGGAGGGCAAGTCT CCAAGATCCAACTACGAGCTT 103bp 60°C 
Table 3.2.2; A detailed listing of primer sets used in this chapter. 
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green mastermix (Life Technologies) according to manufacturer’s instructions. Relative transcript 
levels were normalised against levels of r18s (table 3.2.2; primer set 8) as an internal control. 
 
In situ hybridisation 
In situ hybridisation was performed using sense and antisense digoxigenin (DIG)-labelled cRNA 
probes specific for cre recombinase. Probes were generated through ligation of isolated cre PCR 
product (table 3.2.2; primer set 2) into the pGEM-Teasy vector system (Promega) and subsequent 
linearization and transcription using T7 and SP6 RNA polymerase in the presence of DIG RNA 
labeling mix (Roche). Tissues were pretreated with proteinase K before incubation with sense or 
antisense probes overnight at 65°C. The presence of hybridized cRNA was detected after washing 
through the use of an alkaline phosphatase conjugated antibody (Roche) specific for the DIG 
epitope. Slides were incubated with a BCIP/NBT alkaline phosphatase substrate solution (Roche) 
and monitored for colour development. Tissues were counterstained using nuclear fast red and 
mounted for imaging with an AT2 digital slide scanner (Aperio). 
 
Western Blot 
Proteins for western blot analysis were extracted from snap-frozen tissues through lysis in 
radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail 
(Roche). Protein concentration was determined by BCA assay (Thermo scientific) and 20µg protein 
was loaded onto 10% acrylamide gel for electrophoresis. Separated protein samples were then 
blotted onto activated PDVF membrane and probed using anti-cre recombinase antibody (CST, 
USA) at 1:1000 dilution overnight. Following incubation with an isotype specific IRDye conjugate 
secondary antibody (LiCor) at 1:10,000 dilution, blots were washed and visualised on an Odyssey 
infrared imaging system (LiCor). 
 
Immunofluorescence 
Tissues from mice subjected to intraperitoneal of tamoxifen or corn oil solutions were prepared in 
12µm sections on a cryostat. Nuclear localisation was achieved with DAPI and sections were 
imaged using fluorescent microscopy for the presence of tdTomato fluorescence as a marker of cre 
nuclear translocation. Additionally, sections were probed for the presence of C5aR using a rat anti-
mouse C5aR antibody (Serotech, clone 10/92, 1:250). Sections were blocked for one hour at room 
temperature in blocking buffer (10% goat serum, 0.5% Triton X-100 in PBS) before overnight 
incubation at 4°C with primary antibody or blocking buffer alone. Alexafluor 488 goat anti-rat IgG 
antibody (Life Technologies, 1:1000) was used to probe for bound primary and incubated overnight 
at 4°C, nuclear staining with DAPI and mounting.  
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3.3 Results 
 
Transfection of HeLa cells with transgene constructs 
Prior to the recombination of the BAC, the construct containing the transgene was tested under the 
control of a CMV promotor within the pML3-Ert2CreErt2-IRES-EGFP plasmid. The preceding 
plasmid, lacking the floxed-kan/neo cassette was also tested as a positive control. After 48 hours 
HeLa cultures in both the pErt2CreErt2-IRES-EGFP and pML3-Ert2CreErt2-IRES-EGFP groups 
demonstrated detectable green fluorescence whereas none was detectable in the lipofectamine-only 
control (Non-transfected; figure 3.3.1). Addition of 1µM 4-hydroxy-tamoxifen to the cultures 
successfully transfected with the test plasmids caused expression of nuclear localised DsRed. 
Importantly, the DsRed expression occurred only within cells positive for EGFP expression, and 
was not evident without the addition of 4-hydroxy-tamoxifen to the cultures.  
 
Recombination results 
Recombination of the transgene into the BAC was tested by PCR amplification across the insertion 
site and sequencing of the PCR product. Sequencing results demonstrated satisfactory insertion of 
the transgene at the beginning of exon 2 of C5ar1 (data not shown). Pronuclear injection of 
linearised BAC at AGRF resulted in the development of four genotypically-positive lines on a 
C57BL6/J background. Genotyping PCR demonstrated good distinction between heterozygous and 
wt/wt animals through the presence or absence of a 500bp band amplified by primer directed 
against the cre sequence (figure 3.3.2:A). Two lines were initially culled as no PCR gene product 
was detected by RT-PCR. An additional line had recombination into the locus for Rbfox1, an RNA 
splicing modulator, as determined by inverse PCR and sequencing (data not shown). This line 
exhibited epileptic seizures, as has previously been reported in Rbfox1 knockout animals3. 
Therefore, the one remaining line was used for all following experiments. 
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Figure 3.3.1; Transfection of HeLa-DsRednuc cre-reporter cells with transgene constructs demonstrates 
effective transgene function. Cells transfected with no plasmid (top rows), pErt2CreErt2-IRES-EGFP (middle 
rows) or pML3-Ert2CreErt2-IRES-EGFP (bottom rows) and treated with or without 4-hydroxytamoxifen (4-OH-T) 
and imaged after 48 hours in culture. Cre containing plasmids demonstrate enhanced green fluorescent protein  
(EGFP) expression and treatment with tamoxifen stimulates expression of nuclear localised DsRed. Brightfield 
images are shown to demonstrate cell location. 
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Testing for presence of transgenic gene product 
 
RT-PCR demonstrated the presence of RNA transcript from the transgene within brains of cre/0 
animals, whereas tissue from wt/wt animals produced no band within this region (figure 3.3.2:B). 
Protein expression of the CreErt2 fusion protein was also shown at 74kDa within the liver, brain 
and spleen of Cre/0 animals and was absent within wt/wt littermate lysates (figure 3.3.2:C).  
 
 
Testing responsiveness to C5ar1 promotor 
To determine whether RNA expression of the transgene was subject to the C5ar1 promotor Cre/0 
and wt/wt littermates were subject to intraperitoneal injection of 1mg/kg LPS. LPS produced an 
significant upregulation in liver C5ar1 expression, as has previously been reported4. Addtionally, 
Cre transgene expression was also significantly upregulated in LPS treated mice, but did not 
demonstrate the same degree of change as C5ar1 (figure 3.3.3:D). In situ hybridisation for cre in 
livers isolated from LPS and vehicle treated Cre/0 mice also shows an broadened and elevated level 
of transcript expression (figure 3.3.2:E). 
Figure 3.3.2: Transgene is expressed in a manner similar to C5aR1. A. Representative genotyping PCR from 
wt/wt x Cre/0 litter. “C” indicates control PCR with pML3-Ert2CreErt2-IRES-EGFP plasmid as template. 500bp 
band indicates a Cre/0 genotype, whereas absence of a band indicates a wt/wt genotype. B. RT-PCR demonstrating 
presence of cre transcript in cre/0 cDNA. “H” indicates dH2O negative control, “-“ indicates negative reverse 
transcriptase controls for gDNA contamination. C. Western blot for the presence of CreErt2 fusion protein at 
74kDa. CreErt2 is present in liver, brain and spleen from Cre/0 animals and absent from wt/wt liver. D. Bar graph 
demonstrating the change in liver C5ar1 and creErt2 transcript expression by qPCR 24 hours post LPS or vehicle 
administration to Cre/0 mice. * indicates p<0.05, **** indicates p<0.0001. E. In situ hybridisation analysis of 
CreErt2 transcript expression and localisation in livers of Cre/0 from experiment described in D. 
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Investigating transcript localization in the brain 
As the aim of this thesis is to demonstrate a function of C5aR in neural progenitor cell physiology, 
the localisation and expression of transgene product in the adult brain was a priority. In situ 
hybridisation showed transgene expression strongest within cortical layers IV and VI (figure 
3.3.3:C), the medial habenular nuclei (figure 3.3.3:D,E), the dentate gyrus and CA1 region of the 
hippocampus (figure 3.3.3:F,G) and the subventricular zone of the lateral ventricles (figure 
3.3.3:H,I). Antisense probe on Cre/0 sections was controlled for through the use of a sense probe on 
Cre/0 sections (figure 3.3.3:B,C,E,G,I) and antisense probe on wt/wt sections (data not shown). 
Both sense and wt/wt sections demonstrated no significant staining. 
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Investigating transgene functionality 
Transgene functionality was investigated through the use of tamoxifen or vehicle intraperitoneal 
injection over a period of five days administered to C5aR-CreErt2-IRES-EGFP crossed with a 
tdTomato Cre reporter mouse, or reporter mouse alone. Sections of brain, kidney, liver and spleen 
did not demonstrate tdTomato or EGFP fluorescence in all samples, despite being all being positive 
for C5aR immunostaining (brain and kidney shown; figure 3.3.4). The medullary region of the 
kidney, and choroid plexus is displayed. C5aR positive cells in these areas likely represent capillary 
endothelial-cells. 
Figure 3.3.3: In situ hybridisation analysis of CreErt2 expression in the brains of Cre/0 animals. Images 
represent whole brain (A, antisense; B, sense), cortical layers (C, antisense, left; sense, right), median habenular 
nuclei (D, antisense; E, sense), dentate gyrus of the hippocampus (F, antisense; G, sense) and subventricular zone 
of the lateral ventricle (H, antisense; I, sense). Approximate location of cortical layers in C is denoted by roman 
numerals. Scale bar in images A and B indicates 1mm. 
  
 
Figure 3.3.4; Immunofluorescent analysis of cre functionalty. Mice heterozygous for C5aR-CreErt2-IRES-EGFP (Cre) crossed with homozygous tdTomato cre reporter 
line, B6;129S6-Gt(ROSA)26Sortm(CAG-tdTomato)Hze/J (tdTomato), generated Cre/0 tdTomato/0 double positive mice and 0/0 tdTomato single transgenics. Both genotypes were 
administered 75mg/kg/day tamoxifen or vehicle control (corn oil) for five days. A) Representative kidney sections at the medulla co-labelled for C5aR, large right panel is 
enlarged area demonstrated by the white box in merge panel. B) Representative sections of the choroid plexus co-labelled for C5aR, large right panel is enlarged area 
demonstrated by the white box in merge panel. White scale bars in negative control images indicate distance of 100µm. 
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3.4 Discussion 
There is a need for genetic models to investigate C5ar1 physiology. Currently, there is only the 
C5aR knockout mouse available to explore the role of C5aR in pathology and physiology. Whilst 
this model suffices for elucidating the functions of C5aR in acute models of inflammatory disease, 
it falls short when investigating its functions over short time frames of development. This chapter 
aimed to create a transgenic mouse that could function as a way of lineage tracing C5aR-expressing 
progenitor cells for use in understanding the function of C5aR in development. Unfortunately, this 
chapter failed to address its major aims as the expressed cre-recombinase in this mouse was non-
functional. 
 
The transgenic mouse, created in this chapter, demonstrated expression of the transgene that was 
responsive to LPS stimulation, in a similar manner to C5aR. Additionally, mRNA expression within 
the brain and confined to anatomical regions already reported in the literature for C5ar1 in situ 
hybridisation5. Protein expression at the correct molecular weight was shown by western blot for 
the CreErt2 fusion protein, probed for by Cre-recombinase antibody. However, no functionality of 
the CreErt2 protein could be shown by tamoxifen treatment after crossing to a cre-reporter line, 
despite expected functioning of the transgene in vitro. The EGFP, which should have been present 
in cells currently expressing C5aR via IRES-mediated expression, was also not evident in the 
isolated tissues. 
 
Interestingly, the in situ hybridisation results for cre transcript within the brain correlate well with 
previous in situ hybridisation results for C5ar15. In situ hybridisation demonstrated strong cre-
expression within the subventricular zone surrounding the lateral ventricles, the medial habenular 
nuclei, the piriform cortex and the CA1 region/dentate gyrus of the hippocampus. In addition, 
cortical staining was strongest within layers IV and VI. However, this result is unable to be 
replicated using immunofluorescence methods to demonstrate protein expression within these 
regions. The antibody used in these experiments (clone 10/92, Serotech) has previously been shown 
to specifically bind to murine C5aR in transfected cells6, however experiments in our laboratory 
have demonstrated additional binding to an unknown intracellular protein on knockout tissue (John 
Lee, personal communication). These previous results encouraged the aim of this chapter, as a 
healthy skepticism of the results derived from antibody experiments emerged; the transgenic animal 
proposed here would have also allowed for real-time, indirect monitoring of C5aR expression via 
EGFP. 
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The C5ar1 gene in the mouse is ill-characterised and it is presently unclear how much of the 
surrounding sequence (both 3’, 5’ and intronic) contributes to endogenous expression. Previous 
attempts at using the C5ar1 promotor for expression of transgenes have also yielded unexpected 
results. A recent report demonstrated that disruption of the 3’UTR through insertion of a IRES-
EGFP sequence prevented C5aR1 cell surface expression and resulted in intracellular accumulation 
of the receptor2. In the present study the results suggest that there is both expression and translation 
of the transgene under control of the C5aR promotor, as evidenced by the in situ hybridisation and 
western blot results. It is most likely that the protein produced is non-functional, perhaps due to a 
chance mutation during production. 
 
It is disappointing that this transgenic mouse is unable to be used for the intended purpose of 
developmental cell-linage tracing. However, several other mouse models that may be suitable to 
this purpose are currently being developed, or have recently been reported. These include a 
mCherry-tagged C5aR1 mouse being engineered under the direction of Prof. Rick Finnel’s 
laboratory at the University of Texas (Personal Communication), for use in intracellular trafficking 
experiments. This mouse is an exciting prospect as it is an inducible C5ar1-knockout, which reports 
successful Cre-recombination by expression of EGFP. However, there have been issues with the 
targeting of this vector into embryonic stem cells, which has slowed progress on this model (Trent 
Woodruff, personal communication). Due to the apparent importance of the 3’UTR of C5ar1, 
another, unconventional, attempt was made to generate a C5ar1 reporter line. The approach of 
adding the EGFP-IRES sequence at the 5’ end of exon 2 has resulted in the successful creation of a 
GFP-reporter mouse that retains cell surface expression of C5aR1. This mouse has the added 
benefit of allowing conditional knockout of C5aR1, with LoxP sequences flanking the second 
exon7. These new mouse models under development limit the future use of the model presented in 
this chapter. Together, these mouse models represent a significant step-forward in the investigation 
of C5aR1 physiology and allowing for temporally-dependent knockout of the receptor is especially 
important in the developmental context. In particular, this will allow for the unmasking of any 
compensatory mechanisms to chronic loss of the receptor and further delineate its role in directing 
cell fate. Future use of these models will allow for more thorough interrogation of the role of 
C5aR1 on neural progenitor population in a similar way to the aims of the transgenic mouse 
presented in this chapter. 
 
In conclusion, the major aim of this chapter, to create a transgenic mouse capable of lineage-tracing 
C5ar1 expressing cell during development, was not met. Despite detected mRNA and protein 
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expression, the transgene was experimentally shown to be non-functional. However, there are 
several other mouse models, currently available or under construction, that may meet the needs of 
investigating the role of C5aR1 from a developmental perspective.  
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Investigating C5aR in Neural Progenitor Cell 
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Chapter 4 C5aR1 and Neural Progenitors 
 
 123	
4.1 Background 
The present chapter comprises the bulk of the work associated with this thesis and is an 
investigation into the physiological role of C5aR1 in embryonic neural progenitor cells. I have 
presented it in format of a draft journal article submission in order to acknowledge the assistance I 
received from co-authors during the undertaking of this work. Additionally, we plan to submit this 
work for publication with the inclusion of further experiments to enhance the paper. Unfortunately, 
the inclusion of these experiments are beyond the temporal scope of this thesis submission but 
include; characterisation of NE-4C cell polarity changes with C5a treatment, viral transduction of 
C5aR1 into the embryonic telencephalon to track cell fate, and histological analysis of the brain 
samples used for the behavioural/ex vivo MRI sections. Despite the absence of this work, this 
chapter provides tantalising evidence of the importance of C5aR1 function in directing neural 
progenitor proliferation and polarity. 
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4.2 Introduction 
 
The complement proteins and their associated receptors have a long association with the innate 
immune system; this function of the complement cascade as the first line of defence against 
pathogenic insult is undisputed. As a result of the activation of the complement cascade, 
complement factor 5a (C5a) is generated as one of two cleavage products derived from complement 
factor 5. The other cleavage product, C5b, is the initiating factor of the membrane attack complex. 
Until recently it was assumed that the cleavage of C5a could only occur as the end product of one of 
the three complement pathways that are initiated by pathogenic surfaces or antibody complexes. 
However, recently it has been demonstrated that C5a can be generated from C5 directly through the 
actions of a wide variety of serine proteases. This ‘extrinsic’ pathway of C5a generation means that 
C5a can be generated locally, in a controlled manner, without the need for the systemic zymogenic 
amplification that occurs in response to pathogenic insult. This extrinsic generation of complement 
split products has leant credence to numerous studies that have demonstrated surprising expression 
and function of the complement anaphylatoxin receptors outside of their traditional innate immune 
roles1-3.  
 
C5 is reportedly expressed in the neural plate and cephalic regions during Xenopus development 
and in the wound epithelium of regenerating newt limbs2,4. Our laboratory has demonstrated similar 
expression during neural tube closure in the mouse for both C5 and C5aR15. In this study we 
demonstrated that the combination of C5aR1 blockade in utero and maternal folate deficiency 
caused severe and frequent neural tube defects. However, we also demonstrated neuroepithelial 
apical localisation of C5aR1 that persisted following the formation of the neural tube in untreated 
embryos, suggesting a broader, physiological role for the receptor in progenitor populations. 
 
The zone of neurogenesis, surrounding the ventricles of the embyonic brain is a pseudostratified 
layer. Progenitor cell nuclei are positioned between the apical and basal surfaces depending on their 
stage of the cell cycle. All progenitor cells within this zone maintain an attachment to the apical 
surface and the inheritance of this attachment point upon division appears to correlate with 
continued stemness6. The apical attachment is a congregation point for several proteins involved in 
promoting the proliferation and polarity of neural progenitors. Principal amongst these is the 
PAR3/PAR6/aPKC complex, which is expressed in all epithelial cells and functions to maintain 
apical polarity7. Localisation of the PAR3/PAR6/aPKC complex to the apical membrane is essential 
for self renewal of neural progenitors8,9. The signalling protein aPKC (PKCζ), in particular, has 
been demonstrated to increase proliferation and symmetrical division of progenitor cells, 
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maintaining stemness10-12, and is involved as a second messenger downstream of the growth factor 
receptors FGFR and EGFR13. Signalling through aPKC in this manner results in activation of the 
MAPK pathway, leading to an increased proliferation of progenitor cells13. The pivot toward 
neurogenesis in the neural stem cell population has been demonstrated to be controlled by cell cycle 
length14,15. Shortening of G1 phase by artificial expression of cyclin D1 maintains pluripotency of 
neural progenitor cells and prevents differentiation14. Rapid cell cycle progression is also 
maintained by endogenous mitogens, such as EGF or FGF, acting through their respective 
receptors; it may be hypothesised that loss of the machinery needed for rapid cell cycle progression 
from the apical membrane is the cause of neuronal differentiation through a slowed cell cycle. 
 
The known importance of the apical membrane attachment to neural progenitor cell fate makes the 
apical localisation of C5aR1, in the context of neurodevelopmental abnormalities, of great interest5. 
Therefore, the aim of this current study was to determine the normal physiological role of C5aR1 
during embryonic development. 
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4.3 Methods 
 
Tissue Collection and Processing 
All animal experiments in this study were performed with prior approval from the animal ethics 
committee of the University of Queensland. Animal housing and time-mating of mice was 
provided, with thanks, from University of Queensand Biological Resource. Tissues used in this 
study were collected after sacrificing the mouse by cervical dislocation. Tissues preserved for 
RNA/protein analysis were snap frozen in liquid nitrogen and stored at -80°C until extraction. 
Protein was extracted using modified RIPA buffer prepared in house. Tissues used for histological 
analysis were incubated at 4°C overnight in freshly prepared 4% paraformaldehyde. Tissues were 
prepared for cyrosection by sequential passaging through sucrose solutions (10%, 20%, 30%), 
removed into OCT for freezing and sectioned at 12µm, unless otherwise stated. 
 
Embryonic cerebrospinal fluid (CSF) was obtained from 13.5dpc embryos using a pulled glass 
pipette attached to a vacuum. Pooled CSF from three litters was used in analysis of C5a 
concentration through ELISA. CSF was treated with EDTA (5mM final concentration) to prevent 
coagulation and extrinsic complement activation, and stored at -80°C until analysis. 
 
Reagents 
Mouse recombinant C5a was obtained from Sigma Aldrich and reconstituted in 0.25% BSA in PBS. 
PMX53 was synthesized in house, stored lipophilised and reconstituted in water before use. 
 
RT-PCR and qPCR 
RNA was extracted using RNeasy plus spin columns (QIAGEN, The Netherlands) and treated for 
gDNA contamination using Turbo DNase (Life Technologies, USA). All RNA was additionally 
checked for gDNA contamination by PCR anaylsis. Primer sequences and PCR conditions can be 
found in table 4.3.1. qPCR performed using SYBR green PCR mastermix (Ambion, USA) and 
machine settings according to the manufacturer’s instructions. The ΔΔCt method to assess fold-
change of gene expression was employed and all data points within an individual sample were 
referenced back to 18s expression levels. 
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Name Forward Sequence (5’-3’) Reverse Sequence (5’-3’) Amplicon Temp 
C5aR1 GACCATCTCCCAAGTGTCGT CACCACACCCAGGTCTTCTT 566bp 58°C 
C5aR1 qPCR GGGATGTTGCAGCCCTTATCA CGCCAGATTCAGAAACCAGATG 131bp 60°C 
ActB GTGGGCCGCCCTAGGCACCAG CTCTTTGATGTCACGCACGATTTC 540bp 58°C 
Cyclin B1 CTTGCAGTGAGTGACGTAGAC CCAGTTGTCGGAGATAAGCATAG 94bp 60°C 
Cyclin D1 GCGTACCCTGACACCAATCTC ACTTGAAGTAAGATACGGAGGGC 94bp 60°C 
Cyclin E1 GTGGCTCCGACCTTTCAGTC CACAGTCTTGTCAATCTTGGCA 101bp 60°C 
Cyclin E2 ATGTCAAGACGCAGCCGTTTA GCTGATTCCTCCAGACAGTACA 198bp 60°C 
r18s CCCTCCAATGGATCCTCGTT TCGAGGCCCTGTAATTGGAA 61bp 60°C 
 
 
Western blot 
Protein samples (20µg) were subjected to electrophoresis at 100V on a 10% polyacrylamide gel 
until good separation was achieved. Primary antibodies directed against C5aR1 (1:500, HBT clone 
10/92), phospho-Erk (1:1000, CST #9106), total-Erk (1:1000, CST #9102) and beta-tubulin 
(1:2000, Sigma Aldrich clone TUB2.1) were diluted in 0.5x odyssey blocking buffer (LiCor, 
Germany) and incubated with the membrane rocking overnight at 4°C. Incubation with specific 
Licor odyssey secondary antibodies was carried out according to the manufacturer’s instructions. 
Blots were imaged using the Licor odyssey system and software. Optical densitometry values were 
derived from analysis of the image in ImageJ (NIH, USA).  
 
Immunofluorescence 
Tissues or cells were permeablised and blocked using 0.1% Triton X-100/4% goat serum in PBS for 
one hour. In the case of live staining for NE-4C cultures, primary antibody was added to unfixed 
cells on ice for 30 minutes prior to fixation. Primary antibodies C5aR1 (HBT clone 10/92, 1:200), 
Pax6 (R&D #MAB1260, 1:500), Phophohistone H3 (CST #9706, 1:1000), doublecortin (CST 
#4604, 1:500), Sox2 (CST #3728, 1:500), acetylated alpha-tubulin (Sigma Aldrich #T7451, 1:500), 
Zo-1 (Life Technologies, #402300, 1:500) or isotype control antibodies were incubated overnight at 
4°C. Appropriate alexafluor secondary antibodies (Invitrogen, USA, 1:1000) were incubated with 
the samples for 2 hours at room temperature before counterstaining (1µg/mL DAPI, 5 min) and 
mounting. 
 
Table 4.3.1; Table of primer sequences, amplicon length and annealing temperature used in this study. 
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C5a ELISA 
Maternal and embryonic brain sample concentrations were determined by BCA assay 
(ThermoScientific, USA). Aliquots of each sample were measured in technical triplicate for C5a 
concentration by enzyme-linked immunosorbent assay (R&D systems, USA) according to 
manufacturer’s instructions. C5a concentrations were normalised to protein concentration (ng/mg, 
brain samples) or volume (ng/mL, CSF). 
 
Neurosphere culture 
Telencephalon from litters of 14.5dpc C57BL6/J mice were isolated and mechanically dissociated. 
Cells were maintained in DMEM/F12 media supplemented with 1x B27 supplement, L-glutamine 
10ng/mL bFGF, 10ng/mL EGF and penicillin/streptomycin. To assess the effect of C5aR1 
modulation on neurosphere growth 103 cells at passage 3 were seeded into each well of a 96 well 
plate in the presence or absence of 10nM C5a or 1µM PMX53. Wells were imaged after one week 
in culture and the number and diameter of neurospheres assessed. For monolayer culture, 
neurospheres were split into plates coated with PEI. Before treatment with 10nM C5a cells were 
deprived of growth factors (bFGF/EGF) for 6 hours. For qPCR analysis cells were harvested 12 
hours post-treatment for RNA qPCR analysis. 
 
NE-4C culture 
NE-4C cells were acquired from ATCC and expanded in MEM (Sigma Aldrich) supplemented with 
10% FCS (Lonza, Switzerland), L-glutamine and Non-essential amino acids (Life Technologies, 
USA). For migration assay cells were plated into poly-L-lysine coated 24-well plates and grown to 
confluency. A scratch within the monolayer was achieved using a p200 pipette tip and each well 
was imaged. PKCζ inhibitor GF109203X (Sigma Aldrich 2µM final concentration) or vehicle was 
added 30 minutes before addition of 10nM C5a or vehicle (0.25% BSA). Wells were imaged for 
cell migration at 18 hours and the decrease in scratch diameter was estimated using the distance 
between polylines plugin for ImageJ (NIH, USA). 
 
For transwell culture, NE-4C cells were plated on poly-L-lysine coated 0.2µm transwell membranes 
in a 24-well plate. Cells were maintained in media as described above and treatment (C5a or 
vehicle) was added to the upper compartment 12 hours before fixation for immunofluorescence. 
 In utero injections 
 
Time mated dams at E13.5 were anaesthetised under 1% isofluorane for surgery. 1uL of 100nM 
C5a, 10µM PMX53 or respective vehicle control was injected into the ventricular system of the 
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embryos. Abdominal inscisions were closed with sutures and dams were administered 0.1mg/kg 
buprenorphine for analgesia post-surgery. Dams were sacrificed and tissues collected at 24 hours 
post-surgery for tissue analysis. 
 
For analysis of proliferation post-drug administration the embryonic telencephalon was sectioned 
coronally and sections at the level of the preoptic area were used for histological analysis. M-phase 
cells, as determined by phosphohistone H3 staining, were counted using ImageJ at the apical surface 
of the telencephalic ventricular zone. Phosphohistone H3 positive cells per 100µm was calculate for 
each individual embryo and differences between treatment groups analysed by students T-test. 
 
Treatment of animals for behavioural experiments and MRI 
Twelve time-mated dams were acquired from UQBR and housed under standard conditions under 
the care of animal house staff. Mice were administered 1mg/kg PMX53 or sterile water vehicle 
control in a 100µL volume via intraperitoneal injection over three days (12.5dpc – 14.5dpc). Dams 
were allowed to litter in individual cages. Gestational age at birth was defined as the number of 
days after discovery of the vaginal plug (0.5dpc). Litter number, weight, crown-rump length and 
cranial width were taken at birth. In addition, pup weight was tracked over the first five weeks of 
life to determine if any differences existed in growth parameters. 
 
At eight weeks of age male and female mice from the litters were randomly selected for 
participation in behavioural experiments (n = 8 per group). After behavioural experiments mice 
were anaethetised with zylazine/xoletil cocktail and perfused with PBS followed by 4% PFA via an 
intracardiac cannula situated in the left ventricle. Whole heads were incubated in 4% PFA for a 
further 3 days before washes with PBS and careful removal of the brain. Brains were stored in fresh 
PBS until MRI analysis. 
 
Grip strength 
Mice were assessed for motor weakness using the grip strength test. Briefly, mice gripped a bar 
attached to a force transducer. The experimenter gently pulled backwards on the base of the tail 
until the mouse dislodged from the bar. The maximum force recorded over three trials was 
designated as the grip strength. Both forelimb and hindlimb grip strength was assessed.  
 
Balance Beam 
Mice were assessed for higher motor coordination using the balance beam test. The apparatus 
consisted of a 70cm (length) x 3mm (width) beam suspended 1m above a surface. The beam was 
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held in a room with bright overhead lights kept at a constant output of 150 lumens, a covered 
platform was set at the end of the beam. Mice were trained, through four training attempts, to move 
towards the covered platform through the use of a training beam of 80mm width. After training, 
mice were exposed to the test apparatus. Time taken to cross beam and foot fall errors were 
recorded. A footfall error was deemed to have occurred if the paw of the animal moved from a 
position on the beam and crossed a threshold 10mm beneath the beam.  
 
Open Field Test 
The open field test utilised 50 x 50cm infrared photobeam tracking arenas (Med associates, USA) to 
measure activity in a novel environment. Mice were placed in the center of the arena and, after a 
30s initiation period, movement in the x, y and z planes was tracked for the following 30 minutes. 
Arenas were cleaned with 70% ethanol and allowed to dry between experiments. Thigmotaxis over 
the initially 5 minutes was used as a measure of anxiety in the new environment and was assessed 
as beam breaks within the centre (25 x 25cm) square of the arena. Other measurements calculated 
included average velocity, distance travelled, time immobile and rearing activity (z beam breaks). 
 
Y-maze 
The Y-maze consisted of a Y shaped maze of opaque white plastic with three identical arms set at 
120° angles. The arms were consisted of a home arm, of plain design and two exploratory arms 
where the walls were decorated with different repetitive geometric patterns. For the exploratory 
task, one exploratory arm was blocked from the maze by use of a plastic divider. A subject was 
placed in the home arm and allowed to explore the home arm and remaining exploratory arm for 5 
minutes. The subject was then re-introduced to the maze after a 30 minute period with the arm 
divider removed, allowing for entry into the second, novel, exploratory arm. The movement of the 
mouse around the maze was tracked with EthoVision video tracking software (Noldus, The 
Netherlands). Frequency of entry into the novel arm was used as a measure of short term memory. 
 
MRI analysis of brain regions 
Brains stored for MRI analysis were washed extensively in PBS, followed by 48h incubation in 
gadolinium contrast agent (0.2% Magnevist, Bayer Healthcare Pharmaceuticals, in PBS). Brains 
were imaged on 16.4T small animal vertical wide bore NMR spectrometer (Bruker BioSpin) at the 
Centre for Advanced Imaging, University of Queensland. Brains were immersed in fomblin oil 
(Solvay Solexis, Italy) inside a glass test tube of 10mm diameter and fitted inside a quadrature 
birdcage coil (M2M imaging Inc., USA). T1 weighted images and three dimensional neurite 
orientation and density diffusion images (NODDI) were obtained within a total scan time of 18 
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hours as previously described16. Briefly, NODDI datasets were composed of three B0 and sixty 
optimised direction diffusion-weighted images obtained from Camino software package. Three 
separated b values were used to generated the NODDI dataset, 1000, 4000 and 8000s/mm2, δ/Δ = 
1.1/22, 2.3/7 and 5.6/23ms respectively. The three b value shells were used for generation of the 
NODDI data (ficvf, odi) and the b4000 shell used for generation of the diffusion parameters (FA, 
RD, AD, MD). 
 
Volumetric analysis of the obtained T1 images was achieved using Advanced Normalisation Tools 
(ANTs) software. Briefly, all T1 images were warped to produce a common template image. Warp 
fields containing Jacobian values for the individual images were subjected to a modified T-test 
using the randomise function of FSL (Oxford centre for functional MRI of the brain software 
library, Oxford, UK) in order to determine significantly different Jacobian value voxels between the 
vehicle and PMX53 treated groups. Inverse warp fields were applied to anatomical area mapping of 
the common template to generate volumetric values for regions of sample brains. T1 images and 
generated anatomical masks were visualised and refined in ITKsnap software (University of 
Pennsylvania, USA). Differences in brain regions volume were tested for using Student’s T-test. 
NODDI data was obtained using Matlab (MathWorks, USA) and the NODDI Matlab toolbox 
(UCL, UK). NODDI was used to obtain estimates of intracellular volume fraction (ficvf) and 
neurite orientation and dispersion index (odi). Voxel values for ficvf and odi range from 0 – 1, with 
the scale being correlated to estimated degree of intracellular volume and neurite dispersion, 
respectively. Images were registered using the FSL linear registration tool in order to compare 
anatomically similar voxels between samples. Comparison of each of the diffusion parameters was 
achieved using the randomise function of FSL to generate a probability map of differences between 
vehicle- and PMX53-treated samples. Probabilty maps were thresholded to significance (p ≤ 0.05) 
and displayed on a generated template image. 
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4.4 Results 
 
C5aR1 is expressed in neural progenitor cells and localised in vivo to the apical ventricular zone. 
RT-PCR analysis of whole brain RNA extracts of embryos 12.5-18.5dpc demonstrated C5ar1 
expression throughout the period of embryonic neurogenesis (Figure 4.4.1C). In addition, 
neurospheres derived from the telecephalon of E14.5 mice and the immortalised neural progenitor 
cell line, NE-4C also demonstrated C5ar1 expression by RT-PCR analysis (figure 4.4.1C). Protein 
expression of C5aR1 was demonstrated in embryonic brain, neurospheres and NE4C cell lines 
(representative blot for NE4C culture; figure 4.4.1E) by Western blot at the correct molecular 
weight (50kDa). In vivo, C5aR1 was shown to localise to the apical surface of the ventricular zone 
(figure 4.4.1A). The progenitor cells of the ventricular zone were immunostained with a Pax6 
antibody and nuclei were counterstained with DAPI. In vitro, C5aR1 cell surface expression was 
evident on some, but not all, NE-4C cells in culture when unpermeabilised cells were stained 
(figure 4.4.1D). Membrane permeabilisation through detergent treatment of cells demonstrated 
significant intracellular expression of C5aR1 (data not shown).  
 
Expression of C5aR reduces as neural progenitor cells differentiate 
NE4C cells differentiated in the presence of retinoic acid to neurons over 12 days were collected at 
defined morphological stages17. C5aR1 mRNA expression exhibits a significant reduction in 
abundance between stage II and IV of differentiation, corresponding to the beginning of neuronal 
outmigration in the cultures. Interestingly, the abundance of C5aR1 protein as measured by semi-
quantitative Western blot analysis remains static until reducing at stage VI, the beginning of 
gliogenesis in culture (figure 4.4.1F). 
 
C5a is present in the embryonic CSF at E13.5 
Given the localisation of C5aR1 at the apical ventricular zone in vivo the presence of C5a was 
assayed in the embryonic CSF (figure 4.4.1B). Embryonic and maternal brain tissues were used as 
reference points for the assay. Isolated embryonic CSF demonstrated significantly higher C5a 
concentrations at 13.5dpc than the embryonic telecepalon (14.45 ± 4.189 ng/mL vs. 1.054 ± 0.017 
ng/mg). There was no significant difference found between embryonic brain and maternal brain 
tissues for C5a concentration (figure 4.4.1B). 
  
Figure 4.4.1; Localisation of C5aR1 
and ligands. A) C5aR1 (red) is 
expressed in the developing neocortex 
at the apical surface of the ventricular 
zone from 12.5-18.5dpc. Apical 
progenitors are labeled with Pax6 
(green), nuclei are labeled with DAPI 
(blue). Upper panels show individual 
images from 14.5dpc brain. Lower 
panels demonstrate merged images from 
12.5-18.5dpc. Additionally, C5aR 
localises to the apical surface of 
neurospheres in culture (right panels). 
Scale bar = 50µm. B) Embryonic CSF 
contains C5a at significantly greater 
concentrations than embryonic or 
maternal brain tissue. C) RT-PCR 
demonstrates C5aR1 expression in 
embryonic brain tissue, culture primary 
neural progenitors (neurosphere) and 
immortalized neuroepithelial line (NE-
4C). D) Non-polarised NE-4C cells 
grown in monolayer exhibit inconsistent 
cell surface expression of C5aR1 (red) 
as determined by live-staining. Blue 
indicates DAPI nuclear stain E) C5aR is 
detected within NE-4C cultures by 
western blot at the predicted molecular 
weight. F) Expression of C5aR1 mRNA 
and protein decreases with 
differentiation of NE-4C cells. Stages 
indicate morphologically distinct 
progression of NE-4C differentiation. I 
– Non-induced; II – Initial changes; III 
– Aggregate formation; IV – Neuronal 
outmigration; V – Neuronal maturation; 
VI – Onset of gliogenesis. Relative 
expression is normalised to stage I. 
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C5a causes MAPK signaling in neurosphere culture through a PKCζ dependent pathway 
Western blot analysis of neurosphere cultures treated with 100nM C5a demonstrated a significant 
increase in phosphorylated p42/44 (Erk) over those treated with vehicle (figure 4.4.2A). Treatment 
with 10nM C5a demonstrated a trend towards increased p42/44 phosphorylation, although this was 
not statistically significant. bFGF was used as a positive control for this assay. The increase in 
p42/44 phosphorylation was inhibited by the use of a specific PKCζ pseudosubstrate, GF109203X 
(figure 4.4.2A), indicating a signaling role for PKCζ in the propogation of extracellular signals 
through C5aR. 
 
C5aR1 signalling in NE4C culture causes increased cell polarity 
NE4C cells grown to confluency on transwell supports demonstrate secondary characteristics of 
increased polarity. Treatment with C5a for 6 hours caused a close association of the microtubule 
organising centre (MTOC) with the calculated centre point of the apical membrane (figure 4.4.2B). 
In addition, the apical surface area of C5a-treated cells was markedly reduced when compared to 
the vehicle treated group, suggesting active constriction of this area in response to C5a. 
 
C5a increases NE4C migration in scratch assays 
To assess the downstream actions of C5aR1 on second messengers within neural progenitor cells 
we employed the NE-4C line in vitro. Migration assays demonstrated a significant increase 
(p=<0.01, one-way ANOVA) in migration after 12 hours upon administration of C5a, an effect that 
could be blocked through the use of the PKCζ inhibitor GF109203X (p=<0.01, one-way ANOVA) 
(figure 4.4.2C). There were no significant differences in migration between the vehicle wells and 
those with either PKC inhibitor alone, or PKC inhibitor + C5a. We were unable to demonstrate Erk 
or Akt phosphorylation by Western blot, however this may be due to only a fraction of these cells 
expressing membrane bound C5aR1 at any one time (figure 4.4.1D). 
 
  
Figure 4.4.2; Signalling through C5aR1 is PKCζ dependent. 
A) Treatment of neurospheres with C5a causes a dose-dependent 
increase in phospho-p42/44 (erk), which is abrogated through 
pre-treatment with PKCζ inhibitor. B) NE-4C cells grown on a 
transwell membrane respond to 10nM C5a treatment through 
constriction of the apical surface area (area within ZO-1 stain, 
red) and centralisation of the MTOC, marked by acetylated 
alpha-tubulin stain (green). White arrows indicate distance 
between apical centre point and MTOC. C) C5a induces 
migration of NE-4C cells in scratch assay and can be inhibited 
through pretreatment with PKCζ inhibitor. Representative 
images with approximate cell boundaries are displayed. * = 
p≤0.05, ** = p≤0.01, *** = p≤0.001. 
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C5a increases the number and diameter of neurospheres in culture 
Repassaging and growth for 7 days of neurospheres in media containing C5a resulted in 
neurospheres of greater number and diameter than those repassaged in media containing vehicle 
(figure 4.4.3A&B). However, administration of PMX53 did not alter either diameter or number of 
neurospheres, suggesting that there is negligible endogenous generation of C5a by neurospheres in 
vitro. Culture of neural progenitors over 3 days in the presence of C5a caused an increase in 
proliferation as measured by nucleic acid indirect fluorescence (figure 4.4.3C). Administration of 
C5a to neural progenitor culture also results in an upregulation of cyclin genes, significant 
upregulation of cyclin B1 (G2-M transition) and D1 (G1-S transition) were noted (Diagram, figure 
4.4.3D). 
 
 
Figure 4.4.3; C5a treatment increases proliferation of progenitors in vitro. A) Neurosphere diameter is 
significantly greater in cultures containing 10nM C5a. The presence of a C5aR1 antagonist, PMX53, did not change 
neurosphere diameter. B) Neurosphere number in culture is significantly increase in the presence of 10nM C5a, 
PMX53-treatment did not change number. C) There is upregulation of cyclins B1 and D1 in neurosphere culture after 
12 hours in the presence of 10nM C5a. D) Diagramatic representation of cyclin expression throughout the cell cycle. 
*p≤0.05, **p≤0.01. 
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Figure 4.4.4; C5aR1 signalling results in increased proliferative divisions in vivo. A) In utero intraventricular 
injection at 13.5dpc of 1µL 100nM C5a results in an increased number of M-phase cells per 100µm in the telecephalic 
ventricular zone after 24 hours. Conversely, injection of 10µM PMX53 reduces the number of M-phase cells. 
Representative images of M-phase cells marked by phosphohistone H3 staining are displayed. B) In utero treatment 
with PMX53 increases the number of asymmetric divisions at the expense of symmetric divisions. Cleavage planes of 
apical ventricular zone cells were catagorised as symmetric (60-90°), oblique (30-60°) or asymmetric (0-30°) 
according to the diagram on the right. C) Systemic treatment of dams from 12.5-14.5dpc with 1mg/kg/day PMX53 
resulted in a reduced ratio of mitotic (Sox2) to post-mitotic (Dcx) layer thickness in 15.5dpc embryos. Representative 
images are displayed at 100µm sections of telencephalon. **p≤0.01, ***p≤0.001, ****p≤0.0001. 
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C5aR1 signalling increases the proliferation of neural progenitor cells of the embryonic ventricular 
zone. 
C5aR1 was stimulated or inhibited in ventricular zone neural progenitors by in utero injection of 
C5a or C5aR1 antagonist, PMX53, into the embryonic ventricular system at 13.5dpc. 24 hours post-
injection embryos administered C5a demonstrated a significant increase in the number of apical 
progenitors in M-phase of the cell cycle as indicated by phosphohistone H3 staining. Blockade of 
C5aR1 signalling by injection of PMX53 resulted in a decrease in the number of M-phase apical 
progenitors after 24 hours when compared to vehicle injected littermates (figure 4.4.4A). In 
addition, analysis of the cleavage plane of actively dividing cells in these samples demonstrated a 
significant shift from symmetric to asymmetric division with PMX53 treatment (figure 4.4.4B). 
 
Blockade of C5aR1 from 12.5-14.5dpc resulted in behavioural abnormalities in the adult mouse 
To determine whether this apparent cell cycle inhibition resulted in an increase in neurogenesis we 
administered PMX53 over an extended period to pregnant dams and use markers of mitotic and 
post-mitotic cells to evaluate gross changes in cell populations. Daily intraperitoneal administration 
of PMX53 to the dam over the period of 12.5-14.5dpc, to globally block C5aR1 signalling resulted 
in a reduction in the size of the ventricular zone in the embryo. The reduction in progenitor cells in 
the ventricular zone, as measured by Sox2 staining, was accompanied by an increase in the 
thickness of the maturing cortex demonstrated by the post-mitotic maturing neuron marker 
doublecortin (DCX). Pharmacological blockade of C5aR in these animals resulted in a significantly 
decreased Sox2/DCX ratio (figure 4.4.4C). 
 
Mice subjected to PMX53 dosing in utero demonstrated behavioural abnormalities in adulthood 
(experimental timeline; figure 4.4.5A). Litters showed normal fetal number (figure 4.4.5B), weight 
at birth (figure 4.4.5C) and growth postnatally (figure 4.4.5E), however there was a slight, but 
significant, reduction in crown-rump length of the PMX53 treated litters. On behavioural testing the 
adult mice showed no significant difference in peripheral nervous system motor scores, as measured 
by grip strength (figure 4.4.5F). However, on balance beam testing of motor coordination, PMX53-
treated animals demonstrated significant differences from their vehicle treated counterparts. 
PMX53-treated males also showed and increase in time-taken to cross the beam and footfall errors 
for both hindlimb and forelimb (figure 4.4.5G-H). PMX53-treated females did not 
  
Figure 4.4.5; PMX53-treatment 
during development causes 
behavioural abnormalities in the 
adult. A) Diagrammatic 
representation of time-line for 
experiment. Animals were 
administered 1mg/kg/day PMX53 
or vehicle control 12.5-14.5dpc. 
Animals were tracked from birth 
and underwent behavioural testing 
between 6 and 8 weeks postnatal. 
Animals were then culled for ex 
vivo MRI analysis. B) Fetal number 
per litter (n≥5). C) Birth weight 
(n≥30). D) Crown-rump length E) 
Weight gain over 33 days post-
natally F) Grip strength. F, 
forelimb. H, hindlimb. G & H) 
Balance beam, time to cross(G), 
footfall errors (H) F, forelimb. H, 
hindlimb. I) Open field test, 
distance moved in centre area over 
5 minutes. J) Y-maze, frequency of 
entry to novel arm. K) Forced swim 
test, time spent immobile. n≥8 per 
group (F-K). n.s, not significant, 
*p≤0.05, **p≤0.01.  
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exhibit a difference in time to cross and only showed a significant difference in the number of 
footfall errors of the forelimb (figure 4.4.5G-H). This difference between gender likely represents 
the weight difference between males and females at this age, accentuating any errors made in motor 
coordination. On open field test, PMX53 animals of both genders demonstrated a decrease in 
distance travelled in the centre areas of the cage (figure 4.4.5I). This increase in thigmotaxis is often 
interpreted as a relative measure of anxiety in the novel environment. The Y-maze was used to 
assess short-term memory, and frequency of entry into the novel arm was reduced in both genders 
of the PMX53-treated animals. Finally, PMX53-treated animals also demonstrated a significantly 
decreased time spent immobile in the forced swim test, used to assess depressive symptoms in 
laboratory mice. 
 
 
Blockade of C5aR1 from 12.5-14.5dpc resulted microstructural differences on MRI analysis 
Ex vivo MRI analysis of the brains of male PMX53-treated animals from the behavioural 
experiments demonstrated microstructural differences when compared to their wild-type 
counterparts. In the volumetric analysis, warp fields of the Jacobian values required to shape each 
sample to a collective template were compared. Jacobian values are inversely correlated to the 
amount of stretch required to fit an area to the template image, and therefore are suggestive of 
volumetrically different areas between the sample groups. Vehicle treated animals showed 
significantly (p < 0.05) increased clusters of Jacobian values throughout the cortex and thalamus 
(volumetric red/yellow figure 4.4.6) indicating that more stretch was required to fit the PMX53 
images to the template in these areas. However, analysis of whole brain regions of the T1 weighted 
images failed to show any significant volume differences (table 4.4.1). Interestingly, in multiple 
brain regions the data for the PMX53 treated animals showed wider variation in values than the 
vehicle treated group (table 4.4.1), suggesting a perturbation of normal development. 
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 Vehicle treatment PMX53 treatment  
Area Volume (mm3) Std Error n Volume (mm3) Std Error n p value 
Amygdala 10.24 0.1425 7 10.18 0.2929 9 0.8764 
Caudate/Putamen 23.25 0.4326 7 22.85 0.5933 9 0.6175 
CC and External Capsule 8.213 0.102 7 7.891 0.331 9 0.4203 
Central Grey Matter 4.476 0.05 7 4.339 0.07 9 0.1762 
Cerebellum 46.96 0.3563 7 42.83 1.764 9 0.0624 
Fimbria 2.007 0.028 7 1.928 0.05576 9 0.2702 
Globus Pallidus 2.485 0.055 7 2.368 0.046 9 0.1209 
Hippocampus 24.71 0.287 7 24.31 0.5846 9 0.5832 
Hypothalamus 11.61 0.162 7 11.17 0.284 9 0.234 
Neocortex 125.5 1.84 7 121.5 3.45 9 0.3668 
Olfactory Bulbs 17.88 0.2216 6 16.53 0.7673 9 0.1858 
Thalamus 25.19 0.095 7 24.69 0.732 8 0.5444 
 
Microstructural analysis demonstrated multiple regions of difference in the FA values between 
PMX53- and vehicle-treated animals. FA values were higher in the white matter tracts, olfactory 
bulbs, hippocampus and frontal cortex of PMX53 treated animals (figure 4.4.6). This is suggestive 
of increased myelination, increased axonal density or a reduction in crossing fibres in these areas18. 
Directional diffusion (RA, AD, MD) demonstrated no significant difference between treatments 
(figure 4.4.6). NODDI parameters were compromised by shadowing due to brain movement during 
scanning, which is likely the cause of the unilateral appearance of significant voxels. Ficvf values 
showed a significant increase in the vehicle treated brain in the posterior neocortex. Specific areas 
demonstrating increased ficvf include; visual/auditory cortex, primary somatosensory cortex, 
posterior parietal association cortex and CA1 pyramidal layer of the hippocampus. Significantly 
increase odi values were detected in PMX53 samples in the amygdala, CA1/dentate gyrus regions 
of the hippocampus, external and internal capsules, and the visual/somatosensory regions of the 
neocortex (figure 4.4.6).  
 
Table 4.4.1; Anatomical area MRI volumes derived from T1 weighed images. 
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Figure 4.4.6; MRI analysis of adults brains subjected to vehicle- or PMX53-treatment (1mg/kg/day 12.5-
14.5dpc) in utero. Sagittal sections of template images are masked with significant areas of difference between 
groups. Red masking represents areas for which voxels within the vehicle-treatment voxel signal is significantly 
greater than PMX53-treatment. Conversely, blue masking represents voxels where PMX53>Vehicle. Significance 
threshold was set at p≤0.05. FA, fractional anisotropy; AD, axial diffusivity; RD, radial diffusivity; MD, mean 
diffusivity; ficvf, intracellular volume fraction; odi, neurite orientation and dispersion index. 
Chapter 4 C5aR1 and Neural Progenitors 
 
 144	
4.5 Discussion 
 
This study follows on from the novel demonstration that the complement anaphylatoxin receptor, 
C5aR1, is present during embryonic neurogenesis on neural progenitor cells5. Proteins of the 
complement system have previously been shown to be present during embryogenesis and play 
novel roles in regeneration1,2,4. However, here we have shown for the first time that C5aR1 
functions in vivo to retain neural progenitors within the ventricular zone, likely through PKCζ 
activation.  
 
C5aR1 was found to localise to the apical membrane of ventricular zone progenitor cells throughout 
embryonic development (12.5dpc – 18.5dpc). This localisation is intriguing given the importance of 
the apical membrane attachment to the fate of the progenitor cell6. The apical membrane of 
ventricular zone progenitors is crucial for the polarisation of the cell and loss of this apical 
attachment during mitosis is a catalyst for differentiation toward a post-mitotic state. The apical 
membrane attachment acts as an anchor for determinants of polarity such as the Par3/Par6/aPKC 
complex and stem cell marker, prominin-16. Additionally, in neurosphere culture, expression of 
C5aR1 also localised to the apical (outer) surface of the neurosphere, indicating a predilection of the 
receptor to the apical membrane in this cell type. Interestingly, in NE-4C monolayer culture, live 
staining revealed that C5aR1 was not readily expressed on the cell surface, despite significant 
mRNA and protein expression. Given that we also demonstrated a reaction of these cells to C5a 
when polarized, either by scratch assay or transwell culture, it is tempting to hypothesise that the 
polarity of the cell dictates C5aR1 cell surface expression. NE-4C cells also demonstrated a >5-fold 
down-regulation of C5aR1 expression, both protein and mRNA, with the onset of differentiation, 
and loss of polarisation.  
 
Given the apical localisation of C5aR1, it was suspected C5a concentrations within the embryonic 
CSF would be elevated when compared to the surrounding brain tissue as it directly borders the site 
of C5aR1 expression. Indeed, this was found to be the case and significantly differed from C5a 
concentrations in both embryonic and maternal brain tissue. Little is known about the 
concentrations of C5a present in normal adult CSF, but studies in humans suggest that the 
concentrations found in the present chapter are equivalent to those in survivable pneumococcal 
meningitis, and greater than those found in patients with multiple sclerosis19,20. This suggests that 
the C5a concentrations in mouse embryonic CSF, found here in the order of 1nM, are biologically 
relevant.  
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In vitro, we have demonstrated that C5aR1 signals via PKCζ to induce p42/44 phosphorylation in 
neural progenitors. This association with PKCζ fits with the subcellular localisation of C5aR1 in 
vivo at the apical membrane of neural progenitor cells21. Here PKCζ acts upstream of p42/44 to 
promote proliferation and maintenance of cell polarity21,22. Functionally, blockade of PKCζ inhibits 
p42/44 phosphorylation in neurospheres and the migrational effect of C5a in a NE-4C scratch assay. 
Additionally, in NE-4C cells grown to confluency on a transwell membrane, C5a treatment appears 
to increase characteristics of polarisation, as evidenced by the centralised MTOC and constricted 
apical membrane. However, this observation warrants further investigation, specifically z-stack 
images incorporating staining for apical membrane markers. However, taken together with the 
localisation and signalling data, it is likely that C5aR1 promotes polarity through PKCζ in these 
progenitor cells. 
 
In neural progenitor cells, polarity and the cell cycle are intrinsically linked6,14. In neurosphere 
culture, C5a treatment increased neurosphere diameter and neurosphere number over the period of a 
week in culture. This suggests that C5a promotes the proliferation and survival of neural progenitor 
cells and is supported by the observation that 12 hours of C5a treatment increases cyclin B1 and D1 
expression in neurosphere culture. In vivo, we have demonstrated that intraventricular injection of 
C5a to embryos in utero results in an increased number of apical progenitors in M-phase. 
Conversely, blockade of C5aR1 signalling results in a decreased number of apical progenitors in M-
phase. Combined with our findings of C5a in embryonic CSF, this supports an endogenous 
physiological role for C5a-C5aR1 signalling in neurogenesis. Systemic treatment of dams with the 
C5aR1 antagonist, PMX53, over the period of 3 days (12.5-14.5dpc) also demonstrated a reduction 
in the ratio of mitotic/post-mitotic cells in the embryonic telencephalon. This finding may be 
explained by analysis of the cleavage plane of apical progenitors post-injection of PMX53, which 
shows an increase in the number of asymmetric, neurogenic division at the expense of symmetric, 
proliferative divisions. Again, these observations support a role for C5aR1 in the maintenance of 
polarity in the apical progenitor population. 
 
Whilst the cellular functions of C5aR1 in this chapter have focused on the apical progenitors of the 
embryonic telencephalon, its actions on neural progenitors may have wider implications. There 
have been previous reports of C5aR1 stimulating progenitor proliferation in post-natal cerebellar 
development and post-ischaemic stroke23-25. The behavioural and MRI analysis in the present 
chapter targeted the effect of C5aR in the period of telencephalic neurogenesis by administering 
systemic PMX53 to the dams throughout the period of 12.5-14.5dpc6. However, the results from 
these experiments demonstrate a broad pattern of impaired neural development, rather than an effect 
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concentrated within the neocortex. Behaviourally, mice treated with PMX53 displayed impaired 
central motor control (suggestive of cerebellar anomalies), impaired memory (suggestive of 
hippocampal involvement) and increased anxiety (a marker of limbic system function). 
Additionally, the forced swim test, typically a measure of depressive symptoms as recorded by time 
spent immobile, showed that PMX53-treated animals spent less time immobile than their wild-type 
counterparts. This test is contentious in the literature as, although it is responsive to a test of human 
anti-depressants, its use in the elicitation of neurobiological causes of depression is less 
concrete26,27. Regardless, the behavioural data presented in this chapter are suggestive of broad 
neurological differences as a result of acute C5aR1 antagonism in utero. 
 
Structurally, C5aR1 blockade in utero did not result in any significantly altered volumes of 
anatomically distinct brain areas. However, whilst brain region volume was tightly clustered in the 
vehicle-treated group, animals subjected to PMX53 treatment demonstrated a wider range of brain 
region volumes. Additionally, Jacobian analysis of volume suggests small clusters of decreased 
volume within the neocortex of the PMX53 treated animals, that volumetric analysis of whole 
regions may not be sensitive enough to detect. Interestingly, previous studies in our laboratory that 
treated folate-deficient dams systemically with PMX53 demonstrated a 50% penetrance of neural 
tube defects, with the remainder of the litters being morphologically normal5. It may be that the 
treatment dose of 1mg/kg/day intraperitoneally is towards the lower end of efficacy. This dose is 
frequently used for studies of immune-mediated disease, however in these models distribution of 
the drug is not impeded by the feto-maternal interface and additional pharmacokinetics of the 
embryo28,29. In future studies, it would be valuable to analyse the pharmacokinetics of PMX53 in 
this model. 
 
Despite a lack of volumetric differences between vehicle- and PMX53-treatment groups, there is 
tangible evidence of microstructural differences on MRI. PMX53-treated animals showed a 
significant, anatomically broad increase in FA values when compared to vehicle-treated controls. 
The FA value represents the confinement of water diffusion within a given voxel, with high values 
indicating restriction of diffusion to one axis, and low values indicating free diffusion, or crossing 
of equally restricted fibres30. The FA value is not easily correlated to pathology, as multiple studies 
have indicated that deviation from the normal FA value is seen in several neural pathologies. For 
instance, lower FA values are present, predictably, in demyelination disorders, such as multiple 
sclerosis31. However higher FA values do not necessarily indicate better neuronal function, and are 
evident in cases of alcoholism, meningitis and traumatic brain injury32-34. No differences were 
evident in the rate of axial or radial diffusion between the two treatment groups. 
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NODDI imaging allows for estimation of the compartmentalisation of water within the brain tissue 
and gives outputs of estimated intracellular volume fraction (ficvf), extracellular volume fraction 
(iso) and neurite orientation and dispersion (odi)16. The NODDI analysis demonstrated differences 
between the vehicle and treated groups for ficvf, where increased intracellular volume was found 
vehicle-treated brains in the posterior neocortex and is suggestive of a greater cell density in these 
areas. Additionally, odi analysis showed an increased neurite orientation and dispersion index 
throughout the amygdala, hippocampus and posterior neocortex of PMX53 treated animals. 
Increased odi typically denotes a less organised or immature microstructure, and is suggestive of 
impaired brain development within the PMX53 treated group. Collectively, the MRI data suggest a 
lower cell density and reduced branching of the neurons within the PMX53 treated brains. These 
MRI results, whilst promising, need to be further evaluated through detailed histological analysis to 
truly interpret their meaning. 
 
C5aR1 knockout mice have not been reported to have any apparent gross neuronal or neurological 
deficits. This is further discussed in chapter 6, where knockout animals are taken through a series of 
behavioural tests. However, given the marked differences, both at the molecular and functional 
level, with the pharmacological modulation of C5aR1 signalling during embryonic brain 
development shown in the present chapter it is tempting to hypothesise that C5aR1 deficiency from 
conception onwards promotes early compensatory mechanisms within the embryo. C5aR1 is 
present and functional at the earliest points of development on human embryonic stem cells35, an 
observation that suggests compensatory mechanisms for function must be developed at least at the 
blastocyst stage. Addtionally, folate-deficient stress of the C5aR1 knockout embryo leads to 
impaired brain development, indicating that C5aR1 signalling is not entirely redundant despite the 
presence of any compensatory mechanisms for loss of function5. Currently, the pharmacological 
approaches to modulating C5aR1 signalling in the embryo had the caveat of global inhibition of 
C5aR1. However, there is a C5aR1 conditional knockout under construction (Trent Woodruff, 
personal communication) that may help elucidate the receptors true role in the development of the 
brain, without the question of compensation present in the full knockout. 
 
In conclusion, the present study has demonstrated a novel signalling pathway and function for 
C5aR1 on neural progenitor cells within the mouse embryo. With regards to clinical implications, 
this discovery should serve as a warning to the development of C5aR1 antagonists as a treatment of 
pregnancy-related inflammatory disease. In addition, in combination with recent work that 
demonstrates a two-phase role for C5aR1 in neural injury (promoting inflammation followed by 
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repair), it is becoming clear that use of C5aR1 modulators in these pathologies should be temporally 
regulated to avoid potential unintended inhibition of tissue regeneration25,36. 
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Chapter 5 
 
C3aR promotes differentiation of neural progenitor 
cells
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5.1 Introduction 
This thesis has previously discussed, in chapter 4, the role of C5aR in regulating neural progenitor 
cell fate. C5a is often grouped with its upstream cousin, C3a, as a complement anaphylatoxin. 
While this nonclamenture has recently been challenged1, there is no doubt that these molecules 
share evolutionary and, some, functional similarities2. This chapter aims to investigate the role of 
the canonical receptor for C3a, C3aR in neural progenitor proliferation. 
An extensive background on C3aR and its ligand, C3a, can be found in appendix A and chapter 1.6, 
respectively. These chapters summarise the literature in general surrounding C3a, C3aR and their 
interactions. This introduction briefly recaps the pertinent points for the understanding of this study. 
C3aR in the CNS 
C3aR is expressed within the adult CNS on both neurons and glia and has been implicated in the 
response to CNS disease3. The expression pattern of neuronal C3aR in adult brains appears 
restricted to the granular layers of the neocortex, the hippocampal neurons and Purkinje cells of the 
cerebellum3,4. Expression on astrocytes and microglia within the non-diseased brain is low and 
restricted to subgroups of cells, but significantly upregulated in disease states4-6. 
Importantly, the expression of C3aR in neural stem cells within the adult brain has also been 
reported. In culture, neural progenitor cells derived from adult brains show altered Erk1/2 response 
to SDF-1α in the presence of C3a7 and increase migration8. In vivo, interruption of C3aR signalling 
results in reduced basal neurogenesis9. These data demonstrate that modulating the C3a-C3aR axis 
has the potential to aid in neurogenic recovery post-cerebral ischaemia. However, in the disease 
state, the experimental conditions may affect the conclusions drawn over whether stimulation or 
inhibition of C3aR would be beneficial10. Seemingly contradictory reports of infarct volume size 
following MCA stroke have been reported in C3-/- mouse models; infarct size was increased in 
permenant MCA occlusion of C3-/- animals when compared to wild types, but relatively reduced in 
a transient model9,11. Additionally, C3-/- animals have been reported to exhibit reduced neurogenesis 
in response to cerebral ischaemia, whereas treatment with C3aR antagonist, SB290157, increases 
neurogenesis and functional outcomes post-injury9,12,13. The relative balance between the 
inflammatory and regenerative aspects of the C3a-C3aR axis specific to each experimental model 
may go some way to explain these perplexing results1. 
Intriguingly, C3a may not be the sole perpetrator of C3aR-mediated actions within the CNS. It was 
recently discovered that the cleavage product of neuropeptide VGF, TLQP-21, is a ligand for 
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C3aR14. This peptide has been demonstrated to exert effects on metabolism and energy storage, and 
perhaps provides and route of C3aR activation devoid of immune implications15. 
C3aR in development and regeneration 
The C3a-C3aR axis has been reported to have functional roles in both adult tissue regeneration and 
the developing embryo. There is strong evidence of a role for C3aR in the developing brain. 
Cerebellar development in rodents continues post-natally and there is proliferation and 
differentiation present within the granular layers8. Administration of C3aR agonists during the 
postnatal period initiated differentiation of progenitor cells within the cerebellum resulting in 
marked histological differences between C3aRA- and vehicle-treated animals8. In non-mammalians, 
Xenopus laevis embryos express both C3 and C3ar1 during development. C3 appears as markedly 
restricted expression to the neural groove and follows the path of neural crest migration during the 
period of neural tube closure16. C3aR stimulation acts to mediate co-attraction between neural crest 
cells within the migratory streams, and abrogation of this signal leads to disordered migration 
within Xenopus embryos17. 
Additionally, the C3a-C3aR axis has been reported to have functional roles in the regeneration of 
both embryonic and adult tissues. In the chick retina post-retinectomy in ovo, exogenous C3a acts 
through STAT-3 signalling to induce retinal regeneration from the stem cell niche18. Similarly, after 
toxic injury to the liver, C3-/- mice demonstrate reduced proliferation and tissue repair when 
compared to wild type counterparts. The increased proliferation in C3+/+ animals was shown to be 
mediated entirely through the actions of C3a, as exogenous C3a could restore the phenotype of C3-/- 
mice19. C3a also acts on Kupffer cells, post-hepatectomy, to induce the production of factors 
necessary for hepatocyte survival and regeneration20. In support of this, C3-/- animals demonstrate 
increase liver necrosis and reduced proliferation post-surgery20. In newt limb and lens regeneration 
C3 is expressed at the mRNA level in the wound ectoderm and suggested to signal to the blastema 
due to the observation of elevated C3 split products in that region 21,22.  
Interesting work with cardiac stem cells demonstrates that C3a is able to promote the migration and 
proliferation of this population. However, its role here and putative functions post-infarct, are a 
double-edged sword. Whilst the promotion of regenerative potential is promising, C3a also acts to 
guide these cells through a myofibroblast differentiation pathway, increasing the likelihood of scar 
formation over functional tissue repair23. 
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A New Approach to C3aR in Embryonic Neurogenesis 
In light of the perspectives offered by the literature on C3aR in development and regeneration, this 
chapter investigates a role for C3aR on embryonic neural progenitor cells. This aspect of C3aR 
function has recently come to the fore on multiple types of progenitor cells, in addition to reports of 
a functional response to C3a on both adult and postnatal neural progenitor cells7-9. Here we ask 
whether C3aR contributes to the normal physiological development of the CNS, and whether it 
alters neural progenitor physiology in culture. 
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5.2 Methods 
Neurosphere Culture 
Neurospheres were cultured as previously described (Chapter 4). Briefly, the neocortex of E14.5 
embryos was dissected using sterile technique in Hanks balanced salt solution (HBSS) (Sigma 
Aldrich, USA). Trypsin-EDTA solution (Sigma Aldrich, USA) supplemented with 2 kU Bovine 
pancreas DNase (Sigma Aldrich, USA) was used to dissociate the tissue and a single cell 
suspension was achieved by passing the dissociate through a 40µm cell filter (Biologix, USA). 
Trypsin was removed from the culture through 2 wash/centrifugation cycles with 1x HBSS. Cells 
were cultured to form neurospheres for one week in DMEM/F12 (Sigma Aldrich, USA), 1x B27 
supplement (Life Technologies, USA), 1x Penicillin/Streptomycin (Sigma Aldrich, USA), 20ng/mL 
FGFb (Millipore, Germany) and 20ng/mL EGF (Millipore, Germany) at 37°C, 5% CO2. Passaging 
of neurospheres was achieved as described above, using Trypsin-EDTA/DNase solution after 
centrifugation. 
Immunofluoresence 
For immunofluorescence analysis of C3aR expression, wild type C57BL6/J time-mated mice were 
sacrificed at E14.5. Embryonic brains were dissected into 4% PFA and fixed overnight at 4ºC 
before the generation of coronal cryostat sections at 12µm. Matched sections of the mid-neocortical 
region were used in this study. After washing with PBS, sections were blocked in 5% goat 
serum/0.1% Triton X-100 and incubated with primary antibody (1:250 Chicken anti-mouse C3aR 
BMA Biomedical, Switzerland; 1:300 Rabbit anti-mouse CD133, AbCam, UK) overnight at 4ºC. 
Sections were washed and incubated with a complementary secondary antibody (1:1000, Alexafluor 
secondaries, Life Technologies, USA) for 2 hours at room temperature. Nuclei were stained with 
1:50,000 dilution of 4’,6-diamidino-2-phenylindole (DAPI) before mounting using Prolong gold 
(Life Technologies, USA). Sections were imaged using an Olympus BX51 confocal microscopy 
system. 
PCR 
Neurospheres were collected for RNA isolations by centrifugation from normal culture conditions. 
LPS-stimulated, BV-2 control cells, a mouse microglial cell line, were collected as a positive PCR 
control. RNA was extracted using a RNeasy kit (QIAGEN, The Netherlands) according to the 
manufacturer’s instructions. Post-extractions RNA was treated with DNase-I (New England 
Biolabs, USA) to removed genomic DNA contamination and 1µg RNA reverse transcribed to 
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cDNA using a Tecto reverse transcription kit with random hexamer priming (Bioline, UK) 
according to the manufacturer’s instructions. Primers for C3ar1 (F – 
CCCCCAGCCTCTTCTTTATC; R – AGCCTAAGGCCCTTCTCTTG, 60°C annealing 
temperature, 732bp expected product), C3 (F – ATGCTGATGCTGGATGCTAGGCTGA; R – 
TAGGCTGATCGGATGCTGAGCTAGCT, 60°C annealing temperature, 567bp expected product) 
and ActB (F – GTGGGCCGCCCTAGGCACCAG; R – CTCTTTGATGTCACGCACGATTTC, 
540bp expected product) were used to amplify transcript using MyTaq Redmix (Bioline, UK), 60°C 
annealing temperature, 35 cycles. PCR products were visualized under UV light post agarose gel 
electrophoresis and staining in 0.5µg/mL ethidium bromide solution. 
In utero delivery of drug 
Time mated C57BL6/J mice at E13.5 were obtained from University of Queensland Biological 
Resources (UQBR). E13.5 embryos were subjected to surgical delivery of C3aR modulators as 
previously described (Chapter 4). Briefly, anaesthesia of dams was achieved using 1.5% isofluorane 
in 2L/min O2. The uterus was exposed in the abdominal cavity through an incision following the 
linea alba. 100nM EP141 (Wuxi Peptides, China) in dH2O, 10µM SB290157 (Calbiochem, USA) 
dissolved in dH2O/0.05% DMSO/0.95% ethanol and appropriate vehicle controls were 
supplemented with DNA loading buffer (New England Biolabs, USA). Within a litter embryos were 
designated to receive a treatment or vehicle control and approximately 1µL of solution was 
delivered to the embryonic ventricle through microinjection using a pulled glass pipette. Post 
surgery the dams were provided 0.1mg/kg subcutaneous burprenorphine analgesia and 
subcutaneous fluid resuscitation with ~2mL Ringer’s solution. 24 hours post surgery dams were 
sacrificed by cervical dislocation and embryonic brains isolated to 4% paraformaldehyde for 
fixation. 
Determining M-phase cell density at E14.5 
M-phase cell density in the embryonic ventricle was assessed as previously described (Chapter 24 
ref). Briefly, sections were incubated with anti-phosphohistone H3 antibody (#9706 1:1000 CST, 
USA) overnight at 4ºC, washed and subjected to secondary antibody incubation with alexafluor 
anti-mouse 555 (A-21422 Molecular Probes, USA) at room temperature for two hours. Sections  
were imaged at 20x magnification on an upright BX51 fluorescent microscope (Olympus, Japan). 
Phosphohistone H3 positive cells were counted and displayed as mean positive cells per 100µm. 
Significance was determined by ANOVA with Dunnett’s post-test using Prism 6 software 
(Graphpad, USA). Final n’s per group for this analysis were; EP141-treated - 6, vehicle control – 6; 
and SB290157-treated - 7, vehicle control - 7 embryos. 
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BrdU assay 
Neurospheres were taken to single cell suspension as described above and plated 1000/cells per well 
in 200µL media, 96-well cell culture plate. After three days of culture BrdU was added to culture 
media to a final concentration of 3µg/mL and wells were treated with either DMEM/F12 (vehicle 
control), 10nM EP141, 100nM EP67 (Wuxi Peptides, China) or 1µM EP54 (Wuxi Peptides, China), 
3 wells per group. Cells were incubated at 37°C/5% CO2 f r 48 hours before centrifugation and 
lysis. Proliferation in neurospheres within the 48 hour time period was assessed using the BrdU cell 
proliferation kit (EMD Millipore, Germany) according to manufacturer’s instructions. Cell lysates 
were probed for the presence of BrdU through the use of an anti-BrdU antibody and horse-radish 
peroxidase conjugated complementary secondary antibody. BrdU incorporation was quantified 
colourmetrically using a 3’,3’,5,5’-tetramethylbenzidine substrate and spectrophotometric analysis 
at 650nm. 
qPCR for Tis21 
Mature neurospheres were washed in HBSS and plated in DMEM/F12 media +/- 100nM EP67. 
Spheres were incubated at 37°C/5% CO2 for 12 hours before centrifugation and lysis for RNA 
extraction. RNA extraction and cDNA synthesis was performed as described for RT-PCR. Primers 
for Tis21 (F – ATCAGTTGTCCTGAGCTCCGTCTG, R – 
TGGAAGCAACCTCGTCACAAACC) and 18s (F – CCCTCCAATGGATCCTCGTT, R – 
TCGAGGCCCTGTAATTGGAA) were used at 70nM concentration with 1x Platinum SYBR green 
qPCR mix (Applied Biosystems, USA). qPCR was performed on a OneStep system (Life 
Technologies, USA) at 60°C annealing temperature and 18s Ct values were used to normalize the 
Tis21 data. All data was normalized to the average control value. Data was analysed in Prism 6.0 
(Graphpad, USA) using a student’s T-test. 
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5.3 Results 
C3aR is expressed on neural progenitor cells in vivo 
In vivo, C3aR is localised to the apical surface of the ventricular zone in embryonic brains, from the 
point of neural tube closure to birth (figure 5.3.1). The expression pattern for C3aR bears a striking 
resemblance to the expression pattern of C5aR1, previously described in chapter 4. In contrast to 
C5aR1, C3aR expression is more prominent on distinct cells within the subventricular zone and 
cortical plate, which may represent newly-born migrating neuroblasts. 
 
 
Figure 5.3.1 C3aR is expressed by neural progenitor cells throughout the period of embryonic neurogenesis. 
Immunofluorescence demonstrating C3aR expression (green) concentrated on the apical surface of the ventricular 
zone in the embryonic neocortex. Upper panel images from left to right indicate representative images from samples 
12.5-18.5dpc. Lower images demonstrate matched secondary-only controls. Ventricular surface is the inferior 
portion of the image. White scale bar represents 20µm. 
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C3aR is expressed on neurospheres in vitro 
In order to utilise neurosphere culture as a model system for the investigation of C3aR in neural 
progenitor physiology, the expression of C3aR was demonstrated and compared to the in vivo 
results. RT-PCR demonstrated the expression C3aR in RNA extracts from neurosphere cultures 
seven days after passaging. Interestingly, the precursor for the C3a, C3, was also detected in 
neurosphere culture. 
 
 
Neurospheres were collected for immunofluorescence analysis in tandem with RT-PCR samples. 
Neurospheres were sectioned at 12μm in order to determine localisation of C3aR within the culture 
model. C3aR was localised in neurospheres to the apical surface, represented within culture by the 
outer portion of neurospheres (figure 5.3.3). Here, C3aR demonstrated co-localisation to apical 
surface – and progenitor cell marker – prominin-1 (CD133). This pattern of expression in culture, 
mimics the observations in vivo (figure 5.3.1). 
  
Figure 5.3.2 C3aR is expressed by neurospheres. Neurospheres seven days in culture after passage one were used 
for RNA extraction and analysed for the presence of C3 (top panel) and C3aR (middle panel). Activated microglial 
cells line (BV-2) was used as a positive control, and water (H2O) as a negative control. Beta-actin expression 
(bottom panel) controlled for gDNA contamination through the use of primers spanning an intron (540bp product 
RNA; 1060bp product gDNA). 
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Figure 5.3.3 C3aR is expressed on the apical surface of neurospheres. Neurospheres seven days in culture after 
passage one were isolated and sectioned for immunofluorescence analysis. C3aR (top right) localises to the apical 
(outer) surface of neurospheres, with little to no staining evident within the core. Nucleus is visualised with DAPI 
staining (top left). Merge image (bottom left) includes neural progenitor marker prominin-1 (CD133). Negative, 
secondary-only control image shown (bottom right) with scale bar representing 30µm. 
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Figure 5.3.4 C3aR signaling contributes to decreased 
apical ventricular zone proliferation. In utero ventricular 
injection of C3aR agonist EP141 (1µL, 100nM) at E13.5 
results in a significant decrease in M-phase cells per 100µm 
at the apical ventricular zone when assayed at E14.5, in 
comparison to vehicle-injected littermates. Administration 
of C3aR anatagonist, SB290157 (1µL, 10µM) results in a 
significant increase in ventricular zone M-phase cells. 
Columns represent mean +/- SEM,* p <0.05, *** p < 0.01. n 
≥ 8 per group 
Figure 5.3.5 C3aR signaling contributes to decreased 
BrdU incorporation in neurosphere culture. 
Neurospheres derived from E14.5 embryos and treated with 
C3aR agonists EP141 (10nM), or EP67 (100nM) 
demonstrated significantly decreased BrdU incorporation 
over 48 hours when compared to vehicle control. In 
contrast, treatment with dual C3aR/C5aR agonist, EP54 
(1µM), showed no significant difference when compared to 
vehicle treated neurospheres. Columns represent mean +/- 
SEM,* p <0.05 n = 3 per group 
Figure 5.3.6 C3aR signaling increases Tis21 transcript in 
neurosphere culture. Neurospheres derived from E14.5 
embryos were treated with C3aR agonist EP67 (100nM) for 
12 hours and assayed using qPCR for Tis21 transcript. 
Columns represent mean +/- SEM, *** p <0.01 n ≥ 4 per 
group. 
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C3aR signalling results in decreased neural progenitor proliferation 
In utero injection of C3aR agonist EP141 (1μL, 100nM) into the embryonic ventricles of E13.5 
C57BL/6J mice caused a decrease in M-phase cells within the ventricular zone at E14.5, as 
measured by phosphohistone H3 immunofluorescence analysis (Fig 5.3.4). By contrast, the use of 
C3aR antagonist, SB290157 (1μL, 10μM), caused an increase in proliferating cells in this region 
(Fig 5.2). Use of C3a agonists in neurosphere culture demonstrated this effect was not limited to the 
in vivo environment, as treatment with the C3aR agonists EP141 (10nM) and EP67 (100nM) caused 
a decrease in proliferation of neurospheres, as measured by BrdU incorporation over 48 hours. 
Intriguingly, treatment with the dual C5aR/C3aR agonist EP54 (1μM) showed no difference in 
BrdU incorporation when compared to control cultures (Fig 5.3.5). Neurospheres were then assayed 
after 12 hours of EP67 treatment for relative expression of Tis21, a marker of differentiation in 
neural progenitors. C3aR stimulation through EP67 treatment in differentiation conditions resulted 
in a significant increase in Tis21 mRNA expression (Figure 5.3.6). 
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5.4 Discussion 
This study demonstrates a role for C3aR in neural progenitor physiology that has not previously 
been ascribed to such an early stage of development. The results suggest that C3aR plays an 
essential and non-redundant function in embryonic brain development. 
Here we show, for the first time, that C3aR is expressed by embryonic neural stem cells during 
normal development. Previously, C3aR has been demonstrated to be expressed by adult neural 
progenitors in culture and to function in the neurogenic response to ischaemia9.  In the embryo, 
expression of C3aR is restricted to the apical surface of the ventricular zone in vivo and the apical 
surface of neurospheres in culture (Figures 5.3.1, 5.3.3). This expression pattern is similar to other 
fate determining proteins in neural progenitors, such as CD133, Par3 and aPKC24,25.  
Expression of the receptor at the apical surface also put it in direct contact with embryonic 
cerebrospinal fluid. In adults, CSF has been demonstrated to contain C3a in physiologically active 
concentrations (~100-300 ng/mL), with the concentration increasing exponentially in the presence 
of CNS disease or trauma26-28. The results of the present study beg the question of whether the 
overall effect of increased C3a in the CSF is detrimental to functional outcomes. There is positive 
correlation of C3a concentration to severity of disease, but little is known about the relative 
contributions of CSF-derived C3a to CNS pathology29,30. It is likely that C3a may have both 
physiologically beneficial and pathologically detrimental actions in this situation, as has previously 
been highlighted in the setting of the immune response1. To our knowledge, there has been no study 
investigating the presence or concentration of C3a in embryonic CSF. 
Treatment of embryos in utero through injection of C3aR modulatory compounds into the lateral 
ventricles demonstrated a role for C3aR in modulating proliferation of neural progenitors. At 24 
hours after injection, treatment with C3aR agonist, EP141, caused a significant decrease in M-phase 
cells at the ventricular surface (figure 5.3.4). Conversely, treatment with the C3aR antagonist, 
SB290157, resulted in increased proliferation as measured by M-phase cells (figure 5.3.2). This was 
supported by in vitro results demonstrating decreased BrdU uptake in primary neural progenitors 
treated with the C3aR agonists EP141 and EP67. Interestingly, treatment with the dual agonist of 
C3aR and C5aR, EP54, resulted in no significant difference in BrdU uptake when compared to the 
vehicle treated group (figure 5.3.5). Given our previous results demonstrating a role for C5aR in 
promoting neural progenitor proliferation (chapter 4), it is interesting to consider whether there is 
physiological antagonism between C3aR and C5aR in neural progenitors, resulting in no overall 
change from control when treating with the dual agonist. Future experiments using EP54 combined 
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with a C5aR1 antagonist, or use of a future commercially available rC3a, could address this 
problem. 
Previously, C3aR has been implicated in the migration of post-natal neural progenitor cells in vivo, 
and the regulation of SDF-1 mediated differentiation in vitro7,8. In light of these previous results we 
assayed EP67-treated cultures for Tis21 expression, an early marker of neural progenitor 
differentiation. EP67 treated cultures demonstrated double the Tis21 expression when compared to 
vehicle treated controls (figure 5.3.6), indicating that the reduction in neural progenitor proliferation 
seen in the BrdU assay (figure 5.3.5) may be attributed to an increase in terminal differentiation in 
these cultures. 
Interestingly, there have been no reports of gross functional defects in C3ar1-/- animals, which may 
be surprising given the important role we have highlighted here in neurogenesis. However, we show 
in chapter 6 of this thesis that there are subtle defects in cognitive processes reliant on neurogenesis 
in C3ar1-/- mice, indeed this is the first reported investigation of cognition in these knockouts. 
However, developmentally, the knockout animals appear grossly normal, and not in keeping with 
the magnitude of effect demonstrated in this study. This may be an example of redundancy 
developed during development in the knockout that is not appreciable with acute pharmacological 
modulation of the receptor. 
In summary, this chapter has provided evidence for the localisation and function of C3aR on 
embryonic neural progenitor cell as a driver for differentiation. This is in keeping with studies of 
C3aR function in adult neural progenitors9, and suggests conserved mechanisms of progenitor fate 
determination between developmental and regenerative processes. Future studies in this area should 
address the intracellular mechanisms behind this action and the effects of modulating C3aR 
signalling throughout development. Utilisation of the methods employed in chapter 4, with a focus 
on C3aR, would strengthen this research and add gravitas to these preliminary results. In addition, 
given the apparent physiological antagonism between C3aR and C5aR (chapter 4), and the results 
presented here using a dual-agonist, it would be interesting to know at what point this antagonism 
occurs.   
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Chapter 6 
 
C3aR and C5aR1 deficient mice exhibit behavioural 
deficits in adulthood
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6.1 Introduction 
This thesis has previously demonstrated the role of C3aR and C5aR1 in neural progenitor 
physiology during embryonic development. Given the previous results of altered neurogenesis with 
pharmacological blockade, we aimed to determine whether C3ar1 and C5ar1 knockout animals 
exhibited similar deficits in neural development. There have been no reports of gross developmental 
abnormalities associated with the knockout animals, particularly no reports associated with 
abnormalities in neuronal function. Our laboratory has previously demonstrated a dramatic increase 
in neural tube defects in C5ar1-/- animals under conditions of folate stress1 and similar results have 
been obtained under the same conditions in C3ar1-/- animals (Angela Jeanes, personal 
communication). However, these defects in neurulation are not apparent in folate-sufficient mice, 
suggesting that any physiological roles that the anaphylatoxin receptors take during this stage of 
development can be compensated for under normal developmental conditions.  
 
A short experimental report has previously analysed the rate of basal neurogenesis at several areas 
in the adult cerebrum between C5aR1-/- mice and their wild type littermates and demonstrated no 
observable difference2. This study also demonstrated that the expression of C3a and C5a-like 
molecules under the control of GFAP promoter also resulted in no changes in basal neurogenesis. 
However, in the anaphylatoxin expression experiments, the authors were unable to detect any C3a 
or C5a expression by immunohistochemistry, which raises some doubts about the validity of the 
model for examining the effects of anaphylatoxins on basal neurogenesis. Additionally, this result 
contrasts with reports in pathological and developmental scenarios where complement 
anaphylatoxins have been shown to be actively involved in normal development and the response of 
neural progenitor cells to injury3-5. 
 
This thesis has previously summarised the evidence in the literature supporting a role for the 
anaphylatoxins in neural development (chapter 1.4). Briefly, the initial reports of function on 
progenitor cells in the developing CNS came from studies into post-natal cerebellar development. 
Final organisation of the cerebellar layers occurs postnatally in rodents and corresponds to a 
transient increase in C5ar1 and C3ar1 cerebellar expression. The movement of progenitor cells 
from the external granular layer to maturation in the internal granular layer is promoted by subdural 
injections of C3a, whilst C5a stimulates proliferation3. In vitro, C3a stimulated increased migration 
of isolated granule layer progenitor cells and this effect could be inhibited through use of a C3aR 
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antagonist. Taken together, these results suggest a mutually antagonistic role for C3aR and C5aR1, 
with C3aR stimulating migration and differentiation in the internal granule layer and C5aR1 
encouraging proliferation of the progenitor population. 
 
This view of the roles of C3aR and C5aR1 in neurogenesis is supported by studies into cerebral 
ischaemia. The presence of progenitor cells, in this model, is reduced in both C3-/- and C3ar1-/- 
animals5, suggesting a similar role for C3aR in this area of neurogenesis as the cerebellar 
observations. This also demonstrates that the altered neurogenesis is a result of the C3a-C3aR axis, 
rather than other, or unknown, ligands for C3aR6. This study also demonstrated C5aR expression on 
neural progenitor cells of the adult brain, although the function of this receptor is not investigated5. 
 
Whilst these studies provide solid evidence of anaphylatoxin directed migration and proliferation of 
neural progenitors, there have been no reported studies into the effect of knockout of anaphylatoxin 
receptors on neurological function in the adult mouse. Behavioural studies have been employed on 
complement knockout mice for which behaviour is a key marker of disease recovery, such as in 
spinal cord injury or neurodegenerative disease7-9.  However, to our knowledge, no study has 
specifically investigated behavioural differences between naïve complement knockouts and their 
wild type counterparts. Thus, this chapter aimed to elucidate this. 
 
It is not particularly surprising that the previous chapters have demonstrated a role for C3aR and 
C5aR1 signalling in neural development, and no behavioural abnormalities have been reported in 
the knockout animals. The perturbation of embryonic neurogenesis has previously been shown to 
result in subtle behavioural phenotypes, rather than gross morphological defects. In 17dpc rats 
(15dpc equivalent in mice), injection of a transient, neuronal-specific, antimitotic compound caused 
deficits in special memory that were associated with histological abnormalities in the pre-frontal 
cortex10. Alterations in developmental neurogenesis at this age also affect the electrophysiological 
properties of individual neurons and result in a schizophrenia-like phenotype behaviourally11. These 
studies lend credence to the investigation of behavioural abnormalities in complement knockout 
mice that appear grossly normal, but may have subtle underlying neuronal deficits. Thus, here we 
examine neuronal function in C3ar1-/- and C5ar1-/- mice using a range of behavioural tests in order 
to assess locomotor function, affect, learning and memory. 
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6.2 Methods 
Tissue collection 
C5aR1-/-, C3aR-/- and C5aR1+/+, C3aR+/+ (wild type) mice were generated through mating 
heterozygous knockout animals to generate C5aR1-/- and C5aR1+/+ (and C3aR-/- and C3aR+/+) 
littermates. The presence of a vaginal plug was deemed E0.5 and dams were sacrificed at E14.5 or 
E16.5. The embryonic dates of E14.5 and E16.5 were chosen as a direct comparison to previous 
experiments using complement modulatory drugs (chapter 4). Embryonic brains were dissected into 
4% PFA and fixed overnight at 4ºC before the generation of coronal cryostat sections at 12µm. 
Embryonic tail tissue was collected for genotyping embryos. Matched sections of the mid-
neocortical region were used in this study. 
 
Determining M-phase cell density at E14.5 
M-phase cell density in the embryonic ventricle was assessed as previously described (chapter 4). 
Briefly, sections were incubated with anti-phosphohistone H3 antibody (#9706 1:1000 CST, USA) 
overnight at 4ºC, washed and subjected to secondary antibody incubation with alexafluor anti-
mouse 555 (A-21422 Molecular Probes, USA) at room temperature for two hours. Sections were 
imaged at 20x magnification on an upright BX51 fluorescent microscope (Olympus, Japan). 
Phosphohistone H3 positive cells were counted and displayed as mean positive cells per 100µm. 
Significance was determined by ANOVA with Dunnett’s post-test using Prism 6 software 
(Graphpad, USA). Final n’s per group for this analysis were; wild-type 12, C3aR-/- 17 and C5aR1-/- 
21 embryos. 
 
Calculating Sox2/Dcx ratio at E14.5 
Sox2 to doublecortin (Dcx)-positive ratios for knockout and wild type littermates were determined 
as previously described (chapter 4). Briefly, serial sections were incubated with either rabbit anti-
mouse Sox2 (#3728 1:400 CST, USA) or rabbit anti-mouse Dcx (#4604 1:300 CST, USA)  
overnight at 4ºC, washed and subjected to secondary antibody incubation with alexafluor anti-rabbit 
488 (A-11088 Molecular Probes, USA) at room temperature for two hours. Sections were imaged at 
20x magnification on an upright BX51 fluorescent microscope (Olympus, Japan). Thickness of 
Sox2- and Dcx-positive layers of the neocortex was calculated using ImageJ (National Institutes of 
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Health, USA) and displayed as a ratio of Dcx to Sox2 thickness. Statistical analysis and graphing 
was performed using Prism 6 software (Graphpad, USA), significance was determined by ANOVA 
with Dunnett’s post-test. Final n’s per group for this analysis were; wild-type 9, C3aR-/- 7 and 
C5aR1-/- 6 embryos. 
 
Animals used for behavioural experiments 
C5aR1-/- (n = 8), C3aR-/- (n = 8) and wild type (n = 7) male mice at six months of age were used for 
the following behavioural experiments. Wild type mice were sourced from the heterozygous 
matings in the knockout colonies to reduce inter-litter variation. Mice were transferred to the 
behavioural testing facility housing at TetraQ, within the University of Queensland, one week 
before testing to habituate to a new environment. Mice had previously been housed under SPF 
conditions within the University of Queensland Biological Resources facilities. 
 
Open field protocol 
Activity was tracked in a 50 x 50 x 40cm arena using Ethovision software (Noldus, The 
Netherlands) for 30 minute periods over five days. Lighting and temperature conditions in the test 
room were controlled to match the housing 
conditions of the mice. Mice were placed in the 
centre of the arena and, after 30s habituation, the 
behavioural parameters of distance moved, average 
velocity, distance from centre, time immobile and 
mean turn angle were scored by the software. Faecal 
boli were manually counted on conclusion of each 
test. The arena was cleaned and dried with a 70% 
ethanol solution between tests. 
 
Morris water maze protocol 
Mice were assessed for learning and memory using 
the Morris water maze protocol. A 105cm radius 
Figure 6.2.1: Layout of the Morris Water Maze. The 
water maze (r = 105cm) was divided through the North-
South and East-West axes into four quadrants labelled 
NW, SW, SE and NE (unlabelled). The platform was 
placed within the NE quadrant 1cm below the water 
surface. 
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tank with sides of 51cm was filled with ambient temperature water supplemented with opacifier 631 
(Morton SA, France). The arena was divided into four segments through the North-South and East-
West axis, a platform of 5cm radius was placed 1cm beneath the water surface in the centre of the 
North-East quadrant (figure 6.2.1). Distal visual cues, temperature and ambient light were constant 
throughout the training and test periods. Mice were released into the area, facing the arena wall, at 
one of the North, South, East and West points of the maze. The sequence of release was randomised 
throughout the five days of the training protocol for each of the four trials per day. Each animal was 
tracked in the arena using Ethovision software (Noldus, The Netherlands) for a period of five 
minutes or until the platform was reached. Parameters assessed were distance moved, mean 
velocity, latency to enter platform quadrant, percentage time in platform quadrant, time to reach 
platform and mean distance to platform. After five days of training, mice were subjected to a test of 
memory by removing the platform from the arena. Mice were released from the South release point 
for the trial day, and tracked for 5 minutes within the arena. Parameters assessed in the test were 
distance moved, mean velocity, latency to enter platform quadrant, mean distance to platform zone 
and frequency of entry to platform zone.  
 
Statistical Interpretation 
Data from the open field test and Morris water maze was analysed using Prism 6 software 
(Graphpad, USA). Two-way analysis of variance was employed to determine effects of trial day and 
genotype followed by Sidak’s post-hoc test to determine intra-trial day differences and overall 
changes between genotypes. Significance was set at p ≤ 0.05. 
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6.3 Results 
Anaphylatoxin knockout animals have altered neural progenitor proliferation rates, but no changes 
in mitotic cell populations 
At E14.5, C3aR-/- animals demonstrated reduced numbers of M-phase cells per 100µm than wild 
type animals (p<0.05). In contrast, M-phase cells per 100µm in C5aR1-/- mice were increased 
(p<0.001)(Figure 6.3.1A). This apparent difference in proliferative rates at E14.5 does not translate 
into differences in the mitotic/post-mitotic cell ratio at E15.5 (Figure 6.2B). 
 
C3aR-/- animals display reduced anxiety-related behaviours in the open field test 
Open-field testing demonstrated differences between the wild-type and anaphylatoxin receptor 
knockout mice in multiple parameters. There was a significant time-dependent decrease in total 
distance travelled in all groups (figure 6.3.2A), with no significant difference demonstrated overall 
between wild-type and knockout mice (table 6.3.1). There was a trend towards increased distance 
travelled in the C3aR-/- animals (p=0.0644), which only deviated significantly from the wild type 
animals on day 4 of the protocol. In contrast, C5aR1-/- animals demonstrated no difference when 
Figure 6.3.1: Developmental analysis of anaphylatoxin 
receptor knockout mice. (A) Bar graph demonstrating 
phosphohistone H3 positive cells per 100µm at the ventricular 
surface of E14.5 mouse embryonic brains. (B) Bar graph 
displaying the ratio of mitotic (Sox2-positive) to post-mitotic 
(doublecortin-positive) cells in the embryonic neocortex at 
E15.5. Bars represent mean ± standard error. *p < 0.05. ***p < 
0.001. p-values determined by one-way ANOVA with Dunnett’s 
post-test. 
A 
B 
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compared to wild-type mice in this parameter. Anxiety, is generally held to be represented in the 
open field test by an increase in thigmotaxis, immobility and risk-assessing behaviour (turn angle). 
Thigmotaxis was measured indirectly from this dataset through calculation of the mean distance to 
the centre of the arena throughout each trial. In this parameter, both C3aR-/- and C5aR1-/- animals 
demonstrated a significant reduction in distance to centre on days 3 and 5 of the protocol (figure 
Figure 6.3.2: Open field analysis of anaphylatoxin receptor knockout mice. Bar graphs representing change in open field 
parameters over the five trial days. (A) Mean distance from centre of field (B) Total distance travelled (C) Average velocity (D) 
Time spent immobile (E) Mean turn angle (F) Faecal boli in field. Bars represent mean ± standard error. *p < 0.05. ***p < 
0.001. p-values determined by two-way ANOVA with Dunnett’s post-test. 
A B 
C D 
E F 
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6.3.2A), however overall there was no significant effect (table 6.3.1). The time spent immobile was 
significantly positively correlated to the trial day (table 6.3.1). Overall, C3aR-/- animals spent a 
decreased proportion of time in the arena immobile (table 6.3.1), an effect that was most 
pronounced towards the final days of the open field test period (figure 6.3.2D). Although the time 
spent immobile for C5aR1-/- animals did not differ significantly from wild type mice overall, there 
was significant deviation from the wild type animals at trial day 5 (figure 6.3.2D). Risk assessing 
behaviour was analysed using mean turn angle as a measure of the directional changes in the arena. 
Mean turn angle was positively correlated with trial days and both C3aR-/- and C5aR1-/- animals 
demonstrated a significant reduction in turn angle when compared to wild type mice (table 6.3.1). 
Finally, faecal boli is a disputed measure of anxiety in open field testing, as there is debate on 
whether this is a true measure of anxiety in mice12. In the present study, there was a significant 
increase in faecal boli over time (table 6.1), and C5aR1-/- animals produced significantly more 
faecal boli than than their wild type counterparts (figure 6.3.2F). 
 
  
Table 6.3.1: Two-way ANOVA summary data for open field test.  
  Two-way ANOVA effect Overall difference vs 
Wild Type 
Parameters Indication Time Genotype C3aR-/- C5aR1-/- 
Distance from 
Centre 
Anxiety/Exploration é *** - ns - ns - ns 
Distance Travelled Exploration ê **** - ns é * - ns 
Mean Velocity Locomotor activity ê **** - ns é * - ns 
Time Immobile Anxiety/Exploration é **** ê * ê ** - ns 
Turn Angle Risk Assessment é **** ê * ê ** ê * 
Faecal Boli Anxiety/Emotionality é *** é *** - ns é ** 
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C3aR-/- and C5aR1-/- mice demonstrate deficiencies in memory, but not learning, in the Morris 
water maze protocol 
Learning in the anaphylatoxin receptor knockout animals was assessed over five trial days of the 
Morris water maze. Parameters assessed during the training period are displayed in figure 6.3.3. 
Both C5aR1-/- and C3aR-/- animals demonstrated no overall difference when compared to wild type 
in distance moved (figure 6.3.3A), average velocity (figure 6.3.3B), latency to enter platform 
quadrant (figure 6.3.3C), percentage of time in platform quadrant (figure 6.3.3D), time to platform 
(figure 6.3.3E) and mean distance to platform (figure 6.3.3F). Both knockout groups demonstrated a 
significant reduction in latency to enter platform quadrant from the wild type animals on day one of 
the protocol, however this trend was no carried forward over the five-day trial period (figure 
6.3.3C). On the test day, both knockout groups showed no significant difference when compared to 
wild type in distance moved (figure 6.3.4A), average velocity (figure 6.3.4B), mean distance to 
platform (figure 6.3.4C) and latency to enter platform quadrant (figure 6.3.4D). However, the 
frequency of entries into the platform zone was significantly reduced in both C3aR-/- and C5aR1-/- 
animals, indicating a deficit in spatial memory (Fig 6.3.4E). 
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Figure 6.3.3: Water maze trial analysis of anaphylatoxin receptor knockout mice. Bar graphs representing 
change in water maze parameters over the five trial days (x-axis). (A) Total distance moved. (B) Average velocity. 
(C) Latency to enter platform quadrant. (D) Percentage of time spent in platform quadrant (E) Time to reach 
platform (F) Mean distance to platform. Bars represent mean ± standard error. *p≤0.05. ***p≤0.001. p values 
determined by two-way ANOVA with Dunnett’s post-test.  
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Figure 6.3.4: Water maze test day analysis of 
anaphylatoxin receptor knockout mice.  Bar graphs 
representing change in water maze parameters during 
the test day trial. (A) Total distance moved. (B) 
Average velocity. (C) Mean distance to platform. (D) 
Latency to enter platform quadrant. (E) Frequency of 
entries into platform zone. Bars represent mean ± 
standard error. *p≤0.05. ***p≤0.001. p values 
determined by two-way ANOVA with Dunnett’s post-
test. 
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6.4 Discussion 
To our knowledge, although anaphylatoxin receptor knockout mice have been present in the 
scientific literature for the greater part of two decades, no behavioural screen has been performed to 
assess for any overt neurological differences13,14. 
 
Immunofluorescence analysis 
Immunofluorescent analysis of M-phase cells at the apical surface of the neocortex in C3ar1-/- and 
C5ar1-/- animals yielded some unexpected results. Previously, in this thesis we have demonstrated 
C5aR1 activity to promote proliferation of neural progenitor cells, whereas C3aR stimulation may 
promote differentiation, and therefore a reduced population. The results in the current study run 
contrary to those results previously obtained by pharmacological methods, C3ar1-/- animals 
demonstrated a decreased number of M-phase cells, whereas C5ar1-/- animals showed a significant 
increase. These results did not translate into any observable difference between the gross size of 
mitotic and post-mitotic populations at E14.5, however cell density or layer composition in the 
neocortex was not assessed. Therefore this analysis does not rule out the presence of subtle 
histological differences between the groups. 
 
However, the seemingly contradictory results between using pharmacological and genetic means of 
suppressing complement receptor signaling may be attributable to the chronicity of treatment, and 
perhaps the activation of adaptive mechanisms for promoting normal neurogenesis in the absence of 
these receptors. Previously we have demonstrated the presence of C5aR1 on embryonic stem cells 
and its function as a signaling mechanism for cell survival and growth in this environment 15. It is 
conceivable that, given the early expression of this molecule, adaptive mechanisms to cope with the 
loss of input may be active early on to direct normal embryogenesis. Indeed, the application of 
folate-deficiency as a stressor in C5ar1-/- embryogenesis leads to gross morphological defects that 
are not present in the wild type counterparts1. This suggests that the role of C5aR1 may only be 
redundant under normal developmental circumstances, and not under any maternal or embryonic 
physiological stressor. 
 
Open field test 
Given the previously demonstrated importance of C3aR and C5aR1 in neurogenesis, open-field 
testing was conducted to analyse the behaviour in a novel environment and the effect of learned 
environment on the C3ar1-/- and C5ar1-/- animals. Interestingly, previous groups have demonstrated 
no difference in adult basal neurogenesis between C5ar1-/- animals and wild type littermates, using 
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a pulse-chase BrdU protocol2. However, this study did not subject the mice to an enriched-
environment, which may actively stimulate neurogenesis in these animals.  Additionally, in the 
open-field test, a balance exists within the individual mouse between the compulsion to explore and 
the fear of dangers in a new environment. Ultimately, this balance will shift in favour of exploration 
with increasing time spent in the environment, with the perceived likelihood of danger from 
predation decreasing. This habituation to the new environment requires the formation of memories 
specific to the situation, as a form of spatial learning. 
 
No differences existed between C3ar1-/-, C5ar1-/- and wild type mice in the initial exposure to the 
activity cage, with results demonstrating similar levels of exploratory- and anxiety-related activity 
in all groups (figure 6.3.4). However, C3ar1-/- and C5ar1-/- animals demonstrated impaired 
habituation to the activity cage environment, which may be associated with impaired learning or 
memory of the novel environment. Wild type mice demonstrated habituation to the novel 
environment through a progressive increase in time immobile, increase in exploration as measured 
by turn angle, decrease in average velocity and decrease in distance travelled (figure 6.3.2).  Both 
C3ar1-/- and C5ar1-/- animals demonstrated some significant differences in these parameters at days 
four and five of the protocol, not demonstrating the same magnitude of change in behavioural 
parameters as their wild type counterparts. 
 
Morris water maze 
Interestingly, in the Morris water maze protocol, C3ar1-/- and C5ar1-/- animals did not differ, in 
terms of habituation, from the wild type. However, habituation to the activity cage environment 
involves a milieu of subtle behavioural facets that may not be tested in the MWM, the balance 
between anxiety and exploration and the memory of the learned environment all contribute to 
behavior in the activity cage12. In the MWM environment, the driving force behind movement is the 
survival instinct, as time progresses mice learn where the hidden platform can be found using the 
visual cues in the room. This compulsion for movement in the MWM may explain the discrepancy 
between the results seen with regards to habituation. 
 
Over the 5 days of trials, C3ar1-/- and C5ar1-/- did not differ significantly from the wild type group, 
suggesting that spatial learning is not impaired in these animals. However, the test day showed that 
memory of the platform’s position was not as accurate in both the C3ar1-/- and C5ar1-/- groups. The 
knockout groups demonstrated only half the passes into the platform area when compared to the 
wild type group (figure 6.3.4E). Interestingly, the mean distance to platform (figure 6.3.4C) and 
latency to enter platform quadrant (figure 6.3.4D) did not demonstrated any difference from the 
Chapter 6 Knockout Behavioural Analysis 
 
 181	
wild type group, suggesting that any spatial memory deficit present in the knockout groups is 
subtle. 
 
Conclusion 
The foundation of learning and memory in the adult is based on an active process of neurogenesis. 
Given that we have previously demonstrated a role for C3aR and C5aR1 in the regulation of 
embryonic neurogenesis we aimed in the present study to identify any functional deficits in adult 
knockout mice through the perturbation of their embryonic neurogenesis, or impairment of learning 
and memory as adults. Here we have shown that there are differences in mitoses at E13.5 that are 
opposed to the pharmacological investigations. Additionally, adult anaphylatoxin knockout animals 
demonstrate subtle behavioural deficits in memory. However, additional experiments are required 
before these can be conclusively linked to any deficits in neurogenic potential. There are promising 
mouse models in production (detailed in chapter 3) that will further research in this area. In 
particular, the use of a conditional C5aR1-knockout animal during development would allow for 
further understanding as to whether these behavioural abnormalities are of a developmental or adult 
neurogenesis origin. As it stands, the use of absolute knockout animals, such as in this chapter, is 
unable to provide this distinction. In addition, this chapter only assessed the effect of anaphylatoxin 
receptor knockout on male mice, therefore, whilst this data may be reasonably extrapolated to 
female animals, it is unclear whether sex alters the role of the anaphylatoxin receptors in the mouse 
brain. 
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7.1 Discussion 
This thesis investigated the function of the anaphylatoxin receptors of the complement system on 
neural progenitor cells during mouse embryogenesis.  
 
The aims of this thesis were to: 
1. Investigate the localisation and expression of C5aR and C3aR during brain 
development. 
 2. Determine the functional role of C5aR and C3aR on neural progenitors during brain 
  development. 
 3. Elucidate the second messenger signalling involved after C5aR activation on neural 
  progenitor cells. 
 
Summary of the aims and findings 
This thesis demonstrated expression of C5aR and C3aR on the apical membrane compartment of 
apical neural progenitor cells in vivo. This localisation was maintained in 3-dimensional, polarised 
neurosphere culture, but lost in monolayer culture, suggesting an importance for the development of 
cell-polarity before membrane expression of the anaphylatoxins in this cell type. With regards to 
aim 2, this thesis demonstrated opposing roles for the anaphylatoxin receptors within the same cell 
type. Whilst chapter 4 covers the role of C5aR as a driver of neural progenitor proliferation, the 
evidence provided in chapter 5 indicates that C3aR, conversely, is a driver of differentiation. This is 
in keeping with previously reported observations demonstrating that both receptors direct the 
balance of proliferation and differentiation in the post-natal rat cerebellum1,2. Aim 3 was addressed 
within chapter 4 and showed that C5aR stimulation, in neural progenitor cells, initiates Erk1/2 
signalling through a PKCζ-dependent mechanism (summarised in figure 7.1.1). This correlates well 
with the localisation of the receptor in vivo, as PKCζ has previously been shown to be apically 
located within this cell type. 
  
 
  
Figure 7.1.1: Diagrammatic representation of the suggested signalling cascade for C5aR1 demonstrated in this thesis. From A-H: C5aR is present on the apical 
membrane of neural progenitor cells within the ventricular zone. Interaction with C5a leads to PKCζ activation. Actions of PKCζ, through MAPK signalling, leads to a short 
G1 phase and faster progression through the cell cycle. Additionally, PKCζ acts to stabilise polarity increasing the likelihood of symmetric division. Symmetric division of 
progenitor cells results in expansion of the progenitor pool at the expense of neurogenesis. 
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In addition to the major aims, this thesis also demonstrated the presence of complement and other 
innate immune factors in early neural development (chapter 1). Significantly, there was absence of a 
number of propagating factors of the canonical pathways of the complement cascade, and absence 
of C9 of the membrane attack complex. Given the fragmented and toothless nature of this pattern of 
expression, it is not unreasonable to consider alternate roles for complement components expressed 
at this stage of development, outside of innate immunity. Finally, a preliminary investigation into 
the behaviour of anaphylatoxin knockout animals was included (chapter 6). Despite the evidence 
garnered in chapters 3 & 4, demonstrating a role for the anaphylatoxins in directing proliferation in 
the developing brain, the receptor knockout animals are not embryonically lethal, nor have they 
been reported to have any neurological deficits. Chapter 6 demonstrated some subtle behavioural 
differences between the knockout mice and wild-type littermates. However, although slight 
numerical differences were demonstrated within M-phase apical progenitors during development, 
these were opposite to the effect of acute pharmacological treatment and the mitotic population pool 
did not differ from wild-type littermates. These data suggest that the effects of the anaphylatoxin 
receptors in brain development are somewhat redundant and their chronic, genetic loss may be 
compensated for adequately. 
 
Wider implications of innate immune molecule expression within the developing embryo 
The demonstration of widespread expression of both complement- and other innate immune factors 
within the early embryo should provide an impetus for further research into the roles of these 
factors in embryogenesis. This thesis has demonstrated a role for C5aR in embryonic neurogenesis 
and shown that disruption of signalling can result in impaired neurological function in adulthood 
(chapter 4). There is increasing evidence of important roles for other components of the 
complement system in neurodevelopmental processes including, C1q/C3b in synaptic pruning3, 
C3aR in neural crest migration4 and C3aR/C5aR in cerebellar developement2. In addition, other 
innate immune factors, such as the toll-like receptors, regulate the balance of proliferation and 
differentiation in the neural progenitor population5,6. 
These observations of immune molecules in development present problems, clinically, for the 
treatment of inflammatory diseases of pregnancy. Complement factors in particular have been 
highlighted as potential targets for the placental inflammation associated with pre-eclampsia7,8. In 
addition, dysregulated complement activation has also been shown to causes poor pregnancy 
outcomes, such as intrauterine growth restriction and miscarriage9-11. This thesis, and similar 
research, suggests that in treating these diseases, by targeting factors of innate immunity, the 
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clinician gambles with the risk of altering processes of embryogenesis. It is difficult to track 
outcomes of anti-inflammatory treatment during pregnancy in human populations as it is unknown 
whether poor fetal outcomes are a result of treatment, or disease, or both. A balance must be 
achieved for both the health of the mother and fetus, and at present it is unclear where this lies.  
Another consideration lies in the fact that a large proportion of embryonic neural development, 
related to the stages examined within this thesis, occurs within the first trimester, often when the 
mother is unaware she is pregnant. Thus, this cautions generically against the use of anti-
complement therapies in females of childbearing age, where the therapeutics may conceivably enter 
the developing embryonic brain. 
 
Linking damage and repair 
The canonical immune role of the complement system is well defined and delineated. Activation 
occurs via pathogen recognition or cellular damage, and numerous damage associated serine 
proteases (e.g. thrombin) are also able to cleave the central complement components12. However, 
there has been an increasing focus within complement research in the past decade on the extra-
immune roles of complement and, increasingly, on the idea that innate immunity and developmental 
or regenerative processes are intimately linked13,14. 
It has previously been noted that there is an inverse correlation, within organisms, between the 
maturity of the adaptive immune system and the capacity for regeneration15. In animals with poor 
adaptive immunity there is capacity for regeneration of whole limbs or body regions. The 
hypothesis is that an organism could deal with damage via two distinct mechanisms, proactively 
detecting and avoiding damage through adaptive immunity or regenerating tissues lost to inevitable 
damage. A striking example of this inverse relationship is the hydra. This animal is undoubtedly 
phylogenically ancient, possessing only two germ layers and no mobile adaptive immunity. The 
hydra has the capacity to regenerate into two individuals when bisected through regeneration of the 
foot and head regions within the two halves. Interestingly, within the regenerating region the hydra 
expresses a host of recognisable genes of the innate immune system as characterized by RNA 
sequencing16. Hydra analogues of complement factors, including C1q and MASP, are up-regulated 
at the site of regeneration16. 
This phenomenon remains in more complex animals. After surgical removal of the limb or eye lens 
the newt displays a capacity for regeneration of these tissues. Again, complement factors are 
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expressed within these regions, long after the initial insult. C3 and C5 are expressed in the 
regenerating lens vesicle and limb blastema, although there is no detectable expression within the 
mature tissues17,18.  In both the newt and hydra models, the presence of complement factors at the 
site of regeneration is observational and no function has been ascribed experimentally. It could be 
argued that their expression in these regions functions as protection for the compromised 
regenerating tissue from pathogen colonisation. However, this hypothesis does not adequately 
explain the persistence of expression after the formation of an epithelial barrier. 
Higher order vertebrates provide greater experimental clues as to the biological roles of these 
molecules in regeneration. Although in these phyla regenerative capacity is restricted, certain 
organs, such as the liver and the brain, show capacity for regenerative repair. Liver regeneration in 
mice post-hepatectomy is reliant on the presence of C3 and C5, signalling through C3aR and C5aR. 
Genetic absence of these factors results in reduced proliferation and arrest of hepatocytes in G1 
phase in the regenerating liver19,20. These effects were able to be rescued through the addition of 
their split product, C3a and C5a19. This suggests that the important signalling events in this instance 
are through the anaphylatoxin receptors, rather than through formation of terminal elements of the 
complement cascade. Similar results are found in bone remodelling, where C3-/- and C5-/- animals 
demonstrate reduced callus formation and reduced bone growth post-osteotomy21. Knockout 
animals also exhibit reduced bone strength that may represent impaired remodelling from 
physiological fractures, as there are no noted bone deformities that might indicate impaired 
osteogenesis. Recently, a specific and potent role for C3a in inducing retinal regeneration in the 
embryonic chick also adds weight to the argument for the importance of the anaphylatoxins in 
regenerative processes22. In this context these studies reflect the conclusions of this thesis, that 
abrogation of anaphylatoxin signalling in the acute setting elicits defined roles not evident during 
linked developmental processes in the knockout animal.  
The studies of ischaemic stroke and neuronal injury illustrate the functional linkage between the 
roles of the anaphylatoxin receptors in inflammation and regeneration; it has been described in this 
area as a ‘double-edged sword’23-25. Initially, blockade of C5aR1 was demonstrated to be beneficial 
with regards to outcomes in neuronal injury, in models with a short time to assessment of 
outcomes26. C5aR1 and C3aR were then demonstrated to be present on basally migrating neural 
progenitors of the mouse, and in the context of middle cerebral artery occlusion (MCAO), C3-/- 
animals demonstrated reduced neurogenesis up to three weeks after the ischaemic event23. The 
models focussing on initial outcomes have the drawback of only capturing the inflammatory aspect 
of complement functions, a restriction based on the ethical considerations in stroke research. 
However, it also realised that the anaphylatoxin receptors exhibit a biphasic, opposing function with 
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regards to neurological outcome27. Antagonism of these receptors, whilst beneficial in the 
inflammatory phase, may be detrimental as the tissue progresses towards repair and regeneration27. 
Interestingly, previous research demonstrates that there is no deficit of basal neurogenesis in 
C5aR1-/- adult animals28. This is almost contrary to the present thesis, which shows a crucial role for 
endogenous C5a-C5aR1 signalling, through use of the antagonist, PMX53, in normal CNS 
development. However, this thesis also demonstrated no histological differences between C5aR1-/- 
brains and those of wild type littermates. There are caveats to both the pharmacological and 
knockout models that must be considered in the interpretation of results. Pharmacological targeting 
of C5aR1 has the benefit of being able to be administered acutely, to target a distinct time point in 
development. However, this benefit is tempered by dose-dependent effects, pharmacokinetics, and, 
possible off-target effects on other aspects of cell biology. The genetic knockout models provide 
complete absence of the protein, but raise the spectre of upregulated compensatory mechanisms for 
developmental processes. Using knockout animals for C3 and C5 also further complicates the 
interpretation. It is often unclear, and difficult to experimentally determine, whether observed 
differences result from interruption of direct receptor-ligand interactions (i.e. C3a-C3aR, C5a-
C5aR1/C5aR2) or the opsonin (i.e. C3b) or terminal elements (i.e. C5b-9) of the complement 
cascade. Additionally, in the case of C3-/- mice, results are further compromised as complement 
pathway compensation through extrinsic protease C5 cleavage has been demonstrated to occur in 
the absence of C329. This quagmire of interpretation may be navigatable with the emergence of 
inducible knockouts in this area of research, which will allow for the specific and time-dependent 
abrogation of receptor signalling, without the potential for affecting other aspects of 
embrogenesis30.  
 
Physiological antagonism of the anaphylatoxin receptors 
This thesis demonstrated an apparent physiological antagonism for the anaphylatoxin receptors in 
neural progenitor cell physiology; C5aR promotes proliferation, whilst C3aR promotes 
differentiation. This concept is not new in complement biology, however it is often overlooked as 
both receptors are described as ‘pro-inflammatory mediators’. We have recently attempted to 
dissuade the use of this term by researchers through highlighting the anti-inflammatory facets of 
C3a, in contrast to the largely pro-inflammatory nature of C5a (chapter 1.7)31.  
For instance, in models of ischaemia-reperfusion (IR) injury knockout animals for C3aR and C5aR 
show opposing responses to induced injury. C5aR-/- mice demonstrate reduced pathological scores 
Chapter 7 Discussion and Concluding Remarks 
 
 190	
and increased survival in models of sepsis and gut IR, which results from a reduction in neutrophil 
activation and migration into the affected tissues32,33. In contrast, C3aR-/- exhibit worsened outcomes 
to IR injury, suggesting that C3aR signalling is protective in these models34. The mechanism behind 
this apparent opposing activity is the role that C3aR plays in keeping the reserve neutrophil pool 
within the bone marrow; the knockout animal demonstrate a persistent neutrophilia that leads to 
worsened outcomes in disease34. 
However, the range of antagonistic activities extends far deeper than the respective roles of the 
receptors in the immune system. Previous research has shown distinct and opposing haemodynamic 
responses to the anaphylatoxins in the rat. Infusion of C5a causes a transient hypotension, whereas 
infusion of C3a induces hypertension35. In both cases, these effects can be prevented through 
pretreatment with indomethacin, indicating a prostanoid-mediated response35,36. This demonstrates 
distinct and physiologically opposing signalling effects for C3a and C5a which contrasts with the 
persistent class grouping of these molecules in the literature31. 
In the developing brain, this phenomena is perhaps best illustrated by the opposing roles of C3aR 
and C5aR in the post-natal rat cerebellum. Both receptors are expressed in the progenitor-rich 
external granule layer of the cerebellum and expression is reduced with cerebellar maturation1. This 
observation is similar to that shown for C5aR in this thesis, where expression reduces with 
differentiation of NE-4C cells (chapter 4). Both receptors have effects on the fate of cerebellar 
progenitor cells. Sub-dural administration of a C5aR agonist results in an expansion of the external 
granule layer and an increase in BrdU-positive cells within this region2. By contrast, administration 
of a C3a agonist results in expansion of the internal granule layer at the expense of the progenitor 
population. It is hypothesised that this is due to effects of C3a in mediating differentiation and 
migration of the progenitor cells2. The results of this thesis, in treatment of telencephalic 
neurosphere cultures with C3aR modulators (chapter 5), and that of previous research 
demonstrating reduced neuroblast migration in C3-/- animals, suggests that this role for C3aR may 
extend across all types of neural progenitor cell23. 
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7.2 Concluding Remarks 
The studies presented in this thesis add to the understanding of embryonic neural development and 
support recent, exciting findings into the new aspects of complement biology. It is becoming clear 
that the complement system is not solely confined to roles in innate immunity, but rather links the 
twin aspects of damage control and regeneration15. In this context, the appearance of complement 
factors in developmental processes is less surprising. As ever though, there is always more to do.  
There is currently a deficit in technology available to study complement in developmental processes. 
This thesis has demonstrated that the current conventional knockout animals may not portray a truly 
representative depiction of neural development. Clearly, they respond very differently compared with 
direct pharmacological modulation of the anaphylatoxin receptors, perhaps due to compensatory 
mechanisms. The proliferation of new genome editing technologies, such as the recently introduced 
CRISPR system, and the production of complement receptor inducible knockout mice30 provide 
exciting new avenues through which to expand this research. 
The plethora of innate immune molecules identified in the early embryo in this thesis, and the key 
roles for the anaphylatoxin receptors in directing neurogenesis should caution against rapid clinical 
uptake of anti-complement therapeutics in pregnancy. Currently, anti-complement therapeutics are 
valuable targets in the treatment of inflammatory diseases of pregnancy (e.g. preeclampsia) and 
inflammatory diseases of the mother. Their specific and targeted effect, when compared to other 
available treatments such as corticosteroids, makes them an attractive avenue for drug design. 
However, given the results presented in this thesis, and the previous demonstration of C5aR1 also on 
the neuroepithelium of human embryos37, it would be wise to proceed cautiously in the introduction 
of anti-complement therapeutics until the role of complement in developmental processes is more 
fully understood. 
This thesis has identified a key new player in embryonic neural development in C5aR1, which add to 
the milieu of factors currently identified in the literature. It is still unknown how this fits in with other 
key players occupying the same niche of the apical neural progenitor cell; whether C5aR1 signalling 
acts mainly in isolation, or is part of the greater orchestra of factors that mould a cells fate. However, 
this thesis has provided a basis for the exploration of these important questions. 
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Abstract 
 
The complement cleavage product C3a exerts its biological effects through the 7-transmembrane G-
protein coupled receptor, C3aR. Until recently, research on the infamous cousin of C3aR, C5aR, 
has taken precedence in anaphylatoxin literature. This may have stemmed from the traditional 
interpretation of the complement cascade as beginning with an immune challenge and ending with 
the cleavage of C5, to form C5a and the membrane attack complex (C5b-9). In contrast to C5aR, 
which has well-established pro-inflammatory functions in a number of diseases, the function of 
C3aR is more complex. It has now been demonstrated to exhibit multiple biological effects, which 
are dependent on the cell type and disease model. In recent years, novel advances have also more 
definitively characterised the role of C3aR expression on cells that previously had an unknown, or 
only loosely defined, role for C3aR, particularly neutrophilic granulocytes and certain lymphocyte 
subsets. The multiple functions of C3aR complicate the targeting of this receptor as a therapy in 
inflammatory disorders. Indeed both C3aR antagonists and agonists could be viable therapies 
depending on the disease context. In addition, the lack of research on the receptor has left a dearth 
in pharmacological modulators, although this is a burgeoning area of interest. Here we present the 
current state of knowledge on C3aR and the possibilities for therapeutics targeting inflammatory 
diseases. 
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Introduction 
 
Complement factor 3 is the convergence point of the complement activation pathways and is 
cleaved to form the anaphylatoxin, C3a. C3a is a 77-amino acid polypeptide, with carboxyl-terminal 
residues largely responsible for activating its corresponding receptor, C3aR. Acting via C3aR, C3a 
has traditionally been regarded as a highly potent effector of inflammation and plays several crucial 
roles in immune responses and inflammatory processes. Unlike its infamous cousin, C5a, resting 
concentrations of C3a are high due to high circulation concentrations of C3 (~1.2mg/ml in humans), 
and the continual degradation of C3 through the alternative tickover pathway1. However, elevation 
of serum C3a concentrations is still an early marker of infections or inflammatory disease. C3a is 
also readily degraded by serum carboxypeptidase-mediated removal of the C-terminal Arginine to 
form C3a-desArg, which is unable to bind to C3aR2. Although the C3a-C3aR axis was originally 
associated with the onset of acute inflammatory reactions leading to complications such as acute 
graft rejection3, local tissue injury, and multiorgan failure4, further investigations have revealed 
more multifaceted roles for this signalling axis. The actions of C3aR, to promote, moderate or 
attenuate inflammation, depend on the disease and cell type. In addition, C3aR has now been 
demonstrated to be involved in processes outside of the boundaries of innate immunity, such as 
organogenesis5, tissue regeneration6,7, and neural development8,9. 
 
Expression, structure and signaling 
C3aR was initially shown to be expressed on leukocytes of myeloid lineage, such as neutrophils, 
basophils, eosinophis, mast cells, and monocyte/macrophages10. However, it is now well-accepted 
that C3aR is expressed on cells as diverse as endothelial cells, smooth muscle cells, and cells of 
brain origin, astrocytes, microglia and neurons8,11-13. Recently, C3aR expression has also been 
demonstrated in mesenchymal, neural and haematopoietic stem cells8,14,15. The expression in stem 
cell populations may suggest a role in recruitment for the repair phase of inflammation. Although 
C3aR is widely expressed there are dramatic differences in both the control of expression and 
associated second messenger coupling between cell types. 
 
The C3aR gene (C3AR1) has the chromosomal location 12p13.31 in humans and 6F1 in mice, the 
major animal model for C3aR investigation. In both species, the gene consists of two exons 
separated by a large intron. Exon 1 contains no coding sequence, but is the site of the regulatory 
sequences that determine expression. Both species exhibit a dense, conserved region 70 to 35 bases 
upstream of the transcriptional start site, that are critical to cell-type specific regulation16.  This 
region contains a GATA, Ets-like and AP1 site, but the relative contribution of these sites to gene 
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transcription has been demonstrated to be dependent on the cell-type. For instance, transcriptional 
control in myeloid derived cells, which are reliant on the functionality of both the ETS and AP-1 
elements, differs to that reported in astrocytes, where there is heavy reliance on the AP-1 site, but 
deletion of the ETS-like site does not reduce transcription significantly17,18. Additionally, although 
transcription from the AP-1 site in macrophages was initiated by c-Jun binding, there was no 
indication of this interaction occurring in primary astrocytes or the Ast2.1 cell-line18. 
 
At the protein level, C3aR is a classical 7-transmembrane, G-protein coupled receptor, which shares 
close homology to the receptors for C5a, C5aR and C5L219. C3aR binds its only known ligand, 
C3a, using a proposed ‘two-site’ binding model, consisting of functionally different recognition and 
activation sites20. This is similar to the model reported for C5aR, which may be expected due to the 
shared evolutionary origins of both proteins21. However, unlike C5aR, the N-terminus of C3aR is 
not charged and is functionally insignificant with regards to C3a binding22. C3aR also differs in 
structure through the presence of a large second extracellular loop of 172 amino acids23. The size 
this extracellular loop is largest in mammals, with cloning of Rainbow trout and Xenopus C3aR 
demonstrating smaller loops that are not as remarkable, in terms of size, as the mammalian form21. 
The loop is of interest because the residues that are important for C3a binding appear to be well 
conserved, raising questions over why the mammalian version is so exaggerated21,24,25. It is unlikely 
that this evolutionarily-sequential extension of extracellular loop 2 is without benefits, and it is 
hypothesised that the loop may contribute to the binding of other, as yet unidentified, ligands24.  
 
At the C-terminus, C3aR couples to heterotrimeric G-proteins. C3aR has demonstrated a 
promiscuity of G-protein interaction dependent on cell type, for instance, in leukocytes, C3aR 
couples to the pertussis toxin (PT)-sensitive Giα and to the PT-insensitive Gα16, whereas the 
receptor couples to Gα12/13 in endothelial cells. This alternating coupling of G-proteins affects the 
types of second messenger signalling resulting from the C3a/C3aR interaction. Generally, the 
stimulation of C3aR results in the activation of MAPK pathways, activation of protein kinase C 
(PKC) and mobilisation of intracellular calcium. Although C3aR exerts traditional pro-
inflammatory roles via p38/PKC in cells such as astrocytes, mast cells and endothelial cells12,26,27, 
intriguingly, the more novel functions now assigned to C3aR are not consistently mediated in this 
manner. For instance, in neural precursors C3aR-activation functions as an inhibitor of MAPK 
phosphorylation, demonstrating the pleiotropic functional nature of C3aR28. 
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C3a-induced desensitisation of C3aR involves phosphorylation of the receptor by GPCR kinases 
(GRK) in a rapid dose-dependent and reversible fashion29. This desensitisation is augmented by 
receptor internalisation in response to C3a. Internalisation of the C3a receptor has been 
demonstrated in granulocytes, to be dependent on the activity of PKC, and is insensitive to pertussis 
toxin inhibition of C3aR signalling30.  
 
Additionally, C5a reduces C3a-stimulated C3aR internalisation, an observation that adds weight to 
the view of the C3aR/C5aR system as analogous to yin and yang, rather than a purely pro-
inflammatory duo30. In addition to GRK, recently, β-arrestin proteins have been shown to play a 
novel role on C3aR desensitisation, internalisation, degranulation, NF-kB activation and chemokine 
production in human mast cells31. β-arrestin proteins can also regulate the activity of C3aR by 
inhibiting G-protein-dependent ERK1/2 phosphorylation32. Interestingly, this MAPK signalling 
inhibition by β-arrestins is one of the postulated downstream pathways of the C5a-C5L2 axis33. 
C5L2 has already been demonstrated to regulate C5aR signalling in this manner, although C5L2 
regulation of C3aR signalling remains, as yet, uninvestigated34. 
 
The Function of C3aR on Circulating Leukocytes 
The role of C3aR in the immune system is complicated by seemingly contradictory reports. C3aR 
has opposing roles at the local and systemic level, meaning that broad statements about the general 
function of this receptor in immunity present a superficial and oversimplified view. At the site of 
inflammation, C3aR has several pro-inflammatory properties overlapping with C5aR, however C3a 
is much less potent than C5a in this regard and also has anti-inflammatory facets20. In vitro 
investigations into the effects of C3a on LPS-induced cytokine release by PBMCs demonstrate of 
difference of action depending on the state of the cell. C3a augments the proinflammatory cytokine 
production of adherent cells, but suppresses that of non-adherent cells35. Depending on the adhesive 
state of cells, C3a and C3adesArg suppress TNF-α, IL-1β and IL-6 synthesis in lipopolysaccharide 
(LPS)-primed non-adherent peripheral blood mononuclear cells (PBMCs) and B lymphocytes, and 
enhance their synthesis in adherent cell systems35-37. There is a certain elegance in this hypothesis 
when applied to the in vivo environment - C3a, a split product of one of the most abundant blood 
proteins, enhances the inflammatory response in the local environment of the insult, but inhibits a 
systemic cytokine storm by suppressing production from non-adherent cells.  
 
Myeloid Lineage 
C3aR is expressed by all leukocytes of a myeloid lineage, however the functional characteristics of 
the receptor are dependent on cell type. In human eosinophils, C3a induces calcium mobilisation, 
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oxidative burst and degranulation38,39. In mast cells, C3a and C3adesArg can induce histamine 
secretion in a dose related fashion40-42. Both C3a and C3adesArg can also increase intracellular 
calcium levels in human monocytes, and induce production of IL-1β, TNF-α, IL-6 and PGE2 
12,35,36,43,44,45.  This eosinophil and mast cell-specificity has highlighted C3aR as a drug-target 
candidate for allergic conditions. Such inferences have been strengthened through observations of 
C3aR-/- animals that exhibit reduced responses in atopic diseases such as allergic asthma and 
allergic dermatitis46. Although the C3a/C3aR axis has been demonstrated to cause chemotaxis of 
eosinophils and basophils, interestingly, and in stark contrast to C5a/C5aR activation, neutrophils 
do not undergo chemotaxis, granular release or oxidative burst in the presence of C3a47. Some 
studies have previously reported a functional role for C3aR on neutrophils38, however these were 
observations of indirect mechanisms. For instance, C3a has been shown to cause chemotaxis of 
neutrophils in cultures that contain >5% eosinophils, and eosinophils release a soluble factor in 
reponse to C3a that causes neutrophil chemotaxis47. However, we have demonstrated a unique, and 
direct, role for C3aR in regulating the mobilisation of neutrophils from the bone marrow. 
 
Emerging role in neutrophil/HSC mobilisation 
An unprecedented but critical role in hematopoiesis and stem cell trafficking has emerged in the last 
decade. It is well established that the α-chemokine stromal-cell-derived factor 1 (SDF-1/CXCL12), 
expressed by osteoblasts, bone marrow stromal cells and vascular endothelial cells, plays a central 
role in haematopoeitic stem/progenitor cell (HSPC) trafficking, and has become the textbook 
example of HPSC migration48-51. In 2003, it was demonstrated that C3 is a physiologic constituent 
of the bone marrow (BM) milieu following its secretion by BM stromal cells14. Less than a year 
later, it was reported that G-CSF-induced mobilisation is associated with complement activation 
and the local cleavage of native C3 into fluid-phase C3a, which is degraded into C3a-des-arg and 
C3b/iC3b; the latter is deposited on viable BM cells of G-CSF-treated animals52. Human BM-
derived and mobilised peripheral blood CD34+ HSPCs, as well as in CD34+ cell-expanded lineages 
(including myeloblasts, megakaryoblasts, and erythroblasts) analysed by RT-PCR and FACS have 
been reported to express C3aR, and that administration of C3a to these cells stimulates intracellular 
Ca2+ flux in mobilised peripheral blood CD34+ and lineage-expanded hematopoietic cells14.  
 
Investigations of this functional significance discovered that although administration of C3a alone 
did not affect the proliferation, survival or chemotactic response of human and murine CD34+ 
HSPCs and CD34+ lineage-committed clonogenic hematopoietic progenitors, it greatly enhanced 
their chemotactic response to a low-dose (10ng/ml) SDF-1 gradient14,53. Similarly, using 
reconstituted basement membrane Matrigel to measure the invasive potential of human BM-derived 
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HSPCs and CD34+ peripheral blood cells, C3a alone did not increase trans-Matrigel migration, but 
it significantly augmented SDF-1-dependent migration14. Human CD34+ cells stimulated by C3a 
also secreted 2.6 fold more MMP-9 into the conditioned media than non-stimulated cells, indicating 
C3a facilitates basement membrane degradation14. Finally, C3a was shown to promote HSPC 
homing by enhancing the SDF-1-dependent adhesion of VLA-4 on human CD34+ cells to VCAM-
1, suggesting cross talk between C3a and the SDF-1-CXCR4 signalling axis may increase the 
propensity of HSPCs to attach to the vascular endothelium or BM niches14. 
 
The role of C3a in HSPC trafficking has been further defined using in vivo studies. In lethally 
irradiated mice, transplanted Sca-1+ (Ly6A/E+) BM HSPCs that were primed before transplantation 
with C3a demonstrated significantly enhanced bone marrow engraftment and accelerated 
hematopoietic recovery compared with animals that received transplants of Sca-1+ cells primed with 
C3a-des-Arg or non-primed cells14. Although C3aR-/- mice are haematologically normal under 
steady state conditions, they display significantly increased G-CSF-induced mobilization of 
circulating mononuclear cells (MNCs) and colony-forming unit-granulocyte macrophage 
progenitors (CFU-GM) in their peripheral blood compared to wild-type mice52. We have 
independently confirmed that C3aR-/- mice exhibit accelerated G-CSF-induced mobilisation of 
granulocytic populations into the circulation54. BM chimeric mice have confirmed that C3aR 
deficiency on transplanted and not resident cells are responsible for the increased sensitivity to G-
CSF-induced mobilisation observed in C3aR-/- mice52. Similarly, transplantation of C3aR-/- HPSCs 
into lethally irradiated mice results in delayed recovery of platelets and leukocytes and decreased 
number of donor-derived granulocyte-macrophage progenitors detectable in the BM55. Further, 
antagonism of C3aR with SB290157 significantly accelerated G-CSF-induced mobilization of 
MNCs and CFU-GM progenitors in WT, but not C3aR-/- mice52. Again this particular agonist also 
has off-target agonist activity56. HSPCs from C3aR-/- mice exposed to C3a secrete less MMP-9 and 
show impaired adhesion to stromal cells. C3a may therefore directly modulate HSPC homing by 
augmenting C3aR-mediated secretion of MMP-9 and cell adhesion55. On a molecular level, C3a 
could potentiate HPSC responses to SDF-1 gradients by increasing the incorporation of CXCR4 
into membrane lipid rafts, facilitating its assembly with its downstream signaling molecules57.  
 
Interestingly, evidence suggests that the C3a-enhanced responsiveness of HSPCs to SDF-1 is also 
mediated in a C3aR-independent manner. First, and somewhat contradictory to previous findings, 
Honczarenko et al. (2005) found that freshly isolated human BM CD34+ and B lineage cells do not 
express C3aR as assessed by flow cytometry. It was also reported that C3a enhances SDF-1-
induced chemotaxis of BM progenitors from C3aR-/- mice similar to BM cells from WT mice53. 
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Further, C3a increased the binding affinity of SDF-1 to human CXCR4+C3aR- REH pro-B cells, 
which could suggest a direct interaction between C3a and SDF-153. Collectively this data indicates 
C3 is cleaved in mobilised BM into C3a and C3b, and that C3a is a positive regulator of early and 
more differentiated HSPC retention in the BM. This is via increasing responses dependent on the 
SDF-1-CXCR4 axis in a C3aR-dependent and independent manner, thus preventing uncontrolled 
release of HSPCs into peripheral blood during mobilisation. 
 
Lymphoid Lineage 
The function of C3aR on cells of the lymphoid lineage has been the subject of some debate as the 
presence of the receptor on T- and B-cells has yet to be conclusively proven using the gold standard 
techniques of Western blot, RT-PCR or immunohistochemisty. The C3a-C3aR axis certainly has a 
role in modulating the response of lymphocytes to a pathogenic insult via the actions of an 
intermediate cell-types58-60. Nevertheless, several studies exist in excellent journals demonstrating 
functional roles for C3aR within the lymphoid lineage itself. The mystery surrounding C3aR 
expression in lymphoid cells could perhaps be partially explained by only a subset of cells 
possessing the receptor. For instance, in one of the first publications investigating a lymphoid 
C3aR, Werfel and colleagues (2000) demonstrated absence of C3aR on T-cells in both normal 
human subjects and those with moderate inflammatory disease. However, C3aR-expressing T-
lymphocytes were demonstrated in some patients with severe inflammatory skin diseases and C3aR 
expression could be induced by administration of type I interferons61. Administration of C3a has 
been demonstrated to augment the T-cell response, promote T-cell proliferation and prolong the 
inflammatory response through suppressing regulatory T-cells (Treg) production62-64. In support of 
this, T-cell populations are reduced in C3aR-/- mice in several models of disease62,64,65. T-cell 
receptor stimulation upregulates C3aR mRNA expression in isolated T-cell populations and the 
presence of C3aR in these populations appears to promote a Th1 response, as measured by the 
defining cytokine, IFNγ63. This is supported by observations, in vivo, of increased IFNγ production 
in mice lacking the complement suppressive factor, Daf66. C3aR-signalling also acts in concert with 
C5aR-signalling to suppress the production of TGF-β1 from dendritic cells, reducing the stimulus 
for differentiation to Treg cells64.  The induced Treg cells heavily suppress the proinflammatory CD4+ 
T-cell function, leading to abrogation of the inflammatory process. In addition, C3aR signalling in 
the tissue antigen presenting cells suppresses IL-4 production, inhibiting a TH2 polarised response67. 
However this effect on T-cell biology is not entirely APC-mediated, altered Treg responses also 
occur with adoptive transfer of C5aR-/-/C3aR-/- T cells into a wild type animal64. C5aR-/-/C3aR-/-  
Treg cells also demonstrate prolonged survival and enhanced function, suggesting that C3aR/C5aR 
stimulus of T cells is also important in regulating inflammatory responses65. 
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There is also some interesting preliminary evidence that there may be some direct effect of C3aR 
signaling on cytotoxic CD8+ T cells. In an experimental model of allograft rejection, which is 
mediated by CD4+ priming of cytotoxic T cells, CD4+ T-cell-depleted mice have only a weak CD8+ 
response to heart transplants. Removing Daf, and causing local complement dysregulation, removed 
the protection of CD4+ T cell depletion after heart transplant. The authors postulate that there is a 
direct activation effect of C3a/C5a on CD8+ T cells, however this has not been confirmed by 
pharmacological blockade of any complement receptor68. 
 
C3aR in Pathology 
The heterogeneity of C3aR function at the cellular level creates a more complex picture when 
observing its role in the natural history of a disease. Unlike C5aR, C3aR cannot merely be labelled 
broadly as a pro-inflammatory entity as its function as a suppressor of neutrophil migration from the 
bone marrow serves to systemically dampen the inflammatory response. In addition, the more novel 
roles for the receptor, indicating functions in the regenerative phase post-insult, can further 
modulate clinical outcomes. As a consequence, when considering the overall contribution of C3aR 
to pathology, it is best to consider each disease state separately. 
 
Atopic Disease 
Atopic dermatitis is one instance where C3aR signalling results in a more desirable clinical 
outcome. This is linked to the function of C3aR on dendritic and, perhaps, T-cells, to promote a TH1 
response, rather than the TH2 response associated with atopic disease63,64,67. However, dendritic 
cells still respond to C3aR signalling in a proinflammatory manner by increasing antigen uptake, T-
cell recruitment and TNFa production69,70. As a result C3aR-/- animals do not differ significantly 
from wild type littermates in terms of clinical signs of skin inflammation during the sensitisation 
phase of allergic contact dermatitis71 but longer term knockout animals demonstrate an serum 
immunoglobulin profile characteristic of atopy67.  
In allergic asthma this picture is reversed. C3aR is strongly upregulated on bronchial epithelial and 
smooth muscle cells in mouse models of allergic asthma, and the level of expression in humans in 
positively correlated with severity of disease72,73. This correlation is humans is supported by mouse 
models demonstrating a protective effect in allergic asthma in C3aR knockout animals74. This 
protection has been demonstrated to be derived from a reduced TH17 cell population in knockout 
animals, due to absent C3aR-induced tachykinin release 74,75. 
 
Lupus Nephritis 
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In autoimmune lupus nephritis, there are high concentrations of C3aR and C3 present in the 
glomeruli, correlating with disease severity76. This seems to suggest a pathophysiological role for 
the receptor in this disease, and, perhaps, a therapeutic target for treatment of lupus nephritis. 
Indeed, it has previously been demonstrated that infusion of the C3aR antagonist, SB290157, in the 
MRL/lpr mouse model of lupus nephritis resulted in increased survival and reduced renal 
inflammation77. However, the same mouse model backcrossed with C3aR knockout mice indicates 
that the loss of C3aR accelerates renal injury and increases mortality78. This contradictory result 
was attributed to the ill-defined pharmacological activity of SB290157, which has been reported to 
have agonist activity upon binding C3aR56. However, although the pharmacology of SB290157 
may be controversial, the conclusion drawn by the authors may be overly simplistic, and perhaps 
not take into account the systemic effects of C3aR discovered recently. It is incontroversial that at 
the level of the nephron, C3aR is involved in the pathogenesis of renal disease, including the 
induction of metaplasia in nephron epithelial cells79 but C3aR-/- mice exhibit neutrophilia and 
neutrocytosis in response to acute pathology54. Collectively, this data may suggest that locally, 
C3aR activation potentiates pathological outcomes, whereas systemically C3aR activation may 
attenuate inflammation. 
 
Sepsis 
Despite the prolific volume of research examining C5aR in sepsis, the role of C3aR in this disease 
remains perplexingly understudied. C3 deficient animals have been utilised for investigation of 
complement-mediated pathogen clearance during sepsis, and it has been demonstrated, perhaps 
unsurprisingly, that the lack of C3 reduces survival rates and increases pathogen load in 
experimental models80. One might expect that the increased pathogen load due to the loss of the 
terminal elements of the complement system, namely C3b opsonisation, C5a-induced activation of 
leukocytes and membrane attack complex lysis of pathogens, explains the premature death of C3 
deficient animals. Indeed this is supported by demonstration of a protective effect for administration 
of exogenous C3 in septic animals81. However, the initial report of a C3ar1 knockout mouse 
included an investigation into survival in sepsis and, interestingly, concluded that the loss of C3aR 
contributed to impaired survival82. Extra complement pathway, compensation via the upregulation 
of serum proteases83,84. Conversely, elevated C3a is associated with fatal outcomes in sepsis, 
however this may be a byproduct of uninhibited complement activation rather than a contributor to 
mortality1,85. 
 
Preeclampsia 
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It is still unclear whether the duality of C3aR, in terms of preventing systemic but promoting local 
inflammation, holds true for all disease states in which C3aR has been implicated. For instance, in 
preeclampsia the complement system has a well-defined role in placental inflammation86, and C3 
deposition on placental tissue is one of the hallmarks of the disease87. Complement activation in 
preeclampsia causes angiogenic dysregulation through the upregulation and release of sVEGFR-1, 
although this is a C5a, rather than C3a, mediated phenomenon87. Interestingly, in placentas from 
preeclamptic patients, the expression of C3aR is reduced, whereas C5aR levels are uneffected88. 
Whether this is a cause or effect of preeclampsia is unclear, but the presence of lower 
concentrations of the receptor in local areas of disease runs contrary to the model that C3aR 
functions as a proinflammatory agent at this level. 
 
Pneumonia 
Additionally, in a model of pneumonia C3aR-/- mice exhibited more efficient killing of 
Pseudomonas aeruginosa than their wild-type counterparts89. This increased efficiency was also 
accompanied by a reduction in the adverse effects of local inflammation, such as vascular leakage 
and a significant reduction in leukocyte infiltration. Interestingly, this is in contrast to what we have 
seen in models of intestinal ischaemia-reperfusion injury using C3aR knockout mice, and what 
would be expected from an animal with exaggerated neutrophil mobilisation in response to injury54. 
The authors also demonstrated an increased antibody response to P. aeruginosa in the C3aR-/- 
animals, adding weight to early reports that C3aR is a suppresor of humoral immunity, although 
whether C3aR is expressed on B-cells is, as yet, controversial10,37. However, the authors claim the 
increased antibody titre in C3aR-/- mice could not solely account for the enhanced killing of P. 
aeruginosa, leaving a paradoxical situation of a reduced inflammatory response, but also reduced 
bacterial viability in C3aR-/- animals. 
 
CNS infection 
In order to investigate the role of C3a in acute inflammation of the brain, 90 studied the pathogenesis 
of LPS-induced shock using crosses of C3aR-/- and C3a/GFAP-Tg mice, which overexpress C3a 
under the control of the GFAP promoter and thus generate biologically active C3a in the CNS 
without requiring prior complement activation. Interestingly, C3a/GFAP mice were significantly 
more resistant to endotoxin-induced lethality than WT and C3aR-/- mice and, curiously, C3a/GFAP 
x C3aR-/- mice were also significantly protected90. This suggests that not only can C3a function in 
vivo as an anti-inflammatory mediator, but that it exerts this effect via an alternative, non-canonical 
C3aR, possibly C5L2 or Receptor for Advanced Glycation End-Products91. 
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C3aR is however directly associated with pathology in other neuroinfectious disorders. Reactive 
astrocytes, amoeboid microglia and ramified microglia stain strongly and consistently with C3aR in 
sections of human brain with bacterial meningitis, much greater than in normal human brain 
sections11. This suggests excessive C3aR activity may contribute to progression of this disease. A 
similar observation was reported in the mouse model of CNS-affecting systemic lupus 
erythematosus (SLE) (MRL/lpr mice); C3aR is upregulated in the brains of MRL/lpr mice relative 
to MRL/+ controls92. Interestingly, treatment of the experimental lupus brain with a non-specific 
C3aR antagonist reduced neuronal apoptosis, gliosis, expression of the pro-inflammatory mediators 
TNFα, IFNγ and iNOS, and modulates neuronal excitability by decreasing AMPAGluR1 
expression92. Combined with the observation that systemic C3a levels correlate with disease 
severity in human SLE patients93, this data indicates that therapeutic antagonism of C3aR may be a 
novel therapeutic strategy for attenuating human CNS SLE. Although these findings appear 
somewhat paradoxical compared to the ameliorative effects of C3a in the LPS-induced shock model 
described above, it is important to note that they are dependent on activation of C3aR, whereas the 
neuroprotection observed in with C3a in LPS-induced shock was mediated independently of C3aR. 
Taken together, this data suggests that deregulated complement and excessive C3aR activation 
results in exacerbation of CNS infectious pathology. 
 
Stroke 
Similar detrimental roles for C3aR have been assigned for acute neuroinflammatory conditions 
resulting from injury. Human patients that sustained an ischaemic stroke less than one month prior 
to plasma collection have elevated plasma C3a compared to control patients94. Although this is only 
correlative, the animal model of stroke, middle cerebral artery occlusion (MCAO), has provided 
valuable insights into the functional significance of elevated C3a levels. C3aR mRNA and protein 
levels in the murine ischaemic cortex are significantly increased on macrophage-like cells and 
astrocytes by one day post-injury95-97. This upregulation was partly attributed to infiltration of 
leukocytes to the ischaemic core and penumbra, and suggests that C3a may promote inflammatory 
responses in the ischaemic brain specifically via modulation of infiltrating and glial cell responses. 
In line with this, in vitro there is no effect of hypoxia-re-oxygenation on human NT2-N neuronal 
C3aR expression98, even though these cells constitutively express C3aR. 
 
Given these observations, investigations in the last decade have evaluated the effects of modulating 
C3aR in vivo. In transient (60 min) but not permanent MCAO, pharmacological antagonism of 
C3aR resulted in smaller stroke volumes, less ICAM-1 protein on endothelial cells and less C3aR-
positive granulocytes compared to mice treated with vehicle only99. These data suggest that 
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blocking the binding of C3a to C3aR modulates acute inflammatory events following cerebral 
ischemic-reperfusion injury by limiting the recruitment of neutrophils to the ischemic zone99.  It is 
likely that the tissue damage produced with permanent MCAO was too copious for therapeutic 
effects of C3aR inhibition to be observed. It should be taken into account, however, when 
interpreting these findings that the antagonist used in this study, SB290157, reportedly has off-
target effects, including neutropaenia in vivo100, and full agonist activity in various of cell systems 
in vitro56,101. A study by Mocco et al. (2006)102, which employed mice genetically deficient in C3 or 
C5, may clarify this situation. Only C3-/- mice displayed improved outcomes compared to WT mice, 
shown by an average of 34% reduction in infarct volumes, improved neurological deficit scores, 
and decreased granulocyte infiltration and oxidative stress. It was thus concluded that the 
improvements observed in C3-/- mice must be due to absence of C3a or C3b activity, and not 
downstream complement components such as the membrane attack complex (MAC). The authors 
utilised a C3aR anatagonist in order to distinguish which C3 cleavage product was detrimental to 
recovery. It was found that C3aR blockade resulted in commensurate neurological improvement 
and stroke volume reduction compared to the C3-/- mice, indicating that the worsened outcomes in 
the WT cohort was due to C3a-mediated mechanisms102. The use of C3aR-/- mice may more 
definitively confirm this role in ischemic stroke. 
 
Although only accounting for 15% of all strokes103, haemorrhagic strokes result in a 
disproportionate degree of morbidity104. Interestingly, it has been observed that in plasma105 and 
cerebrospinal fluid (CSF)106 levels of C3a were shown to correlate with functional outcome after 
subarachnoid aneurysm rupture, suggesting that inflammatory processes involving C3a may 
contribute to neurologic dysfunction. C3a/C3aR has therefore been investigated as a putative 
therapeutic target in this pathology. Treatment of mice with a C3aR antagonist prior to intracerebral 
haemorrhage (ICH) induction has been shown to improve neurologic function, brain water content, 
and granulocyte infiltration relative to vehicle-treated animals when assessed at 72 hours post-
trauma107. It would be of interest to determine if these effects would be as substantial if this 
antagonist were administered subsequent to ICH, as this would be more clinically applicable. A 
study by Garrett et al. (2009)104 suggests that C3aR inhibition post-intracerebral hemorrhage may 
have therapeutic potential. Although the authors did not evaluate the effects of a C3a antagonist 
alone, they found that combined C3aR antagonist with a C5aR antagonist improved functional 
outcomes and reduced inflammation and oedema to a greater extent than that observed with a C5aR 
antagonist alone, suggesting C3aR and C5aR function synergistically to modulate the infalmmatory 
response. The authors concluded that simultaneous blockade of the C3a and C5a receptors 
represents a promising neuroprotective strategy in haemorrhagic stroke104. 
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Traumatic Brain injury 
There is a paucity of literature on the role of C3aR in traumatic brain injury resulting from 
mechanical trauma, but it would appear to be a good candidate as a therapeutic target here as well. 
Our recent work has however determined an ameliorative role for C3aR in the acute-to-chronic 
stages after experimental contusive spinal cord injury (SCI). Unlike cerebral injury, C3aR-/- mice 
subjected to SCI perform worse than WT mice in functional, anatomical and histological outcome 
measures, and this is associated with augmented granulocytic inflammatory infiltrate. This indicates 
that C3a/C3aR plays a key role in acute CNS injury, but its therapeutic potential must be tailored to 
specific pathological contexts in order to optimally harness its therapeutic potential. 
 
Neurodegenerative Disease 
There is also a growing body of work examining the role of C3a in chronic neurodegenerative 
diseases. The following section will discuss the known literature regarding C3a/C3aR activation in 
Alzheimer's disease (AD), Huntington's disease, multiple sclerosis, and cuprizone-induced 
demyelination.  
 
In regard to AD, plasma concentrations of C3a partly explain the variance in whole brain volume in 
AD patients, suggesting plasma C3a may represent a predictor of in vivo AD108. Another study 
examined the CSF of patients with Alzheimer's disease (AD) and vascular dementia (VD) in order 
to determine candidate protein biomarkers for the differential diagnosis between the two conditions. 
C3a was among 28 proteins identified which can distinguish between the two pathologies109, 
suggesting C3a is among a collection of mediators orchestrating this pathology. Interestingly, 
amyloid plaques contain C1q and activated C3 fragments110, implying that amyloid plaque 
themselves can invoke complement activation via the classical pathway. One study examined this 
further by applying normal serum depleted of C3 to Aβ1-42 aggregates in vitro. C3 activity on the 
Aβ1-42 was detected, and this was associated with binding of C1 and activation of C4 on the 
aggregated peptide. Thus Aβ1-42 is sufficient to serve as a substrate for complement activation, and 
the subsequently produced C3a may be involved directly the inflammation seen in AD brains111. 
Similarly to AD, the overall level of complement activation in the Huntington’s disease (HD) brain 
is 2-5 times higher than in normal brains112. Notably, neurons and astrocytes in the striatum from 
Huntington’s disease (HD) patients stain positively for C3 and iC3b, C3 was also shown to localise 
to microglia in the internal capsule, and C3aR mRNAs is strongly expressed in HD caudate112. It 
was suggested that local complement production by glia contributes to HD inflammatory pathology 
and possibly neuronal necrosis. 
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C3aR expression has also been shown to be elevated on microglia and astrocytes in the animal 
model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE)11,113. C3aR-/- mice 
develop attenuated experimental autoimmune encephalomyelitis (EAE) in the chronic phase of 
disease, which was associated with reduced demyelination and cellular infiltration of macrophages 
and T cells compared to wild-type mice114.  In contrast, mice that express C3a exclusively in the 
CNS (C3a/GFAP transgenic mice) develop severe and exacerbated EAE compared to wild-type 
mice. Surviving C3a/GFAP mice exhibited profound macrophage and CD4+ T cell infiltrate 
throughout the meninges of the spinal cord, in Virchow-Robins spaces, and around blood vessels in 
the parenchyma. The recovery of C3a/GFAP x C3aR-/- mice was comparable to that of C3aR-/- 
mice, demonstrating that the phenotype of C3a/GFAP mice is mediated via C3aR115. Interestingly, 
there may be some cross-modulation between the anaphylatoxin receptors in this pathology, as mice 
deficient in both anaphylatoxin receptors (C3aR-/-C5aR-/- mice) do not have attenuated disease 
severity compared to wild-type mice, even though C5aR-/- and C5a/GFAP mice have identical 
pathology compared to wild-type mice114,116,117. Overall, this data suggests however that C3a, via 
C3aR, is a key modulator of EAE pathology rather than a bystander fragment.  
 
This data is consistent with that observed in cuprizone-mediated demyelination and remyelination. 
C3a/GFAP expressing mice have worse demyelination severity, increased cellular infiltration and 
thickness of the inflammatory lesion within and surrounding the corpus callosum, greater 
astrogliosis and microglial infiltration than WT mice. Interestingly, C3a/GFAP mice also showed 
increased numbers of Olig2+ oligodendrocytes during the early stages of remyelination118. This was 
suggested to be a compensatory mechanism for the increased severity of demyelination in the 
corpus callosum. C3a was also shown to alter cytokine and chemokine production in glia cultures, 
including CCL4(MIP1β), CCL5, CCL11, IL-6 and IL-13118. It was concluded that C3a worsens this 
demyelinating pathology via stimulating upregulation of chemokine production, which induced 
migration of supplementary reactive astrocytes and microglia to the demyelinating corpus callosum. 
 
Emerging Novel Roles 
The notion of a system of combatting infection as being important for embryonic development or 
tissue regeneration appears initially antithetical. However, this may be due to the fact that the first 
ascribed role for complement, that of a player in immunity, has stuck so tenaciously to our ideas of 
the system that it is impossible to tease the two apart. And so, most recent articles on C3aR outside 
of the immune system begin with the proclamation that the proceeding article will outline a novel 
role for the receptor. This is, justifiably, an area of excitement within complementology, drawing 
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developmental biologists to observe complement in a new light. In actual fact, the link between 
tissue damage and repair is not as disjointed as it may first appear. After injury, apoptotic cells must 
be cleared and new cells must fill their place; is it inconceivable that the key mediators of both 
processes could be the same set of proteins? 
 
An early report of this duality was the role of C3aR in liver regeneration after injury or toxic insult. 
It has been shown that mice deficient in C3 exhibit reduced proliferation and a corresponding 
delayed gain in liver weight after partial hepatectomy, an effect that can be rescued by C3a 
administration7. Although these experiments do not directly demonstrate a role for C3aR in liver 
regeneration, in a model of chemically-induced liver injury, C3aR-/- mice exhibit reduced 
proliferation, supporting the hypothesis that the effects observed in partial hepatectomy are C3aR 
dependent7,119,120. In addition, C3-/- mice have increased necrosis and long term liver damage 
following both toxic injury and partial hepatectomy. This phenotype can be rescued through the 
administration of C3-sufficient sera7,119,120. The authors of these papers suggest that C3aR-mediated 
hepatocyte proliferation after injury is an indirect effect, via Kupffer cell C3aR signalling causing 
the release of pro-mitotic factors7,121. Although C3aR Kuppfer cells that can trigger the release of 
regenerative factors, the importance of C3aR signalling on the hepatocytes themselves has however, 
not been thoroughly investigated7. As an organ that undergoes sustained challenge and constantly 
regenerates, the authors postulated that the scope of this discovery was limited solely to the liver. 
However, it may be tentatively said that the idea of C3aR promoting tissue growth and 
differentiation may also apply to the embryo, and that research in this area is starting to unlock a 
whole new world of complement biology. 
 
In the developing Xenopus embryo, C3 and C3aR are expressed throughout organogenesis5. There 
is expression in the liver diverticulum and posterior gastric endoderm, which may be expected 
given the traditional functions of both C3 and C3aR5,122. However, the expression of C3 and C3aR 
is particularly striking during neurulation, where the transcript is localised, in both Xenopus and 
zebrafish models, to the neural crest and neural groove5,9. Given our laboratory’s recent report of 
the protective effect of C5aR signalling in folate-deficient neural tube closure, similar expression of 
C3aR during neurulation may lead us to hypothesise a role for C3aR in neural tube closure. 
Expression of both ligand and receptor follows the migration routes of the neural crest cells, 
particularly evident within the brachial migration routes5,9,122.  
 
It would be tempting to hypothesise that the function of C3aR in the neural crest may be similar to 
its novel role in the liver, promoting cellular proliferation. However, the C3a-C3aR axis, at least in 
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zebrafish, functions in this area as a regulator of collective cell migration. Migration of neural crest 
cells is dependent on a balance between contact inhibition and coattration, leading to the orderly 
migration of cells through exquisitely defined pathways. Disruption of the C3a-C3aR axis with 
C3aR-targetted morpholinos or anti-C3a antibodies leads to disorderly and attenuated neural crest 
cell migration9. In the case of the C3aR morpholinos, this effect can be rescued through the delivery 
of C3aR mRNA to the affected embryos9. These experiments have demonstrated that the 
chemoattractive effect of C3a on neural crest cells is imperative for correct zebrafish development. 
However, what role does the C3a-C3aR axis have in mammalian development? The existence of 
C3aR-/- animals that do not exhibit any gross developmental anomalies may have clouded our vision 
surrounding that question. Should we be considering the work of compensatory mechanisms in the 
knockouts? Would conditional knockouts be better genetic tools for the investigation of this 
receptor in development? Certainly, the answer to the latter question must be a resounding, yes. 
There have been just a few studies on C3aR in relation to neural development and regeneration, but 
each has demonstrated that modulation of this receptor can dramatically affect the development of 
the brain. 
 
This developmental aspect of C3aR function must be inferred from research surrounding post-natal 
neurogenesis. The affect that C3aR signalling appears to have on the neural progenitor population 
can be described as a complex one. C3aR is expressed on these progenitors, both in in vitro models 
and in the embryonic and adult brain8,28,123. Indeed this expression of C3aR can be traced back to 
the neuroepithelial cells in early neural tube formation (Angela Jeanes, personal communication). 
Signalling through C3aR has been shown to modulate stromal derived factor-1α  (SDF-1α), leading 
to either an amplification or attenuation of SDF-1α-dependent migration28. SDF-1α is a known 
chemoattractant for neural progenitors and other stem cells, acting through its receptor Cxcr4124. 
C3aR modulates this attraction through acting as an inhibitor at high SDF-1α concentrations 
(500ng/mL) and augments the effect at low concentrations (4ng/mL)28. C3aR or Cxcr4 signalling 
alone promotes neuronal differentiation of the progenitors, however this effect is annulled when 
both agonists are applied simultaneously28.  
 
It is difficult to speculate what this means for neural progenitor biology, without knowing when and 
where C3a is present in the brain. Is it that the influence of C3a only becomes apparent under 
conditions of insult and injury, where the complement system is activated, or do these results 
suggest a more subtle, developmental role for the C3a-C3aR axis? This question has been partially 
answered through the observation that, in C3-/- and C3aR-/- mice, basal neurogenesis is reduced, 
indicating that C3aR is a player in the normal physiology of neurogenesis8. This effect can also be 
Appendix A C3aR in Health and Disease 
 
 211	
elicited with administration of the controversial C3aR antagonist, SB2901578,56. In rat postnatal 
cerebellar development C3a is also a chemoattractant for cerebellar granule neurons of the external 
granule cell layer and this effect can be blocked by SB290157125. The use of this antagonist, albeit 
one of controversy, supports the assumption that the effects demonstrated through the application of 
C3a to neural progenitors is indeed through C3aR, a question that was not fully answered in the 
work of Shinjyo and colleagues (2009). In vivo, the subdural administration of C3a caused a 
reduction in the thickness of the proliferative external granule cell layer and a increase in thickness 
of the post-mitotic internal granule cell layer, suggesting that C3a acts to promote exit from the cell 
cycle and migration to form functional neurons125. In addition to a purported role in basal 
neurogenesis, C3aR also functions to accelerate neurogenesis in mouse models of stroke8. C3 
deficient mice demonstrate reduced numbers of progenitor cells in both the infarct area and 
penumbra after middle cerebral artery occlusion, this translates into a reduced number of newly 
formed neurons during recovery8. It is postulated that this decrease in progenitors could be ascribed 
to the previously demonstrated function in vitro of C3aR as a chemoattractive mediator. In models 
such as stroke, which involve a large inflammatory component and glial infiltration, it is easy to 
comprehend how and where C3a is generated in order to promote neurogenesis. The question for 
future research in this area will be how C3aR is stimulated in basal neurogenesis without the 
inflammatory sequalae.  
 
Therapeutic Potential 
As a pivotal regulator of the innate immune response, modulation of C3aR signalling is a valuable 
target in the therapeutic treatment of immune mediated inflammatory diseases. Whilst studies using 
C3aR receptor knockout mice are important in the investigation of C3aR mediated processes, a 
pharmacological approach to C3aR modulation is vital for progression of C3aR based therapies 
from the laboratory to the clinical environment. Though holding vast therapeutic potential, the 
number of C3aR targeted drugs available is limited, in particular, there is currently no specific 
C3aR antagonist available for use.  
 
C3aR Antagonists 
The report of the chemical compound, N2-[(2,2-diphenylethoxy)acetyl]-L-arginine (SB 290157) as 
an antagonist of C3aR (IC50 reported between 30-200nM) created an avenue for the study of 
pharmacological inhibition of C3aR126. Use of this antagonist lead to reports for the potential of 
C3aR antagonism in therapeutic applications such as in the reduction of injury in models of cerebral 
ischemia reperfusion and lupus92,94, and treating metabolic dysfunction127. Whilst these results were 
promising for C3aR therapeutics, other studies, which used SB290157, found unusual or conflicting 
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results bringing into question the antagonistic activity of the compound. In the study of C3aR in 
ischemia reperfusion injuries, our laboratory demonstrated high doses of SB caused transient 
neutropenia and hypertension100, both of which have been associated with C3aR activity128. 
Furthermore, in models of allergic asthma SB290157 was found to have no effect, a result which 
conflicted previous reports for a critical role of C3aR in the pathogenesis of asthma129-131. Due to 
such results, Mathieu and colleagues (2005) examined the compound and, in opposition to the 
reports of C3aR antagonism, demonstrated that SB290157 was a C3aR agonist in a number of in 
vitro assays56. Such a finding explained the unusual results that have been observed when using 
SB290157, and raises critical concerns over the validity of previous results, which have used the 
compound to attribute C3aR antagonism to disease therapy. Whilst the previously mentioned 
reports which used SB290157 may have observed an effect due to C3aR inhibition, they are just as 
equally likely to have been due to C3aR activation, demonstrating that, though not an ideal model 
for potential therapies, that C3aR knockout animal studies are necessary for demonstrating the 
validity of such results. More importantly, this highlights the necessity for further research and 
development of C3aR antagonists. 
 
Recently, Scully and colleagues (2010) reported the discovery of the hexapeptide antagonist, 
FLTChaAR (Binding IC50 = 240nM)132. This peptide was developed through the modification of 
the C5aR agonist, FKP(dCha)(Cha)r, and subsequent screening for C3aR activity. Due to the high 
similarity between C5aR and C3aR, it was hypothesised that modifications to this peptide would 
lead to a shift in 30specificity towards C3aR. No further studies have reported the use of this 
peptide and, with following publications by the group choosing to use SB290157 over their own 
peptide, it is probable that FLTCHaAR is not suitable for animal and therapeutic studies127. 
Whilst no further reports of C3aR antagonists have been made, the application of a de novo protein 
design framework, using computational modelling to predict amino acid sequences which are 
favourable for receptor interactions, was utilised to produce two partial agonist peptides with full 
C3aR antagonist activity133. Though these peptides are not favourable for antagonist studies, they 
demonstrate the potential for this approach in the production of C3aR specific antagonists. 
 
C3aR Agonists 
Due to the multiple functions of C3aR, not only inhibition, but context specific activation of C3aR 
may have important therapeutic potential.  Using receptor knockout mice, it has been demonstrated 
that C3aR loss worsens tissue injury following intestinal ischemia reperfusion (IR)54. This effect 
was attributed to the role of C3aR in preventing neutrophil mobilisation and subsequent 
inflammatory mediated injury following ischemia. The therapeutic potential of C3a activation was 
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further demonstrated with the use of the specific peptide agonist of C3aR, 
WWGKKYRASKLGLAR, which abated IR induced neutrophil mobilisation and tissue injury54. 
 
Development of the C3aR agonist, WWGKKYRASKLGLAR, was based upon the modelling of the 
C-terminus sequence of C3a, the region implicated in C3aR activation134. This peptide contained 
the highly-conserved LGLAR sequence that has been identified to be essential for receptor 
activation, as well as a hydrophobic N-terminal group (WW), which, in support of the two site 
binding hypothesis for C3aR activation, is postulated to be required to bind to the secondary 
activation site on C3aR. As well as both groups being required for peptide activity, distance 
between the two was essential for binding of the receptor sites, and was optimised for maximal 
potency of the peptide. The combination of these properties yielded a peptide with a reported 15-
fold increase in activity compared to C3a. WWGKKYRASKLGLAR is an unconstrained, natural 
amino acid, and linear peptide, all of which are undesirable properties when considering therapeutic 
applications, due to a predicted poor oral bioavailability and rapid breakdown135. When considered 
for use during surgical procedures known to result in ischemic injury, treatment with an acute, 
intravenous dose of WWGKKYRASKLGLAR is feasible for reduction of IR tissue damage. 
Instability of the compound may even be preferred as, when considering the potential for C3aR to 
mediate chronic inflammatory disease, it would be preferable to only prevent immediate neutrophil 
mediated damage following surgery. 
 
In a recent study, Scully and colleagues (2010) utilised modelling of the C5aR agonist, 
FKP(dCha)(Cha)r, to develop a number of C3aR agonist peptides along with the previously 
mentioned antagonist, FLTChaAR132. Substitution of the (dCHa)(Cha)r for the C-terminal C3a 
sequence, LAR, and subsequent modifications of the N-terminus lead to the identification of a 
number of short hexapeptide agonists with specific activity for C3aR, of which the most potent 
were FLPLAR (0.42 uM), FIPLAR (0.95 uM), FWTLAR (0.3 uM) and FLTLAR (0.32 uM). 
Further investigation of FLTLAR identified a bend in the NMR structure in a similar manner as to 
what is seen in C3a132. This suggests a requirement of this conformation for the binding and 
activation of C3aR, and potentially why the shorter peptides were able to activate C3aR in contrast 
to the previously reported necessity for a longer sequence such as WWGKKYRASKLGLAR. It 
may be equally possible that the hypothesised necessity for binding of two C3aR sites is not 
necessary for full receptor activation.  Identification of shorter sequences that are able to 
functionally bind C3aR provides valuable insights into further C3aR ligand development. The use 
of such hexapeptides may also be therapeutically advantageous over the longer peptide, 
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WWGKKYRASKLGLAR, reducing production cost and potentially increasing stability and tissue 
penetrance.  
 
Whilst there is clear evidence for the therapeutic application of C3aR targeting, there is a desperate 
need for research into developing specific and potent C3aR ligands. From animal studies, it is 
apparent that context specific antagonism or agonism of C3aR is a viable option in treating a 
number of diseases. The realisation of such clinical applications is significantly hindered by the lack 
of molecular tools for targeting C3aR. Screening of chemical libraries resulted in the discovery of 
SB290157, a compound widely used as a C3aR antagonist. Recent studies have demonstrated the 
agonist activity of this compound56, highlighting the need for cessation of SB290157 use and 
publication as a C3aR antagonist. Worryingly, there is continued use of SB290157 as a C3aR 
antagonist, with recent publications utilising this compound as the sole method for formulating 
conclusions about C3aR functions in disease progression127,136,137,139. This continued use hinders 
research into C3aR mediated pathologies, and highlights the importance for development of a 
specific, potent, C3aR antagonist, which to date has remained elusive. 
 
Conclusion 
The functions of C3aR are an evolving field of study, novel functions for this receptor exist beyond 
the traditional confines of innate immunity. Additionally, even within its roles in immunity there is 
debate as to whether the receptor operates, in an overarching manner, to promote or inhibit 
inflammation138. C3aR offers a promising target for modulation in pathologies, especially given its 
‘bilingualism’ in the context of inflammation. However, currently there are no stable and clinically 
translatable pharmaceuticals available, and this is most acute with regards to the antagonists. This 
review has aimed to summarise the current state of knowledge for C3aR with the view of 
stimulating interest in this receptor as a potential target in inflammatory pathologies. 
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